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1 INTRODUCTION 
1.1 Scope of the present dissertation 
While mild premenstrual complaints are reported by the majority of women in fertile 
ages and are therefore considered part of the normal menstrual cycle (Nevatte et al., 
2013; Tschudin, Bertea, & Zemp, 2010), a certain proportion of women suffer from a 
severe variant of premenstrual symptoms characterized by principal affective 
symptoms. This condition has been classified as Premenstrual Dysphoric Disorder 
(PMDD). PMDD is associated with clinically significant distress, and affected women 
suffer from marked impairment in their normal functioning, which can be as disabling 
as Major Depressive Disorder (Halbreich, Borenstein, Pearlstein, & Kahn, 2003). The 
disorder has recently been included as a full diagnostic category in the fifth edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5, American 
Psychiatric Association (APA), 2013) and the eleventh revision of the International 
Classification of Diseases and Related Health Problems (ICD-11, World Health 
Organization (WHO), 2018). Despite its inclusion, many questions remain 
unanswered including possible mechanisms associated with the disorder such as 
particularities of the endocrinologic stress axis activity and psychological factors as 
well as characteristics contributing to a poor clinical course of the disorder. The 
present thesis aims to focus on these issues by studying affective, cognitive, and 
endocrinological processes over the menstrual cycle in women with PMDD during 
their daily life using an Ambulatory Assessment (AA) design with electronic diaries. 
As such, this may open the way for a more systematic investigation of new 
therapeutic strategies in the future that help to reduce the burden of PMDD.  
The theoretical background comprises an introduction to PMDD, followed by 
discussed risk and associative factors, existing treatment strategies and new 
research approaches via AA, leading to our research questions, which were 
investigated in three substudies. Study 1 examines stress-related facets of mood, 
cognitions and cortisol over the menstrual cycle in women with and without PMDD, 
Study 2 investigates possible menstrual cycle-related reciprocal effects of cognitive 
and affective processes in these women, and Study 3 focuses on the role of daily-life 
phenotypes for the clinical course of the disorder. In a general discussion section the 
findings from studies 1 to 3 are discussed in detail, with a focus on the integration 
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into previous research and future perspectives in treatment research, taking into 
account the limitations of the findings and concluding with a brief summary. 
1.2 Premenstrual Dysphoric Disorder as a new diagnostic category in DSM-5 
PMDD is characterized by the cyclical recurrence of severe key affective symptoms, 
which are accompanied by other psychological and/or physical symptoms in the 
week before menses (late luteal phase). The recognition of PMDD as a clinical 
condition requiring treatment in DSM-5 (APA, 2013) is a result of intensive research 
activity during the last 40 years. Already in the early 1930s, premenstrual symptoms 
were outlined as a clinical entity by Frank (1931). Much later, in 1987, formal criteria 
were specified for the first time, and the syndrome was described as “late luteal 
phase dysphoric disorder” by the American Psychiatric Association (APA, 1987). 
Subsequently, in 1994 diagnostic criteria were included in the appendix of DSM-IV as 
a “condition requiring further study” and renamed in PMDD (APA, 1994). 
Accumulating clinical and epidemiological evidence finally led to the inclusion of 
PMDD as a distinct clinical entity in the current fifth version of the DSM (Epperson et 
al., 2012; Reed et al., 2019). Here, PMDD is located in the chapter of depressive 
disorders due to the prominence of mood symptomatology (APA, 2013).  
For a diagnosis of PMDD - according to DSM-5 (APA, 2013) - different diagnostic 
criteria need to be met: First, at least five out of eleven specific symptoms must occur 
during the last week (late luteal phase) of the menstrual cycle, which remit during the 
first week after menstruation onset. This must be valid for the majority of menstrual 
cycles during the last 12 months (Criterion A). Second, at least one out of four 
affective key symptoms must be present: affective lability, anger or irritability, 
depressed mood or anxiety. These core symptoms are accompanied by further 
affective, cognitive, and/or physical symptoms including decreased interest in usual 
activities, subjective difficulty in concentration, fatigue or lack of energy, change in 
appetite, hypersomnia or insomnia, the feeling of being overwhelmed or out of 
control, or physical symptoms such as breast tenderness or muscle pain (Criterion 
C). Symptoms must be associated with clinically significant distress or interference in 
the area of work, school, social activities, or relationships (Criterion D). It is important 
to note that these symptoms may not merely represent a premenstrual exacerbation 
of another psychiatric disease. For example, a woman suffering from current Major 
Depressive Disorder needs to show at least one key affective symptom different from 
depressed mood  (e.g. affect lability or anger) to be diagnosed with coexistent PMDD 
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(Criterion E). In order to confirm the PMDD diagnosis, daily symptom ratings over at 
least two symptomatic cycles are required, although a provisional diagnosis of PMDD 
based on clinical history can be made without (Criterion F). Finally, the symptoms 
must not be attributable to physiological effects of a substance or a general medical 
condition (Criterion G).  
Compared to the research diagnosis in DSM-IV, the diagnostic criteria in DSM-5 are 
softened in a few points: 1) The time criterion, which states that the complaints must 
persistent "most of the time during the last week of the luteal phase," has been 
deleted. 2) It is no longer required that symptoms disappear completely within a few 
days after the onset of menstruation, but it is rather if they remit after menses onset. 
3) In addition, the previously required impairment criterion in everyday life has been 
broadened; now women may suffer from clinically significant distress or impairment, 
thereby including those who maintain their functional level under severe suffering. 4) 
It is indicated that PMDD may co-occur with - rather than be superimposed on - other 
disorders. It is possible that these minor changes in the diagnostic criteria will affect 
prevalence rates of PMDD (cf. Beddig & Kuehner, 2017). Besides, the predominance 
of premenstrual high arousal negative mood and mood lability over depressed mood 
in PMDD has led to a change in the respective listing of symptoms from DSM-IV to 
DSM-5 (Hantsoo & Epperson, 2015). The core symptoms “affect lability” and 
“irritability or anger” are now listed first as they are more common than “depressed 
mood”, which was originally listed first in DSM-IV (Hartlage et al., 2012, Epperson et 
al., 2012).  
Epidemiological and clinical data suggest that the onset of PMDD typically occurs 
during late adolescence or young adulthood (for review see Dennerstein, Lehert, & 
Heinemann, 2012), and that the disorder frequently takes a chronic course (Wittchen, 
Becker, Lieb, & Krause, 2002). Symptom severity rises with advancing age until the 
cycle-related symptomatology disappears after menopause (APA, 2013). 
Epidemiological studies have identified PMDD prevalence rates according to DSM-IV 
criteria varying from 3-8% of women of reproductive age (cf. Beddig & Kuehner, 
2017; Dennerstein et al., 2012; Lanza di Scalea & Pearlstein, 2019). In Germany, a 
large epidemiological study with 1,251 women aged between 14 and 24 identified a 
twelve-month prevalence of 5.8% (Wittchen et al., 2002). Other studies have shown 
that women who meet the criteria for PMDD experience their quality of life and 
psychological functioning being reduced to a degree comparable to that seen in other 
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major affective disorders (Halbreich et al., 2003). Especially affective and cognitive 
symptoms appear to be linked to functional impairment, whereas physical symptoms 
seem less relevant (Schmalenberger, Eisenlohr-Moul, Surana, Rubinow, & Girdler, 
2017). Impairment has been found to be particular severe regarding partnership 
relationships and domestic activities (Halbreich et al., 2003; Robinson & Swindle, 
2000; Tschudin et al., 2010). Substantial clinical relevance of the disorder is indicated 
in studies by Pilver, Libby, and Hoff (2013) and Wittchen et al. (2002) who showed 
that PMDD led to an increased rate of suicidal ideation, plans, and attempts, 
independent of psychiatric comorbidity. 
In contrast to PMDD, the premenstrual syndrome (PMS) is considered a less severe 
form of premenstrual complaints affecting 18-35% of menstruating women, 
depending upon applied diagnostic criteria (Yonkers, O'Brien, & Eriksson, 2008). 
PMS is not an official diagnosis in DSM-5 and hence a consensus on universally-
accepted diagnostic criteria is lacking (cf. O’Brien et al., 2011). Consequently, the 
distinction between PMS and PMDD frequently remains unclear (cf. Kues, Janda, 
Kleinstauber, & Weise, 2014). The often-used diagnostic criteria based on the 
American Congress of Obstetricians and Gynecologists (ACOG) is relatively liberal 
(cf. O’Brien et al., 2011). Here, PMS is defined by the presence of at least one 
symptom out of a list of affective and somatic symptoms in the five days prior to the 
onset of menses, which adversely affects social or work related activity (ACOG, 
2000). Respectively, in contrast to the definition of PMDD – which requires the 
presence of affective symptoms while less attention is paid to physical symptoms – a 
diagnosis of PMS can be made in the absence of affective symptoms. 
The inclusion of PMDD as a diagnostic category in DSM-5 has attracted considerable 
controversy (Browne, 2015; Chrisler & Caplan, 2002; Hartlage, Breaux, & Yonkers, 
2014; Ussher & Perz, 2013). While opponents fear that the label could pathologize 
normal female body processes and stigmatize affected women (Chrisler & Caplan, 
2002; Cosgrove & Caplan, 2004; Ussher, Hunter, & Browne, 2000), recent research 
indicates that these concerns lack scientific evidence and that women with PMDD 
are likely to benefit from the new diagnosis (Hartlage et al., 2014). This is due to a 
variety of reasons including greater acceptance of the disorder in the general public, 
encouragement of research and improved opportunities through appropriate research 
funding, a more rigorous characterization of patients participating in randomized 
control studies (RCTs), improvement in the knowledge of adequate treatment 
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approaches and thus ultimately better evidence-based care (Hartlage et al., 2014; 
Epperson et al., 2012).  
The diagnosis of PMDD is also included as a new diagnostic category in the recently-
approved ICD‐11 (WHO, 2018). Here, PMDD is primarily listed as a disease of the 
genitourinary system, although it is cross-listed as a depressive disorder due to the 
prominence of key affective symptoms (cf. Reed et al., 2019). This inclusion 
emphasizes the importance of PMDD as a public health issue and it is likely that this 
will further support appropriate recognition and improved treatment in clinical 
practice, thereby helping more women to relieve the premenstrual burden. 
1.3 Risk and associative factors 
The pathophysiology of PMDD is not yet fully understood. Work in this area largely 
focuses on factors such as genetic vulnerabilities, circulating gonadal hormones, and 
central neurotransmitters such as serotonin or gamma-aminobutyric acid (GABA) 
(Beddig & Kuehner, 2017; Epperson et al., 2012). However, biological factors do not 
seem sufficient to completely illuminate the etiology of premenstrual disorders (cf. 
Eggert, Witthöft, Hiller, & Kleinstäuber, 2016). This is illustrated by the fact that, 
although only women of reproductive age are affected and the timing of symptom 
onset and offset is closely related to the menstrual cycle (i.e. increased symptoms 
during the week before menses compared with the week after menses), no 
abnormalities in gonadal steroid function have been identified in women diagnosed 
with PMDD (e.g. Backstrom et al., 2003; Cunningham, Yonkers, O'Brien, & Eriksson, 
2009; Yen et al., 2018). Therefore, recent research suggests that affected women 
show heightened sensitivity to normal hormonal fluctuation during the premenstrual 
phase (cf. Cunningham et al., 2009; Hantsoo & Epperson, 2015). In this context, a 
phase-specific altered sensitivity to the gamma-aminobutyric acid (GABAA) receptor 
agonist effect of allopregnanolone has been proposed for PMDD (Backstrom et al., 
2014; Hantsoo & Epperson, 2015; Timby et al., 2016). The neuroactive steroid 
progesterone metabolite allopregnanolone enhances GABAergic transmission and 
confers sedative effects during times of stress (Hantsoo & Epperson, 2015). One 
study demonstrated alterations in allopregnanolone reactivity towards stress in 
women with PMDD (Girdler, Straneva, Light, Pedersen, & Morrow, 2001). Given 
these findings on allopregnanolones and GABAs potential role in PMDD 
pathophysiology, recent research provides preliminary evidence that targeting 
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allopregnanolone could potentially improve PMDD treatment (Bixo et al., 2017; 
Martinez et al., 2016).   
Up to date, various experts agree upon a multifactorial genesis, which integrates 
multiple biological, psychological, environmental and social aspects (cf. Beddig & 
Kuehner, 2017; Epperson et al., 2012; Kleinstauber, Witthoft, & Hiller, 2012). In this 
regard, it is suggested that psychological factors interact with hormonal changes 
during the menstrual cycle to produce clinical distress and functional impairment 
(Beddig & Kuehner, 2017; Craner, Sigmon, & Martinson, 2015; Eggert et al., 2016; 
Saglam & Basar, 2019). In order to better understand and identify such interactions, 
research examining associations between vulnerability factors and premenstrual 
symptomatology among women with and without PMDD can contribute important 
knowledge to the psychobiological framework. While existing research points towards 
an imbalanced stress system as a possible mechanism underlying the pathogenesis 
of PMDD (Owens & Eisenlohr-Moul, 2018; Parry, Javeed, Laughlin, Hauger, & 
Clopton, 2000), its contribution to significant premenstrual distress remains unclear 
and methodologically well-designed investigations of subjective and endocrinologic 
stress responses are warranted. Furthermore, future research should also shift more 
towards the role of psychological factors in PMDD. Dysfunctional cognitions such as 
rumination have been found to trigger negative emotions in various psychiatric 
disorders (Lyubomirsky, Layous, Chancellor, & Nelson, 2015; Nolen-Hoeksema & 
Watkins, 2011; Nolen-Hoeksema, Wisco, & Lyubomirsky, 2008), but there is a 
paucity of studies assessing their role in PMDD. In the present thesis, we therefore 
focus on evaluating subjective and endocrinological stress responses as well as on 
the role of cognitive processes as potential mechanisms involved in PMDD. 
1.3.1 Subjective stress perception and stress responses 
Numerous studies have documented that higher levels of subjective and objective 
stress are associated with severe premenstrual symptoms (e.g. Gollenberg et al., 
2010; Owens & Eisenlohr-Moul, 2018). This is supported by a large number of cross-
sectional studies showing that PMDD deteriorates with stressful life events (Huang, 
Zhou, Wu, Wang, & Zhao, 2015; Klatzkin, Lindgren, Forneris, & Girdler, 2010) and 
that work stress is associated with more severe premenstrual symptoms (Namavar 
Jahromi, Pakmehr, & Hagh-Shenas, 2011). Furthermore, women with severe 
premenstrual symptoms experience more stress (Kleinstauber et al., 2016; Lustyk, 
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Widman, Paschane, & Ecker, 2004). In addition, longitudinal studies show that early 
sexual abuse, exposure to domestic violence, and other traumata lead to an 
increased risk of developing PMDD (Perkonigg, Yonkers, Pfister, Lieb, & Wittchen, 
2004; Wittchen, Perkonigg, & Pfister, 2003). Therefore, PMDD is regarded as a 
stress-related condition.  
With regard to a possible heightened stress perception, it further remains unclear 
whether women with PMDD show respective alterations throughout the menstrual 
cycle or if elevated stress appraisal is limited to the symptomatic premenstrual 
phase. Initial results from two earlier studies point towards a cycle-related negative 
bias. Fontana and Badawy (1997) showed that affected women perceived events as 
more severe and unpleasant solely during the premenstrual phase. Brown and Lewis 
(1993) identified an association of premenstrual symptoms with more hassles and 
fewer uplifts in the premenstrual compared with the postmenstrual phase. 
Unfortunately, more recent studies allowing to identify cycle-related variations in 
stress perception in women with PMDD are lacking. Furthermore, there is a lack of 
studies assessing reactivity to daily life stressors in PMDD research. Such 
momentary stress responses might express themselves through momentary affect 
and cognitions (e.g. rumination, self-focused attention). The first evidence of 
increased cognitive stress-reactivity comes from an experimental study by Craner et 
al. (2015) showing that women with PMDD demonstrated increased self-focused 
attention toward a standardized laboratory stressor. In order to assess affective 
stress reactivity in PMDD, it seems fruitful to differentiate between specific mood 
facets. According to the circumplex affect model (Russell, 1980), a subdivision of 
affect can be made based on the degree of arousal states, which have also been 
found to be related to different cortisol patterns (Hoyt et al. 2015). Since 
epidemiological and clinical studies have shown that anger and irritability are the 
most prominent premenstrual symptoms above depression (Hantsoo & Epperson, 
2015; Owens & Eisenlohr-Moul, 2018; Pearlstein, Yonkers, Fayyad, & Gillespie, 
2005), women with PMDD might respond to stress situations especially with high 
arousal negative affect states such as being upset or irritated, which may further 
contribute to interpersonal conflicts. 
Given the currently limited state of research, it is likely that women with PMDD show 
heightened stress perception and stress reactivity in the premenstrual phase of the 
menstrual cycle. In light of increased high arousal symptoms in PMDD, premenstrual 
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stress may lead to high arousal negative affect states in particular. Studies in daily 
life could contribute important knowledge on the role of potential mechanisms 
associated with increased stress perception. From a therapeutic standpoint, a clearer 
understanding of such stress-related characteristics might then allow more targeted 
interventions aimed at reducing the impact of stress experiences.  
1.3.2 Basal and stress-related endocrinologic patterns  
Given findings of heightened stress sensitization in PMDD, there has been an 
interest in possible alterations of the hypothalamic-pituitary-adrenal axis (HPAA) 
system. In this regard, it is thought that the reported increased stress experience in 
affected women might be the result of an altered neurobiological system leading to 
changes in normal HPAA activity (cf. Kleinstauber et al., 2016). Controlled by 
GABAergig signaling (Maguire, 2019), activation of the HPAA due to stress 
perception typically leads to increased cortisol release (Nader, Chrousos, & Kino, 
2010). Respectively, the response of the HPAA to an acute stressor is considered as 
an important biomarker indicating individual stress regulation. 
The phenomenon of HPAA dysregulation has been described for a variety of stress-
related disorders and chronic illness conditions, such as posttraumatic stress 
disorder, bodily disorders or depression (Adam et al., 2017; Doane et al., 2013; Heim 
et al., 2000). Thus, altered HPAA function might not be symptom specific, but may 
rather reflect a generally impaired recovery. Following this reasoning, it is proposed 
that prolonged stress periods elicit enhanced activation of the HPAA, which may 
eventually result in a downstream effect in the long run, leading to blunted activity of 
the HPAA and attenuated responsiveness to stressors (Huang et al., 2015; Adam et 
al., 2017). 
PMDD shows significant comorbidity and considerable symptom overlap (i.e. 
irritability, mood lability, depression, anxiety) with other stress-related conditions (e.g. 
Pilver, Levy, Libby, & Desai, 2011), pointing towards a possible spectrum of stress-
related disorders with similar endocrinologic characteristics. However, studies 
investigating basal and reactive cortisol secretion in women with PMDD are scarce 
and preliminary empirical findings on possible alterations in cortisol patterns are 
mixed. 
A review study by Kiesner and Granger (2016), on 39 studies assessing basal and 
stress-related cortisol secretion across different study types including correlational 
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studies, environmental challenge studies and pharmacological challenge studies, 
revealed no clear picture concerning whether HPAA alterations are indicative for 
PMDD, with the predominance of studies showing null effects. Unfortunately, the 
review is limited in its generalizability due to the lack of a clear distinction between 
women suffering from PMS and those with more severe PMDD with obligatory 
affective symptoms. This is troubling because other studies indicate that women with 
PMDD may differ from those with PMS regarding physiological stress patterns, 
suggesting that only the former show a pronounced and sustained imbalance of the 
HPAA (Hoyer et al., 2013; Odber, Cawood, & Bancroft, 1998).  
A first line of research has focused on basal HPAA activity. Hoyer et al. (2013) found 
a premenstrual increase in basal cortisol levels in women with mild premenstrual 
symptoms, proposing that this could represent a physiological and healthy response 
to subjective stress caused by monthly mood changes. By contrast, in women with 
PMDD a reverse pattern was identified by Odber et al. (1998), who showed a 
premenstrual decrease in basal cortisol levels. These studies suggest that a 
compensation mechanism is still intact in women with less severe premenstrual 
symptoms, whereas it could be impaired in patients suffering from PMDD, thereby 
emphasizing the importance of distinguishing between PMS and PMDD. 
A second research line has investigated HPAA activity in response to stress. 
Preliminary data from laboratory settings lend support towards blunted 
endocrinologic stress reactivity in women with premenstrual disorders. An 
experimental study by Huang et al. (2015) – again by including women with PMS and 
PMDD – revealed attenuated cortisol reactivity in affected women irrespective of the 
menstrual cycle phase. Similarly, Klatzkin and colleagues (2010) found reduced 
physiological stress reactivity (blood pressure, heart rate) in women suffering from 
premenstrual symptoms in response to an experimental stressor, regardless of 
whether these women had a history of depression. Correspondingly, in a subsequent 
study the authors demonstrated that the extent of dysregulation in HPAA responses 
to a standardized stressor predicted stronger symptoms in affected women (Klatzkin, 
Bunevicius, Forneris, & Girdler, 2014). 
Following the reported observations, a blunted HPAA activity may characterize a 
possible mechanism underlying heightened subjective stress reactivity in women with 
PMDD (cf. Owens & Eisenlohr-Moul, 2018). In line with this theory, results from a 
non-clinical study by Het et al. (2012) point to a possible mood-buffering effect of 
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cortisol. In this study, lower cortisol levels in response to acute stressors were linked 
to higher levels of negative affect, suggesting that cortisol buffers emotional arousal 
in stressful situations, possibly by inhibiting autonomic stress reactions. 
Correspondingly, cortisol is regarded as a stress buffer normalizing emotional circuits 
(Schlotz et al., 2008).  
In summary, a detailed investigation of basal and stress-reactive components of 
HPAA activity during daily life appears crucial to understand its role in PMDD. First 
experimental studies provide weak support for blunted HPAA activation combined 
with heightened subjective stress reactivity in women with PMDD (cf. Owens & 
Eisenlohr-Moul, 2018). However, the findings are scarce and remain mixed. The 
observed heterogeneity may partly be the result of a lack of differentiation between 
PMDD and the less severe PMS, the latter lacking clearly defined criteria. This 
differentiation is considered particular important for determining potential 
physiological mechanisms (Hoyer et al., 2013). In this regard, studies applying more 
rigorous PMDD inclusion criteria combined with frequent measures of cortisol 
parameters throughout the menstrual cycle appear ideally suited to shed more light 
on a possible HPAA dysfunction in PMDD. 
1.3.3 Psychological processes 
Considering the high comorbidity and symptom overlap with other unipolar mood 
disorders (Cohen et al., 2002), anxiety disorders (D. R. Kim et al. 2004; Landen & 
Eriksson, 2003; Perkonigg et al., 2004) and somatoform disorders (Angst, Sellaro, 
Merikangas & Eriksson, 2003), but also with bipolar disorders (Fornaro & Perugi, 
2010; D. R. Kim et al., 2004), as well as the increased risk of women with PMDD 
developing postpartum depression (Buttner et al., 2013), research on shared 
vulnerability factors is warranted. As PMDD is defined by a strong emphasis on 
affective symptoms, the possible contribution of dysfunctional cognitions and 
behaviors in response to premenstrual emotional states holds particular interest. In 
this context, rumination, anxiety sensitivity or dysfunctional coping strategies such as 
avoidance are being discussed (Craner, Sigmon, Martinson, & McGillicuddy, 2014). 
In particular, rumination has received attention as a transdiagnostic factor within the 
last decade. It is conceptualized as a thought process that includes persistent and 
repetitive thinking about one’s negative mood and other negative aspects of oneself 
(Lyubomirsky et al., 2015; Nolen-Hoeksema et al., 2008). Aggravating effects of 
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rumination on negative mood have been identified in several mental disorders 
including affective, anxiety and eating disorders (Aldao & Nolen-Hoeksema, 2010; 
McLaughlin & Nolen-Hoeksema, 2011; Michl, McLaughlin, Shepherd, & Nolen-
Hoeksema, 2013). In depressed patients, ruminative thinking is associated with the 
onset of depressive episodes (Nolen-Hoeksema, 2000) and a chronic symptom 
course (Struijs, Lamers, Spinhoven, van der Does, & Penninx, 2018). There is 
evidence that especially women tend to use more ruminative coping strategies than 
men, which partly accounts for the gender gap in depression rates (Kuehner, 2017). 
Research aimed at assessing such phenomena in PMDD would significantly 
enhance our understanding of which cognitive processes might serve as triggers for 
cycle-related mood symptoms. However, only a handful of PMDD studies to date 
have explored characteristics such as ruminative thinking or self-focused attention. In 
this regard, it has been suggested that while self-focussing on cycle-related changes 
represents a dysfunctional strategy to deal with premenstrual symptoms (cf. Craner, 
Sigmon, & Young, 2016), a mindful state of mind may be a protective factor buffering 
from aggravating effects on PMDD symptoms (cf. Lustyk, Gerrish, Shaver, & Keys, 
2009).  
Indeed, this is supported by initial evidence from between-person studies: 
dispositional brooding rumination was heightened in women with premenstrual 
disorders (Craner et al., 2014) and associated with steeper increases in premenstrual 
depressive symptoms (Dawson et al., 2018), whereas high habitual mindfulness 
appeared to be linked to less cycle-related symptoms (Lustyk, Gerrish, Douglas, 
Bowen, & Marlatt, 2011). A daily life study across the menstrual cycle in a non-
clinical sample of women demonstrated that high trait ruminators showed increased 
levels of momentary irritability towards the end of the cycle, whereas women low in 
habitual rumination experienced a more positive mood on these days (Welz et al., 
2016). Similarly, Sigmon, Schartel, Hermann, Cassel, and Thorpe (2009) 
investigated the impact of rumination and anxiety sensitivity on distress from 
premenstrual symptoms in a non-clinical sample, demonstrating that rumination 
mediated the relationship between anxiety sensitivity and premenstrual distress.  
In contrast to the aforementioned literature on trait aspects of dysfunctional 
cognitions based on self-report questionnaires, there is a lack of PMDD research 
examining relationships between cognitive processes and premenstrual distress at 
the within-person level. Only one study to date has assessed the relationship 
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between momentary psychological processes and PMDD. In this study, women with 
PMDD showed increases in self-focused attention during the premenstrual week, 
which partially explained the degree of premenstrual mood changes (Craner et al., 
2016).  
To conclude, in light of significant findings from previous studies assessing trait-like 
aspects of rumination (e.g. Craner et al., 2014, 2015) and transdiagnostic evidence 
of rumination as a dysfunctional key mechanism in various psychopathologies 
(Lyubomirsky et al., 2015; Nolen-Hoeksema et al., 2008), the investigation of 
dysfunctional cognitive states in PMDD women may help to identify menstrual cycle-
related or trait-like psychological mechanisms associated with the disorder. In this 
context, it would be interesting to further explore whether trends from between-
person studies are also evident at the level of individual persons. In this regard, 
within-person changes in daily-life cognitions may serve as drivers for PMDD 
symptom severity. Consequently, it is likely that negative affect is reinforced during 
the premenstrual phase by a maladaptive tendency to react with ruminating thoughts 
(cf. Craner et al., 2014, 2015). Surprisingly, no PMDD study to date has examined 
whether mood worsening and momentary dysfunctional cognitions reinforce each 
other in daily life. If so, accounting for such effects in PMDD treatment could be an 
important step towards improved therapeutic strategies. 
1.4 Therapeutic options  
Several therapeutic approaches have been discussed for premenstrual symptoms, 
ranging from modifying serotonin transmission to suppressing ovulation and 
improving coping skills via psychotherapy.  
In this context, SSRIs (selective serotonin reuptakte inhibitors, e.g. fluoxetine, 
paroxetine, citalopram) are seen as the first line treatment by numerous experts (e.g. 
Hantsoo & Epperson, 2015; Ismaili et al., 2016; Sepede, Sarchione, Matarazzo, Di 
Giannantonio, & Salerno, 2016). Emerging evidence of their efficacy is provided by 
several meta-analyses (Marjoribanks, Brown, O'Brien, & Wyatt, 2013; Shah et al., 
2008). For instance, the most recent Cochrane review by Marjoribanks et al. (2013) 
including 31 RCTs showed that the administration of SSRIs was effective for 
symptom relief. In addition, the review identified that SSRIs have almost the same 
effects when administered continuously or intermittently limited to the luteal phase. 
However, this review again did not differentiate between PMDD and other 
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premenstrual complaints such as PMS. The positive response to SSRIs does not 
appear to reflect a general antidepressant effect. Other antidepressants (i.e. tricyclic 
antidepressants, noradrenergic antidepressants) which are effective in women with 
Major Depressive Disorder have been found to be no more effective than placebo in 
women with PMDD (Cunningham et al., 2009; Nevatte et al., 2013).  
Of particular note, both the rapid onset of action of SSRIs which is considered as a 
prerequisite for intermittent treatment (Marjoribanks et al., 2013) as well as the 
lacking efficacy of augmenting noradrenergic activity alone (Cunningham et al., 2009) 
may imply that different mechanisms underlie the efficacy of SSRIs for PMDD 
compared with Major Depression (cf. Yonkers & Simoni, 2018). This lends support to 
the view that PMDD and Major Depression should be seen as distinct clinical entities, 
an issue that should certainly be investigated in further detail in future research.  
Since symptoms appear cycle-related with occurrence in the premenstrual phase and 
absence in anovulatory cycles, suppression of ovulation and hence inhibiting the 
luteal phase is a popular choice to relieve premenstrual symptoms (Rapkin et al., 
2005). A meta-analysis on hormonal replacement therapy including five RCTs and 
involving 1,920 women with PMS and PMDD reported promising effects for ovulation 
inhibitors, even though studies showed high dropout rates (Lopez, Kaptein, & 
Helmerhorst, 2012). Furthermore, some evidence suggests that ovulation inhibitors 
appear to primarily improve physical rather than mood-related symptoms (Joffe, 
Cohen, & Harlow, 2003; Rapkin, 2005).  
Novel therapeutic interventions in pharmacologic treatment regarding options that 
impact the HPAA via modulation of allopregnanolone and GABAergic function show 
promising effects. A study by Martinez et al. (2016) demonstrated that stabilization of 
allopregnanolone levels from the follicular to the luteal phase of the menstrual cycle 
is useful to treat women with PMDD, and another explorative study by Bixo et al. 
(2017) indicated positive results for a GABAA modulating antagonist to 
allopregnanolone (Sepranolone) as a potential treatment in the premenstrual phase. 
Despite the reported beneficial effects of drug treatment, it is supposed that more 
patients prefer non-pharmaceutical options due to large rates of potential adverse 
side effects (e.g. nausea, decreased energy, sexual dysfunction) (Kleinstauber et al., 
2012; Ussher & Perz, 2017). A treatment alternative could be cognitive-behavioral 
therapy (CBT), which may include self-monitoring, modification of irrational thinking, 
and increasing coping strategies or relaxation strategies (Busse, Montori, Krasnik, 
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Patelis-Siotis, & Guyatt, 2009; Nevatte et al., 2013). However, compared to 
pharmacotherapeutic options, these approaches have not been investigated in 
comparable detail, and only a small number of RCTs have investigated CBT in 
women with cyclically recurring symptoms. Evidence of clinical efficacy has been 
shown in an experimental study by Hunter et al. (2002), who compared CBT, 
fluoxetine (SSRI), and combined treatment with CBT and fluoxetine. The authors 
found no differences between groups after six months, although CBT had superior 
long-term maintenance effects at one-year follow-up. The latter holds particular 
importance given the chronic course of the disorder. Two review studies conducted 
meta-analyses of RCTs on cognitive-behavioral interventions using n=22 
(Kleinstauber et al., 2012) and n=9 studies (Busse et al., 2009). Both reviews provide 
evidence of symptom relief via psychotherapy. Unfortunately, findings on women with 
PMDD and PMS were again pooled together. 
In Germany, a research group from Philipps University Marburg focuses on 
developing and evaluating therapeutic strategies for patients suffering from severe 
premenstrual symptoms. A study by Janda, Kues, Kleinstaeuber, and Weise (2015) 
presents a newly-developed modularized treatment approach comprising different 
modules. It involves psychoeducation, cognitive interventions on dysfunctional 
cognitions, strategies to change dysfunctional behaviors, and targeting lifestyle 
issues. Another recent study by this research group evaluated the efficacy of an 
eight-week internet-based cognitive-behavioral therapy in PMDD treatment (Weise et 
al., 2019). The authors showed that the manualized internet-based therapy was 
highly effective in reducing the burden of PMDD, even after six months. Thus, it may 
offer treatment for a greater number of women due to its internet-based design. The 
study also highlights the importance of addressing coping strategies in PMDD 
treatment by showing that the use of active coping resulted in improved outcomes. 
Nonetheless, the question of which specific components of the numerous included 
psychotherapy modules in this study hold relevance to reduce premenstrual distress 
remains unanswered. 
Taken together, there is a paucity of studies assessing factors that may be relevant 
for therapy. Given the limited empirical evidence for PMDD treatments, the German 
National Disease Management Guideline does not provide evidence-based 
recommendations regarding the efficacy of pharmacological and psychological 
treatments (DGPPN et al., 2017). In this context, earlier studies suffer from a lack of 
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distinction between PMS and PMDD, high placebo response rates as well as missing 
follow-up assessments (cf. Beddig & Kuehner, 2017). Notwithstanding these caveats, 
results from initial research on CBT lend support to the notion that interventions 
addressing active coping strategies in terms of seeking positive-affect-inducing 
activities might be helpful. Here, more research on the core group of women with 
PMDD is needed to confirm clinical efficacy, and further research on potential 
mechanisms (e.g. stress appraisal and the interplay between affective and cognitive 
processes) that can be translated into optimizing therapy outcomes is clearly 
warranted. In order to intervene and further reduce the burden of PMDD, it is also 
worthwhile to determine how these characteristics might predict the clinical symptom 
course. 
1.5 Ambulatory Assessment 
1.5.1 Ambulatory Assessment as an innovative approach to study the role of 
psychological daily-life processes in women with PMDD 
Ambulatory Assessment (AA) is seen as an innovative methodology offering insights 
into daily-life experiences (J. Kim, Marcusson-Clavertz, Yoshiuchi, & Smyth, 2019; 
Myin-Germeys et al., 2018; Trull & Ebner-Priemer, 2014). This method allows 
recurrent and systematic recordings of momentary subjective experiences outside 
the laboratory in daily living environments and has increasingly provided new insights 
to the understanding of the etiology and expression of mental disorders (Myin-
Germeys et al., 2018). Over the last decade, with the release of smartphones and 
tablets, AA has been increasingly applied in many fields of research (cf. Brietzke et 
al., 2019; J. Kim et al., 2019). For example, to date there are reviews on AA studies 
on mood (aan het Rot, Hogenelst, & Schoevers, 2012; Brietzke et al., 2019), anxiety 
(Walz, Nauta, & Aan Het Rot, 2014), and eating disorders (Haedt-Matt & Keel, 2011). 
In contrast, no previous study has used an electronic AA design to study PMDD, 
although this has been repeatedly called for by different experts in the field (e.g. 
Bosman, Jung, Miloserdov, Schoevers, & aan het Rot, 2016; Craner et al., 2014; 
Owens & Eisenlohr-Moul, 2018).  
An AA study design offers important advantages over retrospective ratings. Benefits 
include minimizing the recall bias of self-reports (Carpenter, Wycoff, & Trull, 2016; 
Trull & Ebner-Priemer, 2014), increasing generalizability and ecological validity 
(Brietzke et al., 2019; Trull & Ebner-Priemer, 2013), verifying the correct timing of 
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data collection through automatically time-stamped responses (Trull & Ebner-
Priemer, 2013) and advanced statistical power through the application of 
sophisticated analysis methods such as multilevel modeling (Carpenter et al., 2016). 
A further important advantage of AA studies is their ability to capture both variability 
between and variability within individuals (cf. Hamaker & Wichers, 2017; Schlotz, 
2019). In contrast, within-person variability is difficult to impossible to assess with 
traditional retrospective measures (Hamaker, 2012). In PMDD research, this is 
particularly important given that mood swings belong to the core symptoms of the 
disease. Nonetheless, existing studies typically rely on single assessments using 
daily diaries or questionnaires (e.g. Cohen et al., 2004; Freeman, Sammel, Lin, 
Rickels, & Sondheimer, 2011; Schmalenberger et al., 2017). In this regard, AA with 
multiple real-time assessments per day at unpredictable intervals appears to be 
superior for a more specific detection of symptoms and symptom variability, which 
may not be seen via retrospective reports (cf. Brietzke et al., 2019). Moreover, AA 
data collection enables the coverage of the entire menstrual cycle. Given the cyclic 
nature of PMDD symptoms, this seems to be particularly helpful for research on 
menstrual cycle-related changes. Only by doing so is it possible to compare different 
cycle phases within the same woman. Furthermore, when tracking women over 
different cycle phases, researchers can identify both characteristics occurring only in 
the late luteal phase and those observable throughout the whole cycle. The latter 
might then indicate trait-like characteristics. Finally, while in laboratory conditions it is 
difficult to study reciprocal relationships across time, AA measures allow for an 
advanced modeling of temporal relationships within individuals, e.g. from moment to 
moment (cf. Garland, Geschwind, Peeters, & Wichers, 2015; Walz et al., 2014). For 
instance, former studies with other clinical samples (e.g., patients with depression 
and generalized anxiety disorder) investigated prospective effects of cognitive states 
on subsequent levels of mood and vice versa (Kircanski, Thompson, Sorenson, 
Sherdell, & Gotlib, 2018; Ruscio et al., 2015).  
These aforementioned factors clearly point to the need for well-designed longitudinal 
AA studies covering the course of the menstrual cycle, thereby being able to explore 
within-person associations in the context of PMDD. 
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1.5.2 AA as a research methodology to study cortisol secretion 
AA designs yield opportunities for multimodal assessment due to the integration of 
psychological, physiological and behavioral data (cf. Kubiak & Stone, 2012; Schlotz, 
2019; Trull & Ebner-Priemer, 2014; van Os et al., 2017). In the context of stress 
research, it facilitates the collection of non-invasive saliva cortisol during the flow of 
daily life, which is considered an important marker of HPAA functioning (Schlotz, 
2019; Trull & Ebner-Priemer, 2013). Therefore, it allows tying objective measures of 
cortisol with subjective momentary daily-life experiences. For instance, an AA study 
by Huffziger et al. (2013) explored whether the daily life cortisol pattern in remitted 
depressed persons would differ from healthy controls. The authors found that 
increased levels of rumination were linked to higher cortisol activity over the day in 
both groups, whereas lower mood predicted higher cortisol levels only in healthy 
controls. By using AA as a research tool to assess cortisol levels, former studies 
have reached good compliance rates, suggesting that the repeated collection of 
salivary cortisol while undergoing daily routine appears not to be problematic (e.g. 
Huffziger et al., 2013; Smyth, Zawadzki, Juth, & Sciamanna, 2017).  
Different standard cortisol parameters have been widely used and can be assessed 
by self-collected saliva samples during AA (e.g., see Beddig, Timm, et al., 2019). 
First, the size of the post-awakening cortisol increase – a phenomenon termed 
cortisol awakening response (CAR) – is a key parameter for 
psychoneuroendocrinologic research (Stalder et al., 2016). Cortisol increases 
immediately after awakening and peaks within the first 30-45 min thereafter 
(Boggero, Hostinar, Haak, Murphy, & Segerstrom, 2017; Kudielka, Gierens, 
Hellhammer, Wüst, & Schlotz, 2012). Both increased and blunted CAR have been 
associated with a wide range of pathologies, so deviations from a typical CAR pattern 
are assumed to mark maladaptive neuroendocrine processes (Adam & Kumari, 
2009; Stalder et al., 2016). Second, frequent sampling over the day allows for the 
accurate construction of the diurnal cortisol slope. Cortisol output follows a marked 
circadian pattern with a decline from morning to evening, reaching the lowest point 
near midnight (Schlotz, 2011). A flatter diurnal cortisol slope – indicated by a slower 
rate of decline in cortisol across the day – has been linked to poor health outcomes 
and to stress-related disorders (cf. Adam et al., 2017). Third, in addition to 
investigations of basal HPAA activity, AA also enables capturing cortisol responses 
following real-life stressors. In particular, while stress tasks in laboratory settings 
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represent rather artificial situations, assessing cortisol in response to daily life 
stressors might have more ecological validity (cf. Vaessen et al., 2018). Cortisol 
peaks typically follow stressful events or negative emotional states with a lag of 
approximately 10-20 min (Schlotz et al., 2008), whereby delaying the signal for 
collection of the saliva probes by approximately 15 min is recommended (Schlotz, 
2019). Accordingly, AA allows analyzing individual cortisol responses towards within-
person increases of daily-life stress. Interestingly, while there is emerging research 
on aggregated cortisol measures in various mental disorders, there has been little 
respective research exploring within-person stress-cortisol associations (Schlotz, 
2019). Similarly, the already mentioned recent review on cortisol in premenstrual 
disorders by Kiesner & Granger (2016) stresses the need for such within-person 
analyses on multiple parameters of cortisol regulation. In fact, although existing 
literature suggests that women with PMDD show increased subjective sensitivity to 
stress (Owens & Eisenlohr-Moul, 2018), no study to date has investigated how 
subjective experiences during daily life relate to HPAA function in affected women. In 
order to study such phenomena in detail, a well-designed AA approach is most 
appropriate. 
1.5.3 Investigation of AA phenotypes for the prediction of the clinical course of 
PMDD 
The combination of multiple assessments of daily-life experiences at the micro-level 
using AA and illness-related factors measured at the macro level over longer term 
intervals has recently been regarded as a promising approach to explore mental 
disorders (Barnett et al., 2018; Brietzke et al., 2019; Wichers, 2014).  
Clinical studies have investigated the role of respective AA-derived so called 
“experience sampling phenotypes” as predictors of the clinical course of depression 
(Timm et al., 2017; Wichers et al., 2010), anxiety disorders (Adam et al., 2014) and 
schizophrenia (Barnett et al., 2018). In a study by Timm et al. (2017) it was shown 
that higher instability of daily life mood and rumination predicted recurrence and 
symptom levels of depression three years after baseline. Similarly, Wichers et al. 
(2010) found that reward experience and daily-life fluctuations in negative affect 
significantly improved the prediction of future depressive and anxiety symptoms after 
more than one year. Adam et al. (2014) provided first evidence of a prospective 
relation between HPAA functioning, assessed on three consecutive weekdays, and 
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first onsets of anxiety disorders over the subsequent six years. Furthermore, Barnett 
et al. (2018) identified higher rates of AA-derived behavioral abnormalities in the days 
before relapse in patients diagnosed with schizophrenia.  
By contrast, AA characteristics have not been investigated so far as potential micro-
level predictors for the clinical course of PMDD. This holds particular importance 
given that previous research has shown that PMDD frequently develops a chronic 
course. For instance, in a German community sample, Wittchen et al. (2002) 
demonstrated that the syndrome was stable across 48 months with less than 10% 
complete remissions among baseline cases. In light of the apparent unfavorable 
long-term course of PMDD, the assessment of the predictive value of experience 
sampling phenotypes for the clinical course of PMDD is important and may help to 
develop target treatments. 
1.6 Research questions 
At present, there is a surprising lack of research assessing subjective and 
endocrinologic processes in the natural environment of women with PMDD. We 
addressed this limitation by implementing an electronic AA study design. The 
following three substudies of the thesis are based on an overarching AA study 
“Menstrual cycle-dependent variations in mood, rumination, and cortisol in women 
with and without Premenstrual Dysphoric Disorder: An Ambulatory Assessment 
study” which was funded by the Deutsche Forschungsgemeinschaft (DFG KU1464/6-
1). The AA approach enabled us to study momentary experiences and cortisol 
secretion in the flow of daily life and to compare respective temporal within-person 
processes and their interplay across the menstrual cycle in women with and without 
PMDD, as well as to investigate the predictive value of daily life characteristics (i.e., 
AA-related phenotypes) for the clinical course of PMDD. The study aims and 
hypotheses of the present thesis were as follows. 
 
Study 1 
Specifically, Study 1 aimed to examine stress-related facets of mood and cognitions 
together with basal and stress-related HPAA activity over the menstrual cycle in 
women with PMDD compared to non-affected women. With regard to previous 
research showing that PMDD exacerbates with stressful life events (cf. Beddig & 
Kuehner, 2017) and that PMDD women exhibit higher levels of stress perception 
Introduction 
27 
(Owens & Eisenlohr-Moul, 2018), it was hypothesized that affected women would be 
more sensitive towards daily life stressors and would react with increased levels of 
rumination and negative affect, particularly in the premenstrual phase. We further 
investigated whether women with PMDD would demonstrate altered cortisol patterns 
and if these alterations would be cycle-phase specific. There is initial indication that 
PMDD women show blunted basal and stress-reactive HPAA function (Owens & 
Eisenlohr-Moul, 2018; Huang et al., 2015; Klatzkin et al., 2014). Hence, consistent 
with these prior reports, we expected attenuated basal (cortisol awakening response 
(CAR) and diurnal slope) as well as blunted stress-reactive cortisol activity in affected 
women compared to asymptomatic controls across the menstrual cycle.  
 
Study 2 
In Study 2, we explored menstrual cycle-related variations of cognitive and affective 
daily-life states as well as time-lagged associations between these states. With 
regard to the cyclical pattern of clinical symptoms (APA, 2013), we expected that 
women with PMDD would report highest levels of negative affect and rumination and 
lowest positive affect and self-acceptance in the premenstrual phase. Furthermore, 
following findings from studies with other clinical samples (e.g. Kircanski et al., 2018; 
Ruscio et al., 2015), we hypothesized that PMDD would be linked to stronger 
prospective effects between within-person changes in rumination and negative affect, 
and between within-person changes in self-acceptance and positive affect states. 
Furthermore, in women with PMDD these reciprocal time-lagged relationships were 
expected to be strongest in the late luteal phase.  
 
Study 3 
Study 3 focused on the role of specific AA phenotypes within the framework of 
longitudinal research on PMDD, which is to date generally lacking. Specifically, it 
aimed to investigate the possible predictive value of affective, cognitive, and 
endocrinologic daily-life characteristics for the clinical course of PMDD. For this 
purpose, we conducted a four-month follow-up to examine whether AA 
characteristics measured at baseline would add value in predicting the clinical 
symptom course in PMDD women. Here, we assumed that adverse affective and 
cognitive states, low cortisol levels, and heightened subjective and endocrinologic 
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stress reactivity during daily life at baseline would predict a poor clinical symptom 
course over and above relevant demographic and clinical characteristics.  
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2 STUDY 1: STRESS, MOOD, AND CORTISOL DURING DAILY LIFE 
IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER 
(PMDD) 
An adapted version of this chapter has been published as: „Beddig, T., Reinhard, I., 
& Kuehner, C. (2019). Stress, mood, and cortisol during daily life in women with 
Premenstrual Dysphoric Disorder (PMDD). Psychoneuroendocrinology, 109, Article 
104372. DOI: 10.1016/j.psyneuen.2019.104372. Epub 2019 Jul 23.” 
2.1 Abstract 
Premenstrual Dysphoric Disorder (PMDD) is characterized by significant emotional, 
physical and behavioral distress during the late luteal phase that remits after menses 
onset. Outlined as a new diagnostic category in DSM-5, the mechanisms underlying 
PMDD are still insufficiently known. Previous research suggests that PMDD 
exacerbates with stressful events, indicating a dysregulation of the hypothalamic-
pituitary-adrenal axis. However, studies measuring stress-related processes in 
affected women in real-time and real-life are lacking. We conducted an Ambulatory 
Assessment (AA) study to compare subjective stress reactivity together with basal 
and stress-reactive cortisol activity across the menstrual cycle in women with and 
without PMDD. Women with current PMDD (n=61) and age- and education matched 
controls (n=61) reported momentary mood, rumination, and daily events via 
smartphones at semi-random time points 8 times a day over two consecutive days 
per cycle phase (menstrual, follicular, ovulatory, and late luteal). Twenty minutes 
after assessments participants collected saliva cortisol samples. Three additional 
morning samples determined the cortisol awakening response (CAR). Women with 
PMDD reported particular high daily life stress and high arousal negative affect 
(NAhigh) towards stressors during the late luteal phase. High momentary stress levels 
were linked to lower levels of high arousal positive affect (PAhigh) and to higher levels 
of rumination in PMDD women compared to controls irrespective of cycle phase. 
Across groups, more stress was linked to higher levels of low arousal NA (NAlow) and 
to lower levels of low arousal PA (PAlow). Moreover, PMDD was associated with a 
delayed CAR peak and a flattened diurnal cortisol slope. While neither group showed 
cortisol reactivity towards daily life stress directly, high momentary NAhigh and low 
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momentary PA predicted high levels of cortisol across groups, whereas high 
momentary rumination predicted high cortisol output only in healthy women. In this 
AA-study we identified important stress-related psychological and endocrinological 
within-person variability in women with PMDD during daily life. Further research is 
warranted targeting identified AA-based mechanisms to study their predictive role for 
the clinical course of PMDD and to provide evidence-based therapeutic options for 
affected women.   
2.2 Introduction 
2.2.1 Premenstrual Dysphoric Disorder (PMDD) 
Cyclically recurring premenstrual symptoms to a degree that they interfere with 
normal functioning are characteristic for women suffering from Premenstrual 
Dysphoric Disorder (PMDD). Due to particular core symptoms, a specific cycle-
dependent course and high symptom-specific stability, PMDD has been outlined as a 
new diagnostic category in DSM-5 (American Psychiatric Association, APA, 2013). 
Here, PMDD is defined by the occurrence of at least five symptoms in most 
menstrual cycles during the past year such as affective lability, irritability, depressed 
mood, anxiety (at least one of these four), loss of interest, fatigue, feeling emotionally 
overwhelmed and physical symptoms. These symptoms need to occur during the 
week before and to improve shortly after menses onset (APA, 2013). Epidemiological 
research suggests that PMDD affects 3 – 8% of premenopausal women (cf. Beddig & 
Kuehner, 2017). Lifetime comorbidity with other mental disorders, particularly with 
depressive and anxiety disorders is high; more than 50% of women with PMDD 
report a lifetime diagnosis of Major Depressive Disorder (MDD, Cohen et al., 2002).     
2.2.2 Subjective stress responses in PMDD 
The mechanisms underlying PMDD are still insufficiently known, findings indicate a 
multifactorial genesis (Beddig & Kuehner, 2017; Epperson et al., 2012). An important 
factor might be stress. Higher levels of subjective and objective stress were identified 
as risk factors for the onset of PMDD (Perkonigg et al., 2004), PMDD exacerbates 
with stressful life events (Huang et al., 2015), and women suffering from severe 
premenstrual symptoms perceive more chronic stress (Kleinstauber et al., 2016). In 
an earlier study women with severe premenstrual syndromes perceived stressors as 
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more severe and unpleasant than controls premenstrually, but not postmenstrually 
(Fontana & Badawy, 1997). Hoyer et al. (2013) identified higher subjective stress 
perception in the luteal phase in women with premenstrual symptoms during an 
emotional stroop task. Accordingly, PMDD women appear to show enhanced stress 
appraisal especially premenstrually. However, little is known about their stress 
responsivity during daily life, although this is important to determine generalizability 
and ecological validity of lab results and to identify potential mechanisms relevant to 
everyday life that can be targeted by appropriate therapeutic interventions. 
Subjective stress reactivity is mainly operationalized by negative affect (NA) towards 
stressors (Wichers et al., 2009). According to the circumplex affect model by Russell 
(1980), NA and positive affect (PA) can be further subdivided into low and high 
arousal states. Given that anger and irritability are the most prominent premenstrual 
symptoms (Hantsoo & Epperson, 2015; Owens & Eisenlohr-Moul, 2018) the 
distinction of arousal states might especially be important when studying mood states 
in PMDD. While low arousal NA states (NAlow) in response to stress could be more 
common for MDD, women with PMDD might more frequently react to stress 
especially with high arousal NA states (NAhigh) such as being upset or irritated. 
Similarly, the differentiation between positive affect states high (PAhigh) and low in 
arousal (PAlow) has not been addressed in PMDD research to date.  
Furthermore, retrospective research has shown that women with PMDD use less 
helpful coping strategies such as rumination and increased self-focused attention in 
response to stress (Craner et al., 2015; Craner et al., 2014), and deficits in emotion 
regulation strategies were shown to be linked to higher premenstrual symptom levels 
in PMDD women (Dawson et al., 2018). In a similar line we could show that habitual 
rumination moderated menstrual cycle effects on mood in a nonclinical sample, with 
high ruminating women showing increased irritation towards the end of the cycle 
(Welz et al., 2016). In contrast, the possible significance of cognitions in everyday life 
such as state rumination in response to stress has so far been totally neglected in 
PMDD research.      
2.2.3 Basal and stress-reactive cortisol activity in PMDD 
Sustained stressors can cause alterations in the activity of the hypothalamic–
pituitary–adrenal axis (Adam et al., 2017; Zorn et al., 2017), which is tightly controlled 
by GABAergic signaling (Maguire, 2019). Very few studies investigated basal and 
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stress-reactive cortisol activity in women suffering from premenstrual symptoms, and 
these studies normally did not distinguish PMDD from the milder premenstrual 
syndrome (PMS). The cortisol awakening response (CAR) and the diurnal cortisol 
slope (DCS) are the two main indicators measuring basal cortisol activity during the 
day (cf. Adam et al., 2017; Kudielka et al., 2012), whereas cortisol stress reactivity is 
mainly being measured in experimental settings using standardized stressors (cf. 
Zorn et al., 2017). A review by Kiesner and Granger (2016) found no consistent 
evidence for a basal or stress-reactive cortisol dysregulation in women with 
PMS/PMDD. A small number of studies indicated blunted activation across the cycle, 
and there was only modest evidence that affected women would show blunted 
cortisol reactivity toward environmental stressors (Kiesner and Granger, 2016). 
However, included studies used heterogeneous methodology regarding types of 
stressors, cortisol measures and criteria for diagnosis. More recently, Huang et al. 
(2015) found attenuated cortisol activity in women with premenstrual syndromes 
when experiencing an experimental stressor. Taken together, previous studies give 
first but weak support for attenuated basal and reactive HPAA activity during daily life 
in women with PMDD (cf. Owens and Eisenlohr-Moul, 2018). 
2.2.4 Ambulatory Assessment (AA) in PMDD 
Introducing AA into the study of PMDD has been repeatedly called for (e.g. Bosman 
et al., 2016; Owens and Eisenlohr-Moul, 2018) because it has important advantages 
over retrospective approaches. First, due to the multiple real-time assessments recall 
bias is reduced (Trull and Ebner-Priemer, 2013). The latter represents a limitation 
particularly in mere retrospective studies but also in prospective daily rating studies 
when women are asked to summarize their symptoms over the past day (Bosman et 
al., 2016). Furthermore, AA enables to capture the variability of affect, cognitions, 
and physiological states within and across days and cycle phases, thereby allowing 
to study both between- and within person variability (cf. Bosman et al., 2016; Owens 
and Eisenlohr-Moul, 2018; Schlotz, 2019). The present study mainly focuses on 
within-person relations of stress with subjective and cortisol outcomes, thereby 
reflecting for example the extent to which an individual’s negative affect increases 
when appraising stress and whether PMDD and control women differ with this 
regard. Using a longitudinal AA-design that includes all menstrual cycle phases does 
also allow to distinguish between possible state-like alterations in PMDD occurring 
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only in the late luteal phase of the cycle and trait-like alterations occurring throughout 
the whole cycle. Moreover, the more detailed consideration of arousal in the 
assessment of affect states during daily life (cf. Hoyt, Craske, Mineka, & Adam, 
2015) allows to identify possible distinct patterns of reactivity towards minor daily 
stressors within the PMDD context.   
2.2.5 Study aims and hypotheses 
The present study employed AA to examine subjective stress-reactivity together with 
basal and stress-reactive cortisol activity over the menstrual cycle in women with 
PMDD during their everyday life. We expected that women with PMDD would show 
(1) particularly high stress appraisal and (2) large subjective stress reactivity in the 
late luteal phase compared to other cycle phases whereas no such cyclicity was 
expected in healthy women. Particularly, we expected that PMDD women would 
respond to momentary within-person increases in stress with high levels of NAhigh, 
and (3) with high levels of rumination especially in the late luteal phase. We further 
hypothesized that women with PMDD would display a pattern of basal cortisol 
secretion characterized by (4) a flatter CAR, (5) a flatter DCS, and (6) a blunted 
cortisol response to daily life stressors irrespective of cycle phase. As part of the 
stress response we further investigated cortisol responses to facets of momentary 
NA, PA and rumination. Here, we expected that PMDD women would show blunted 
cortisol responses in particular towards high arousal mood states and rumination, 
especially in the late luteal phase. 
2.3 Method 
2.3.1 Participants 
Women with PMDD were recruited using different sources (newspapers, local family 
doctors and gynecologists practices, homepage of the Central Institute of Mental 
Health (CIMH), social networks). After telephone screening, possible eligible women 
underwent a clinical baseline interview to assess study in- and exclusion criteria (see 
2.2). Inclusion criteria were fulfilling the DSM-5 criteria for PMDD A to E using the 
Structured Interview for DSM-IV TR Defined PMDD (SCID-PMDD, Accortt, Bismark, 
Schneider, & Allen, 2011 see 2.3.2.) with the diagnostic algorithm adapted for DSM-
5. To avoid further participant burden, criterion F (prospective daily ratings during at 
Study 1: Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder 
(PMDD) 
34 
least two symptomatic cycles before study inclusion) was not required. In parallel, 
age- and education-matched controls were recruited. Control participants were 
excluded if they met criteria for any affective core symptoms of PMDD (criterion B) 
according to DSM-5 (see 2.3.2.). In contrast, premenstrual physical symptoms were 
not an exclusion criterion, given the fact that the majority of naturally cycling women 
are experiencing physical symptoms of varying degree during the late luteal and 
menstrual phase (Tschudin et al., 2010). Exclusion criteria for both samples included 
unfamiliarity with the German language, age < 20 and > 42, a reported  cycle length 
of < 22 or  > 34 days, a reported variation of cycle length of more than five days,  use 
of hormonal contraceptives, antidepressants or other medication affecting the HPAA 
during the last three months, heavy exercise (≥1 h per day), late evening or night 
shifts, body mass index <18 or >35, birth of a child or lactation/breastfeeding during 
the last 6 months, history of gynecological diseases, bipolar or psychotic disorders, 
and substance dependence or current substance abuse (see 2.3.2). Consistent with 
DSM-5, other concurrent and past Axis-I disorders such as MDD and anxiety 
disorders were allowed, both in the PMDD and in the control sample. However, to 
differentiate PMDD from premenstrual exacerbation of another mental disorder, we 
included PMDD women with a current comorbid diagnosis only if their affective core 
symptoms for PMDD (A-criterion in DSM-5) differed noticeable from the affective core 
symptoms of the comorbid disorder, as suggested in DSM-5 (see APA, 2013). Of five 
women with a current comorbid depression diagnosis, we therefore had to exclude 
n=2 women from the PMDD sample who reported depressed mood as the affective 
core symptom for PMDD, while we retained n=3 women reporting irritability and 
mood lability as affective core symptoms for PMDD.         
Of 138 women screened for PMDD, n=22 were excluded due to insufficient severity 
of affective core symptoms or insufficient distress/impairment, n=21 due to other 
exclusion criteria, and n=25 refused to participate due to anticipated temporal 
overload linked to study participation.      
Of 118 screened controls, n=15 did not meet the inclusion criteria, n=8 were 
excluded due to the presence of affective core symptoms, n=15 refused to participate 
due to anticipated temporal overload, and n=10 could not be matched due to non-
fitting matching criteria. Participants’ data were analyzed if they had AA-assessments 
during at least three out of four menstrual cycle phases. Women who did not meet 
this criterion and did not repeat the missing assessment in the subsequent cycle 
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were considered dropouts. In total, 18 women (9 PMDD, 9 controls) withdrew 
(12.9%). The reasons for discontinuating were: inconsistencies with menstrual cycle 
reports (n=14), severe technical problems (n=2), decision to start hormonal 
contraceptives (n=1) and positive pregnancy test (n=1). The final sample consisted of 
61 PMDD women and 61 controls. The study protocol was approved by the ethics 
committee of the Medical Faculty Mannheim, Heidelberg University. All participants 
gave written informed consent and received 100 € for participation. 
2.3.2 Study Procedure and Measures 
Data were collected in the period from 3/2016 to 10/2018. The procedure included a 
telephone screening, a baseline session, and AA (see Supplementum, Figure S1). 
During the baseline session at the CIMH the SCID-PMDD was administered to 
assess the inclusion criteria for PMDD. The SCID-PMDD is a structured clinical 
interview for PMDD developed and psychometrically evaluated by Accortt et al., 
(2011). Derived from the PMDD-DSM criteria, it includes all symptom criteria relevant 
for DSM-5 together with the required impairment and exclusion criterion for a mere 
exacerbation of symptoms of another disorder. The interview format is modeled after 
SCID-I (see below) and has shown high interrater reliability (kappa=0.96) (Accortt et 
al., 2011). For inclusion into the PMDD group, the criteria for PMDD according to the 
SCID-PMDD had to be met while control women had to be free of any PMDD 
affective core symptom. Additionally, the SCID for DSM-IV Axis I disorders (SCID–I, 
(Wittchen, Wunderlich, Gruschwitz, & Zaudig, 1997) was administered to assess 
current and lifetime diagnoses of other mental disorders and early trauma (traumatic 
events that occurred before the age of 18 as reported in the Posttraumatic Stress 
Disorder section of SCID-I). All interviews were performed by a trained research 
psychologist. Furthermore, the Premenstrual Symptom Screening Tool (PSST) was 
assessed at baseline to measure the self-rated severity of premenstrual symptoms 
and related impairments in different areas of daily life (Steiner, Macdougall, & Brown, 
2003). In a subsample of participants (n=38 PMDD women, n=53 controls) the PSST 
was assessed twice, namely at the baseline interview (to assess the typical severity 
of premenstrual symptoms and impairments) and after performing the AA-period (to 
assess the late luteal phase covered by the AA). Participants also rated the degree of 
depressive symptoms on the BDI-2 (Hautzinger, Keller, & Kuehner, 2006) at the 
baseline interview.  
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Individual calendars were then prepared for each woman based on the date of her 
last menstruation onset and the average length of her menstruation and of her 
menstrual cycle. The menstrual cycle was divided into the menstrual, follicular, 
ovulatory, and late luteal phase (see Wolfram, Bellingrath, & Kudielka, 2011). 
Assessments during the menstrual phase took place on the second and third day of 
menstruation (mean = 2.95 days, SD = 2.21). The follicular phase was examined on 
the second and third day after the end of menstruation (mean = 8.61 days, SD = 
1.94). The ovulatory phase (mean = 17.15 days, SD = 2.0) was determined by a 
chromatographic ovulation test (gabControl hlH Ovulationsteststreifen, gabmed, 
Cologne) indicating a rise in luteinizing hormone levels in urine. Testing began a few 
days before the predicted ovulation and participants were instructed to continue the 
tests daily until a positive result occurred and then to perform the AA on the two days 
immediately following ovulation. If ovulation did not occur, participants were asked to 
repeat the test in the following menstrual cycle. Assessments of the luteal phase took 
place on the fourth and third day before the next menstruation was expected (mean = 
26.38 days, SD = 3.02). The phases were validated according to the ovulation test 
and the exact time of the onset of the next menses. The calendar specified the exact 
days on which the AA were to be carried out and when to begin with the ovulation 
test. For example, if a woman’s cycle had a regular duration of 28 days and bleeding 
lasted approximately five days, she assessed the menstrual phase at day 2 and 3 
after menses onset, and the follicular phase at day 7 and 8. She began testing 
ovulation on day 11 and assessed the ovulation phase the day immediately after the 
test turned positive, and the late luteal phase at day 25 and 26 (i.e., days -4 and -3 
before new menses onset). Participants were asked to repeat assessments during 
the next cycle if the assessment days were not accurate (e.g., if the actual time of 
menses onset was several days earlier or later than expected). To counteract 
potential sequential effects women started in different phases of their menstrual 
cycle, depending on the time point of the baseline session. Among women with 
PMDD 36.1% started in the menstrual, 24.6% in the follicular, 31.1% in the ovulatory 
and 8.2% in the late luteal phase, among controls 37.7% started in the menstrual, 
26.2% in the follicular, 29.5% in the ovulatory and 6.6% in the late luteal phase. After 
three months of assessment we decided to stop women starting in the luteal phase to 
verify that the luteal phase was in fact assessed during an ovulatory cycle as 
confirmed by the ovulation test.   
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2.3.3 Ambulatory assessment 
The AA was carried out using Motorola Moto G 2nd Generation smartphones with the 
software My Experience movisensXS, Version 0.6.3658 (movisens GmbH, Karlsruhe, 
Germany). The smartphone app was developed specifically for this study. There 
were eight subjective assessments per day, with the first at 9 am and the last at 9:30 
pm. Inter-assessment intervals were semi-randomized and varied between 45 and 
120 min. Each assessment was announced by a beep and took 3-4 min to complete. 
Participants had 5 min to respond, and assessments could be delayed by 15 min. If 
participants were unable to respond or rejected the alarm, the assessment was 
saved as missing. At each assessment participants rated momentary mood and 
rumination.  
1. Momentary NA and PA were assessed with 12 items based on the Positive 
and Negative Affect Schedule (PANAS; Watson, Clark, & Tellegen, 1988) and 
previous AA studies (e.g. Kuehner, Welz, Reinhard, & Alpers, 2017; Timm et al., 
2018) which were collapsed according to the circumplex model of affect (Russell, 
1980) and in line with Nezlek (2005) and Hoyt et al., (2015) into NAhigh (upset, 
irritated, nervous, Cronbach’s alpha = 0.80), NAlow (listless, down, bored, α = 0.73), 
PAhigh (cheerful, energetic, enthusiastic, α = 0.80), and PAlow (content, calm, relaxed, 
α = 0.88) items. Outcomes were calculated by averaging the respective item scores, 
ranging from 1 (not at all) to 7 (very much).  
2. Momentary rumination was measured with the item „right before the beep I 
was stuck on negative thoughts and could not disengage from them” (range 1 to 7, 
cf. Kuehner, 2017; Timm et al., 2018).  
3. Recent event-related stress was conceptualized in terms of subjective 
appraisals of events that continually occur in the natural flow of daily life. Participants 
were instructed to describe via free-text the most important event they encountered 
since the last beep or, at the first beep, since waking up. Participants' appreciation of 
the event was rated on a 7‐point bipolar Likert scale, ranging from “very unpleasant” 
to “very pleasant.” This item was subsequently recoded to allow high scores to reflect 
stress (-3 = very pleasant, 0 = neutral, +3 = very unpleasant; van der Stouwe et al., 
2019; Wittchen et al., 2002). The daily stressor types were coded subsequently 
according to the categorization by Gilbert, Mineka, Zinbarg, Craske, and Adam 
(2017). 
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4. Sleep quality and sleep duration were assessed by single items that were 
presented after awakening; sleep quality:  “How did you sleep last night?” (1 = very 
bad; 7 = very good), sleep duration: “How many hours did you sleep last night 
approximately?”. 
Participants were able to contact a member of the research team by telephone in 
case of questions at any time. 
2.3.4 Salivary measure of cortisol 
Twenty minutes after each subjective rating, participants collected saliva cortisol 
samples with standard salivettes (Sarstedt, Germany). Subjects were instructed to 
refrain from strenuous exercise during the AA-day and not to eat, drink other than 
water, smoke, physically exercise or brush their teeth 20 minutes before completing 
saliva sampling. The smartphone briefly presented a random three-digit code which 
participants recorded on the label of the salivette tube they were using during each 
saliva collection (cf. Schlotz, 2019). After collection of the samples, participants 
indicated on the smartphone whether they had eaten, drunk, smoked or exercised 
during the last 20 min. By realizing a time-lag of 20 min between subjective 
assessments and cortisol samples, we could control for these possibly confounding 
effects and examine the actual influence of subjective variables on cortisol, since 
cortisol peaks with a time lag of 10—20 minutes (Schlotz, 2019). In addition, the CAR 
was measured by three saliva samples, directly after awakening before getting up, 
and 30 and 45 minutes later. Participants were instructed to wake before 8:00 and to 
refrain from eating, drinking (except water) and teeth brushing during the CAR 
assessment period. The DCS was assessed with the awakening sample and the 
eight samples following the subjective assessments, i.e. by excluding CAR samples 
2 and 3. All samples were stored in the participant's home freezer until collection and 
subsequently frozen at −20 °C at the laboratory until biochemical analysis at the 
laboratory of Prof. Kirschbaum (Dresden, Germany). There, samples were 
centrifuged at 3,000 rpm for 5 min, resulting in a clear supernatant of low viscosity. 
Saliva cortisol concentrations were measured using commercially available 
chemiluminescence-immunoassay with high sensitivity (IBL International, Hamburg, 
Germany). The intra- and interassay coefficients for cortisol were <8%. 
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2.3.5 Data Analytic Strategy 
Data were analyzed with multilevel models using IBM SPSS version 23. Analyses 
showed that for all dependent variables the three-level model had a better fit than the 
two-level model according to fit indices (AIC and BIC) (Hox, Moerbeek, & Van de 
Schoot, 2017). Therefore, a multilevel model assuming three levels was applied with 
AA (level 1) nested within days (level 2) nested within persons (level 3). Momentary 
mood scores, rumination and cortisol were entered in separate models as dependent 
variables. Cycle phase was entered as a categorical variable in all models (0= 
menstrual phase, 1 = follicular phase, 2 = ovulatory phase, 3 = luteal phase). In the 
analyses on subjective outcomes we controlled for assessment day and time, which 
was centered at 9:00 to indicate hours since first assessment. For each dependent 
variable we checked whether time² was significant and if so retained it in the models, 
if not, time of assessments was included as a linear effect. All models included 
random intercepts at level 2 and 3, allowing individual levels of the dependent 
variables to differ between persons and days. To evaluate stress appraisal , group 
and menstrual cycle dependent variations for the prediction of mood and cortisol we 
included all predictor variables as well as the two- and three-way interactions 
between these predictors (cf. Huffziger et al., 2013; van der Stouwe et al., 2019). 
Only significant interactions were maintained in the final model. Post hoc tests for 
within- and between group analyses were conducted with Bonferroni corrections. In 
contrast, the hypothesis-driven main analyses were not corrected for multiple testing. 
The level 1 predictors were transformed by centering around the within-person mean, 
thereby yielding within-subject predictors that vary within, but not between individuals 
(Curran & Bauer, 2011). In addition, the main effects of level 1 predictors aggregated 
at the person level were added to the models to adjust for their potential effects. 
Importantly, however, the present paper focuses on within-subject associations of 
relevant variables, whereas between-subject effects will not be reported unless 
otherwise stated.  
Cortisol data was log-transformed to adjust for skewness. Log data were examined 
for outliers, and outliers more than three standard deviations from the group mean 
were winsorized to 3 standard deviations (Stalder et al., 2016). In order to estimate 
basal cortisol secretion (CAR and DCS), time was centered at the waking time 
sample (i.e., higher values correspond to later times in the day). CAR compliance 
was defined as follows: Sample 1 had to be collected within 15 min of awakening, 
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sample 2 30 ± 10 min and sample 3 45 ± 10 min after awakening. Samples extending 
these periods were excluded (25.9%). For reactive cortisol, samples were excluded if 
collected more than 10 min after the prompt (5.5%). The models estimating CAR and 
DCS indicated a significant effect of both time and time², and model comparisons 
(AIC, BIC) indicated a better fit for the quadratic model. Therefore, multilevel models 
assuming that CAR and DCS data followed a quadratic trend were applied. Possible 
confounders were analyzed in three separate models for CAR (1), diurnal slope (2), 
and reactive cortisol (3) in the total sample. Depending on the respective outcome we 
examined the effects of age, current medication use, early trauma, habitual smoking, 
time, time of awakening, sleep quality, sleep duration, whether it was a workday or 
not (models 1,2,3), and if participants had recently ingested drinks, smoked 
cigarettes, had eaten anything, brushed their teeth, and their level of physical activity 
(models 2,3) by including these variables as fixed effects. Possible confounders were 
only retained in the models if significant (p < 0.05), which applied to time² (models 
1,2,3), time of awakening (2,3), workday (yes/no) (1), physical activity (3) and sleep 
duration (3).  
Models were estimated with Maximum Likelihood (ML) to compare model fit and 
Restricted Maximum Likelihood (REML) for all other analyses. The significance level 
was set at α=0.05. For visualization purposes, plots of the analyses were made using 
the raw cortisol values (in nmol/l, retransformed from the valid log-transformed 
values). 
2.4 Results 
2.4.1 Compliance  
Altogether, 6818 of 7808 possible subjective assessments (4 menstrual cycle phases 
x 16 assessments per phase x 122 participants) were recorded, corresponding to an 
overall response rate of 87.3% (PMDD: 86.6%, controls: 88%). Overall compliance 
for cortisol assessments (collected samples) reached 87.5% (PMDD: 87.6%, 
controls: 87.3%). 
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Table 1. Demographic, Clinical, and Daily Life Characteristics for Women with PMDD and 
Controls. 
 PMDD (n=61) 
% / mean (SD) 
Controls (n=61) 
% / mean (SD) 
Test statistic
 
p 
Demographic variables     
Age 29.4 (5.8) 29.5 (5.1) t=-0.03 .977 
Education (% with high school 
degree  
72.1% 75.4% Chi
2
=0.17 .681 
Work situation (% in regular job 
or education) 
80.3% 90.2% Chi
2
=2.35 .126 
Marital status (% married or 
living together) 
60.7% 59.0% Chi
2
=0.03 .853 
Children (%) 24.6% 26.2% Chi
2
=0.04 .835 
BMI 23.6 (4.1) 23.5(4.3) t=0.12 .903 
Clinical variables     
Lifetime diagnosis of Major 
Depressive Disorder (MDD, 
SCID-I) 
54.1% 21.3% Chi
2
=13.96 <.001 
Early trauma 18.0% 3.2% Chi
2
=5.235 .022 
BDI-II
1 
at baseline 10.9 (8.9) 4.8 (5.6) t=4.53 <.001 
PSST² at baseline 34.6 (9.8) 6.6 (6.9) t=18.26 <.001 
PSST² following the AA³ 32.3 (10.0) 7.1 (8.4) t=13.04 <.001 
Cycle-related variables     
Previous use of hormonal 
contraceptives 
82.0% 
 
90.2% 
 
Chi
2
=1.71 
 
.191 
 
Duration (in days) of menstrual 
cycle during AA 
29.0 (3.1) 29.4 (3.7) t=-0.77 .444 
Duration (in days) of period 
during AA 
5.3 (1.1) 5.6 (1.7) t=-0.85 .399 
Momentary variables
4 
(AA)     
Stress appraisal -0.7 (0.5) -0.9 (0.6) t=1.89 0.062 
NAhigh
 
2.8 (0.5) 2.1 (0.7) t=5.64 <.001 
NAlow
 
2.9 (0.6) 2.4 (0.7) t=4.35 <.001 
PAhigh
 
3.9 (0.6) 4.4 (0.8) t=-3.85 <.001 
PAlow
 
4.4 (0.7) 5.0 (0.8) t=-4.26 <.001 
Rumination
 
2.4 (0.8) 1.9 (0.8) t=3.78 <.001 
1
BDI-II=Beck Depression Inventory-Revised. 
2
PSST=Premenstrual Symptom Screening Tool. ³ 
PMDD (n=38), controls (n=53). 
4
Aggregated mean at the person level. 
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2.4.2 Sample description 
As depicted in Table 1, women with PMDD and controls did not significantly differ 
with respect to age, education, marital status, work situation, percentage with 
children, mean duration of menstrual cycle, previous use of hormonal contraceptives, 
and time since stopping contraception. In contrast, women with PMDD displayed 
significantly higher depression scores (BDI-II) and included a markedly higher 
percentage of individuals with a lifetime diagnosis of MDD. Women with PMDD 
scored higher on the PSST both at baseline and with regard to the late luteal phase 
covered by AA. Paired t-tests between PSST scores at baseline and following the AA 
indicated comparable premenstrual symptom severity, both in the PMDD sample (M 
= 34.5 (SD = 10.1) vs. M = 32.3 (SD = 10.0), t(37) = 1.24, p = 0.222) and in the 
control sample (M = 6.7 (SD = 6.2) vs. M = 7.1 (SD = 8.4), t(52) = -0.50, p = 0.618). 
Furthermore, a higher percentage of women with PMDD than controls had 
experienced an early trauma. Moreover, women with PMDD showed higher 
aggregated mean levels of NAhigh and NAlow, rumination, and lower aggregated mean 
levels of PAhigh and PAlow, whereas the aggregated mean levels of stress appraisal 
was only marginally higher in PMDD women. The following daily event types were 
reported: performance-related (23.1%), interpersonal (15.8%), sleep (5.0%), self 
(1.2%), other (24.5%) and no stress (2.4%). 
2.4.3 Stress appraisal 
As hypothesized, the interaction effect of group*cycle phase on stress appraisal was 
significant (F (3, 829) = 5.12, p = 0.002). Separate analyses per group revealed a 
significant effect of cycle phase on stress appraisal in PMDD women (F (3,416) = 
3.58, p = 0.014). Post hoc tests using Bonferroni correction showed significantly 
higher perceived stress during the luteal phase compared to the follicular phase 
(Mean Difference = 0.26, SE = 0.09, p = 0.023). No cyclicity in stress appraisal was 
identified for healthy women (F (3, 412) = 1.72, p = 0.163). 
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Fig. 1. Estimated mean values for NAhigh mean and standard errors per menstrual cycle 
phase toward situations with low (-1 SD, Fig. 1A), and high (+1 SD, Fig. 1B) individual stress 
appraisal for women with PMDD and controls. Note. Error bars represent standard error of 
the mean. Model includes time, time², assessment day, and aggregated stress as covariates. 
 
 
 
Fig. 2. Estimated mean values towards situations with low (–1 SD) and high (+1 SD) 
individual stress appraisal for PAhigh (Fig. 2A) and rumination (Fig. 2B). Note. Error bars 
represent standard error of the mean. Models include time, assessment day, cycle phase, 
and aggregated PAhigh (Fig. 2A), and aggregated rumination (Fig. 2B) as covariates. 
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2.4.4 Momentary within-person effects of stress on mood and rumination 
To examine effects of stress on mood states, NAhigh, NAlow, PAhigh, PAlow, and 
rumination were entered as dependent variables in five separate models (complete 
models with stepwise removal of non-significant interaction terms see 
Supplementum, Table S1). Multilevel analyses revealed a significant three-way 
interaction group*cycle phase*stress on momentary NAhigh (F (3, 6364) = 2.83, p = 
0.037, see Table S1). Post hoc tests with separate models per group showed a 
significant two-way interaction stress*cycle phase in women with PMDD (F (3, 3161) 
= 2.89, p = 0.034). As shown in Figure 1A and B, in PMDD women high within-
person levels of stress appraisal were associated with high levels of NAhigh 
particularly in the late luteal phase, indicating larger subjective NAhigh stress 
responses in this phase compared to other cycle phases. This interaction was not 
significant in controls (F (3, 3214) = 2.02, p = 0.109), indicating no cycle-dependent 
variability in stress reactivity in healthy women (see Figure 1A and B). All other 
models revealed no significant three-way interaction effect of group*cycle 
phase*stress on outcomes (NAlow: p = 0.325, PAhigh: p = 0.198, PAlow: p = 0.308, 
rumination: p = 0.211, see Table S1). After stepwise removal of non-significant 
interaction terms in order to get a more parsimonious model and to facilitate 
interpretation, we identified significant two-way interactions (group*stress) for PAhigh 
(F (1, 6403) = 5.32, p = 0.021) and for rumination (F (1, 6547) = 22.28, p < 0.001). As 
shown in Figure 2A and B, within-person increases in stress predicted lower levels of 
PAhigh and higher levels of rumination in PMDD women compared to controls.  In 
contrast, no group*stress effects were found for NAlow (p = 0.338) and PAlow (p = 
0.208, see Table S1). Here, we identified main effects of stress on low activation 
mood in the total sample (NAlow: F (1, 6383) = 662.55, p < 0.001, B = 0.18, SE = 
0.01, p < 0.001; PAlow: F (1, 6445) = 1517.39, p < 0.001, B = -0.29, SE = 0.01, p < 
0.001, see Table S1). 
2.4.5 Cortisol diurnal rhythm 
To examine whether women with PMDD would show a flattened profile of basal 
cortisol activity two separate models were calculated. For the CAR the multilevel 
model yielded no significant effect of group*cycle phase*time² (p = 0.379, see Table 
S2). After stepwise removal of non-significant interaction terms we identified a 
significant interaction group*time² (F (1, 1547) = 5.87, p = 0.016). Figure 3A shows 
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different CAR peaks in PMDD women and controls with highest values 30 min after 
awakening among controls and 45 min among PMDD women, indicating that PMDD 
was associated with a delayed peak. Similarly, no significant threefold interaction 
(group*cycle phase*time²) was identified for the DCS (p = 0.499, see Table S2). After 
stepwise removal of non-significant interaction terms, the interaction group*time² 
demonstrated a significant effect on DCS (F (1, 6277) = 7.53, p = 0.006). As shown 
in Figure 3B, PMDD was associated with a flatter DCS throughout the day. 
 
 
 
Fig. 3. Estimated CAR in women with PMDD and controls (Fig. 3A), and estimated DCS in 
women with PMDD and controls (Fig. 3B). Note. Error bars represent standard error of the 
mean. Models include cycle phase, workday (Fig. 3A), and time of awakening (Fig. 3B) as 
covariates. 
2.4.6 Momentary within-person effects of stress, mood, and rumination on cortisol    
To examine effects of stress, high and low affect states, and rumination on cortisol, 
we performed six separate models, one for each set of person mean-centered 
momentary daily-life predictors using cortisol secretion 20 min later as the dependent 
variable. In all models the interaction term predictor*group*cycle phase was non-
significant (stress*group*cycle phase:  p = 0.787, NAhigh*group*cycle phase: p = 
0.484, NAlow*group*cycle phase: p = 0.945, PAhigh*group*cycle phase:  p = 0.922, 
PAlow*group*cycle phase: p = 0.740, rumination*group*cycle phase: p = 0.713, see 
Table S3). After stepwise removal of non-significant interaction terms we identified a 
significant group*rumination effect (F (1, 5517) = 4.21, p = 0.040) revealing a 
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different association of within-person rumination variability with HPAA activity in 
women with and without PMDD. Figure 4 shows that higher within-person levels of 
rumination were linked to stronger cortisol activity in controls, while for women with 
PMDD momentary rumination and cortisol were uncoupled. In contrast no significant 
group*predictor interaction effect resulted for stress (p = 0.853), NAhigh (p = 0.797), 
NAlow (p = 0.268), PAhigh (p = 0.106), and PAlow (p = 0.082, see Table S3). After 
stepwise removal of non-significant interaction terms we identified main effects for 
NAhigh (F (1, 5236) = 13.94, p < 0.001, B = 0.04, SE = 0.01, p < 0.001), PAhigh (F (1, 
5201) = 4.58, p = 0.032, B = -0.02, SE = 0.01, p = 0.032), and PAlow (F (1, 4901) = 
9.26, p = 0.002, B = -0.03, SE = 0.01, p=0.002, see Table S3). Thus, across groups, 
higher within-person levels of momentary NAhigh and lower levels of momentary PAlow 
and PAhigh were linked to higher cortisol secretion 20 min later. In contrast, no main 
effects were identified for stress (p = 0.879) and NAlow (p = 0.125, see Table S3). 
 
 
Fig. 4. Estimated mean cortisol levels for women with PMDD and controls for low (-1 SD) and 
high (+1 SD) individual momentary rumination scores. Note. Error bars represent standard 
error of the mean. Model includes time, time², cycle phase, time of awakening, physical 
activity, sleep duration, and aggregated rumination scores as covariates. 
 
2.5 Discussion 
To our knowledge, this is the first AA study to examine stress-related facets of mood 
and cognition together with basal and stress-reactive cortisol activity over the 
menstrual cycle in women with PMDD.  
Consistent with previous reports (for reviews see Epperson et al., 2012; Owens and 
Eisenlohr-Moul, 2018), women with PMDD rated stressors as more aversive in the 
late luteal compared to the follicular phase, whereas no respective cyclicity was 
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found in healthy women. Our results furthermore highlight a specific response pattern 
toward daily life stressors in PMDD women. Women with PMDD showed a significant 
increase particularly in high-arousal negative affect states (upset, irritated, nervous) 
toward daily stressors in the late luteal phase compared to all other cycle phases and 
compared to healthy controls. Thereby, PMDD women appear to react with high 
intensity negative feelings of arousal towards stressors particularly during this phase, 
which may reciprocally contribute to a vicious circle between mood and interpersonal 
conflicts (the latter is also included in Criterion B2 of DSM-5 as “marked irritability or 
anger or increased interpersonal conflicts”). Interestingly, the preponderance of 
premenstrual high arousal negative emotions and mood lability over depressed mood 
in PMDD has led to a change in the respective listing of symptoms from DSM-IV to 
DSM-5 (Hantsoo and Epperson, 2015). In this context, some authors (Kuehner, 
2017; Payne, Palmer, & Joffe, 2009) propose a female-specific reproductive subtype 
of depression given that PMDD links to postpartum and perimenopausal depression 
due to specific symptom presentation, comorbidity, and biological response to 
hormonal changes. Additionally, there seems to be heterogeneity within the 
diagnosis of PMDD itself regarding treatment response, symptom content and 
symptom timing. In a large sample of PMDD women, Eisenlohr-Moul et al. (2019) 
observed different temporal subtypes and conclude that particularly those with late 
occurring symptoms might represent a hormone-withdrawal-sensitive subtype of 
PMDD, which may also indicate increased risk during postpartum and late 
menopausal transition, which are similarly characterized by neurosteroid withdrawal 
or deprivation. Here, AA-studies can importantly contribute to systematically examine 
possible different phenotypes underlying reproductive and nonreproductive subtypes 
of depression but also to identify possible more homogeneous subgroups of PMDD. 
We further identified an enhanced within-subject effect of stress on rumination in 
PMDD women regardless of cycle phase. Affected women seem to cope with more 
stressful situations with stronger ruminative thoughts compared to controls. The 
missing cycle effect suggests that this reflects a trait-like feature. While retrospective 
studies have shown that women with severe premenstrual symptoms use more 
dysfunctional coping strategies such as rumination in general (e.g. Craner et al., 
2014), the present study adds to previous research by showing specific accentuated 
within-subject stress-rumination associations in PMDD women in their everyday life.   
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There is first indication that PMDD women show blunted basal HPAA function 
throughout the menstrual cycle (Owens and Eisenlohr-Moul, 2018), which is clearly 
supported by our results. First, their cortisol peak of the CAR was delayed.  Although 
not entirely consistently, a blunted CAR (particularly the dynamic component) has 
been identified in various stress-related conditions such as posttraumatic stress 
disorder, chronic fatigue syndrome, atypical depression, in women having 
experienced early abuse (Kudielka et al., 2012; Powell, Liossi, Moss-Morris, & 
Schlotz, 2013; Tak et al., 2011), and in individuals with genetic or cognitive 
vulnerability to depression (Kuehner, Holzhauer, & Huffziger, 2007; Kuehner, 
Huffziger, Witt, & Rietschel, 2011). Furthermore, hypoactivation of the CAR was most 
consistently predicted by a “burnout/fatigue/exhaustion” type of psychosocial 
stressors in a large meta-analysis (Boggero et al., 2017). Similarly, the DCS of 
PMDD women was flattened in the present study. In their recent review, Adam et al., 
(2017) identified significant associations between flatter DCS and poorer emotional 
and physical health across studies and conclude that flatter slopes may reflect or 
contribute to stress-related circadian mechanisms affecting multiple aspects of 
health. In the present study, delayed and flattened basal HPAA activation (CAR, 
DCS) was seen across the menstrual cycle, thereby again indicating a trait-like 
characteristic.  
Our study further extends previous PMDD stress research by assessing cortisol 
reactivity towards stress, arousal facets of NA and PA, and rumination in everyday 
life. Contrary to expectation, we did not identify any main or interaction effect of 
stress on cortisol. Our current results therefore do not support research from 
laboratory settings showing a blunted cortisol response towards stressors in women 
with PMDD (Huang et al., 2015). One explanation for the missing effect of stress on 
cortisol in the present study might be that stressors were minor daily life events and 
thus may have had less impact on the HPAA compared to standardized laboratory 
stressors. Further, the interval between two assessments might have been too long 
in some cases (i.e., > 1 hr, cf. Schlotz, 2019) for optimal peak cortisol detection in 
response to a stressor occurring during the interval. For power reasons, we also 
included all types of events that were mentioned during daily life, although specific 
event types such as interpersonal stressors might be stronger predictors for cortisol 
responses than others (Gilbert et al., 2017). Here larger studies are clearly needed to 
be able to subdivide daily life events in a more detailed way.  
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In contrast, high scores of momentary high arousal NA and of high and low arousal 
PA were linked to high cortisol 20 min later regardless of group or cycle phase. While 
facets of PA have been understudied in daily life stress research so far, our results 
confirm earlier findings on within-subject associations between momentary NA and 
cortisol in different study populations (summarized in Schlotz, 2019). Here, 
specifically high arousal NA demonstrated a significant activating effect on HPA axis 
activity while the effect of low arousal NA was nonsignificant. Furthermore, our study 
revealed that in controls, but not in women with PMDD, high levels of momentary 
rumination were linked to high levels of momentary cortisol across the menstrual 
cycle. Therefore, while our results on healthy women are in line with earlier studies 
showing rather consistent positive associations between state measures of 
rumination and cortisol (Zoccola & Dickerson, 2012), momentary rumination and 
cortisol activity appear to be decoupled in PMDD women. 
2.5.1 Clinical Implications 
Our study holds significant clinical implications. The observation that women with 
PMDD rate daily events as more stressful and show increased high arousal NA and 
rumination in face of stressful situations suggests that affected women could profit 
both from the use of helpful emotion regulation strategies and from coping with daily 
life stressors. In addition, since the identified association between stress and 
rumination in affected women was independent of menstrual cycle phase, therefore 
ruminative thoughts in PMDD women appear to reflect a trait-like rather than a state-
like characteristic. Paralleling our results, questionnaire-based retrospective studies 
(e.g. Craner et al., 2014; Petersen et al., 2016) showed that women with severe 
premenstrual symptoms use less helpful strategies to regulate their emotions. Such 
processes were also identified at an implicit level (Eggert et al., 2016). The role of a 
ruminative coping style in PMDD has also been stressed in a recent study by 
Dawson et al., (2018) showing that brooding predicted a more rapid premenstrual 
increase and a slower postmenstrual symptom remission. Mindfulness-based 
technics have been suggested as valuable means for emotion regulation (Chambers, 
Gullone, & Allen, 2009) and single studies have shown that mindfulness may help 
women suffering from PMS (Bluth, Gaylord, Nguyen, Bunevicius, & Girdler, 2015; 
Panahi & Faramarzi, 2016). Methodologically sound mindfulness-based RCTs are 
warranted to evaluate whether these strategies are also useful to treat the more 
Study 1: Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder 
(PMDD) 
50 
severe distress in PMDD. Importantly, these studies should include daily life 
assessments of mood, cognition and stress perception as well as of basal and 
stress-reactive HPAA activation to study intervention effects on respective AA-based 
micro-processes during daily life together with clinical symptomatology at the macro-
level.  
From a pharmacological view, GABAergig and neurosteroid mechanisms influencing 
the biological stress response system and their possible dysregulation in PMDD are 
important. For example, recent work by Kanes et al. (2017) has identified lower 
GABA levels in women with postpartum depression and showed effectiveness of 
neurosteroid-based treatment in these women. Similarly, a phase-specific sensitivity 
of the GABAA receptor has been suggested for PMDD (Backstrom et al., 2014; 
Hantsoo & Epperson, 2015). Therefore, clearly more work is warranted examining 
treatment options that impact the HPAA via neurosteroid modulation of GABAergic 
function in affected women. 
2.5.2 Strengths and Limitations 
Strengths of the current study include the application of electronical AA to compare 
within-person variability of stress, arousal-related facets of NA and PA, rumination, 
and cortisol activity repeatedly during daily life in PMDD women and narrowly 
matched healthy controls, the use of a longitudinal design to cover all phases of the 
menstrual cycle, and the validation of ovulatory cycles through an ovulation test.   
Our study has also some limitations. First, the study sample size was only modest. 
Although it clearly exceeds the recommended minimum size for estimating cross-
level interactions (cf. Hox et al., 2017), statistical power may have been limited 
particularly for estimating three-way interactions. Therefore, the present results 
should be regarded as preliminary and validated in future studies with larger 
samples. Second, although the PMDD diagnosis was assessed with a reliable 
structured interview (SCID-PMDD, Accortt et al., 2011), this is nevertheless a 
retrospective measure, and confirmation by prospective daily ratings over at least two 
cycles was not required for study inclusion to prevent participant burden. Therefore, 
the PMDD-diagnoses in this study must be regarded as provisional (APA, 2013). 
However, our approach is in line with a majority of studies using retrospective reports 
to assess PMDD, and prevalence rates of moderate to severe premenstrual 
symptoms derived from retrospective epidemiological studies are consistent with 
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those using prospective ratings (Cunningham et al., 2009). Furthermore, low 
consistency among daily symptom rating instruments has been observed, with a 
widely varying magnitude of symptom change between the pre- and postmenstrual 
week required for a PMDD diagnosis (Bosman et al., 2016). Future studies could 
profit from applying AA over two cycles (which was not possible for us due to 
financial restrictions) and combining them with daily symptom ratings. Third, our 
sample may have not been representative of patients with PMDD seeking for 
treatment, given the voluntary nature of the study. Even though the sample was 
heterogeneous regarding age, education, job and family situation, women with higher 
education levels were somewhat overrepresented. Further, since antidepressant 
medication and hormonal contraceptives are currently the most frequent treatments 
for PMDD (Epperson et al., 2012) the exclusion of women taking pharmaceutics and 
hormonal contraceptives - although necessary for our study purposes - may have led 
to the exclusion of patients suffering from particularly severe symptomatology.  
Fourth, to restrict participant burden only two assessment days per cycle phase were 
scheduled, which could be critical, however, especially with regard to the late luteal 
phase. Clinical studies have shown that women with PMDD have the peak of distress 
one to two days before menses onset (Epperson et al., 2012), though symptom 
timing and severitiy has been observed to be heterogeneous (Eisenlohr-Moul et al., 
2019). The decision to schedule the third and fourth day was due to the fact that 
these days are in the middle of the premenstrual week (as required for DSM-5) and 
therefore still within the acceptable range if menses had started one or two days 
earlier or later than expected. However it cannot be ruled out that thereby we missed 
days with the most severe premenstrual distress in some women.  Fifth, although the 
PSST scores did not differ between  a retrospectively assessed “typical” late luteal 
phase and the late luteal phase assessed by AA, our study design did not control 
whether an individual PMDD woman became asymptomatic or a control woman 
became symptomatic during the late luteal phase. Future studies could combine AA 
with daily ratings of premenstrual symptoms to investigate how the latter directly 
influence experiences measured by AA. Sixth, given the diurnal pattern of cortisol 
secretion, further studies should control for the possible influence of different 
chronotypes (morningness versus eveningness). Seventh, assessing daily life stress 
in AA studies in general presents some challenges (cf. Schlotz, 2019). In our semi-
randomized design, the most important event could have occurred up to 120 min 
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before the beep. With cortisol probes being sampled with a 20 min lag, we therefore 
might have missed some relevant cortisol peaks. Moreover, the addition of more 
objective stress measurements may be useful in future studies (Owens and 
Eisenlohr-Moul, 2018). Next, while we did not identify an effect of early trauma on 
cortisol, future PMDD studies should examine childhood trauma with more detailed 
measures (e.g. Bernstein et al., 2003). Furthermore, negative affect may have biased 
the recall of negative events and of stress appraisal to some extent. Finally, since all 
subjective constructs were assessed concurrently, a clear causal link from daily 
events to mood and rumination cannot be established with the present data. 
2.5.3 Conclusions 
In conclusion, this is likely the first study to examine stress, mood, cognition, and 
cortisol activity in women with PMDD during daily life using electronic AA. Our results 
revealed particularly high stress appraisal and high subjective stress reactivity in 
terms of NAhigh in women with PMDD during the late luteal phase as well as blunted 
basal HPAA function irrespective of cycle phase. While high levels of NAhigh together 
with low levels of PAhigh and PAlow were related to high momentary cortisol across 
groups and cycle phases, a distinct cortisol response to rumination was only seen in 
healthy women. With the application of electronic AA during daily life and the 
covering of four cycle phases, our study adds to existing knowledge on cycle-related 
and general alterations in PMDD. Identified characteristics in daily life experiences 
might also be predictive for the development and clinical course of PMDD which can 
easily be studied with respective longitudinal designs (cf. Adam et al., 2014; Timm et 
al., 2017 for other mental disorders). Premenstrual changes in affective, behavioural 
and physiological patterns in women with PMDD as assessed by AA do also 
represent dimensional entities particularly suitable for being studied across domains 
within the Research Domain Criteria (RDoC) framework (Insel, 2014), which might 
finally help to gain more insight into the biological and psychological mechanisms 
and their interplay involved in PMDD (cf. Owens & Eisenlohr-Moul, 2018). Further 
research is also warranted targeting identified AA-based mechanisms in the context 
of intervention studies to provide respective evidence-based therapeutic options for 
affected women. 
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2.6 Online supplementary material 
 
 
 
Figure S1. Schematic representation of the study’s procedure. 
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Table S1. Fixed effects of stress, cycle phase, and group on momentary NAhigh, NAlow, PAhigh, PAlow, and rumination. 
  Model 1 Model 2 Model 3 
 df F p df F p df F p 
Outcome NAhigh          
Fixed effects          
Intercept (1,162) 726.07 <.001       
Group (1,118) 27.78 <.001       
Cycle phase (3,829) 17.04 <.001       
Aggregated mean stress  (1,119) 26.54 <.001       
Stress (W-S) (1,6425) 1157.60 <.001       
Group * cycle phase (3,829) 14.03 <.001       
Stress (W-S) * cycle phase (3,6363) 2.27 .079       
Stress (W-S) * group (1,6425) 1.36 .243       
Stress (W-S) * group * 
cycle phase 
(3,6364) 2.83 .037       
Outcome NAlow          
Fixed 
effects 
          
Intercept (1,152) 702.82 <.001 (1,152) 703.12 <0.001 (1,152) 703.02 <.001 
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Group (1,118) 15.19 <.001 (1,118) 15.21 <0.001 (1,118) 15.25 <.001 
Cycle phase (3,830) 18.40 <.001 (3.829) 18.42 <0.001 (3,829) 18.54 <.001 
Aggregated mean stress (1,119) 14.88 <.001 (1,119) 14.85 <0.001 (1,119) 14.89 <.001 
Stress (W-S) (1,6370) 652.21 <.001 (1,6372) 651.61 <0.001 (1,6383) 662.55 <.001 
Group * cycle phase (3,830) 14.44 <.001 (3,830) 14.46 <0.001 (3,830) 14.48 <.001 
Stress (W-S) * cycle phase (3,6308) .13 .940 (3,6318) .19 .901 -1) -1) -1) 
Stress (W-S) * group (1,6370) .87 .351 (1,6373) .92 .338 -1) -1) -1) 
Stress (W-S) * group * 
cycle phase 
(3,6309) 1.16 .325 -1) -1) -1)    
Outcome PAhigh          
Fixed effects          
Intercept (1,159) 1236.44 <.001 (1,159) 1237.71 <.001 (1,159) 1238.01 <.001 
Group (1,119) 10.63 .001 (1,119) 10.71 .001 (1,119) 10.69 .001 
Cycle phase (3,842) 19.21 <.001 (3,841) 19.22 <.001 (3,841) 19.22 <.001 
Aggregated mean stress (1,119) 53.42 <.001 (1,119) 53.54 <.001 (1,119) 53.50 <.001 
Stress (W-S) (1,6398) 1048.88 <.001 (1,6400) 1045.79 <.001 (1,6398) 1048.88 <.001 
Group * cycle phase (3,842) 10.87 <.001 (3,841) 10.89 <.001 (3,841) 10.89 <.001 
Stress (W-S) * cycle phase (3,6338) .08 .972 (3,6348) .04 .991 -1) -1) -1) 
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Stress (W-S) * group (1,6398) 5.29 .022 (1,6401) 5.28 .022 (1,6403) 5.32 .021 
Stress (W-S) * group * 
cycle phase 
(3,6339) 1.56 .198 -1) -1) -1)    
Outcome PAlow          
Fixed effects          
Intercept (1,152) 1361.61 <.001 (1,152) 1363.97 <.001 (1,152) 1365.75 <.001 
Group (1,119) 14.49 <.001 (1,119) 14.56 <.001 (1,119) 14.55 <.001 
Cycle phase (3,839) 21.05 <.001 (3,838) 21.18 <.001 (3,838) 21.51 <.001 
Aggregated mean stress (1,119) 58.26 <.001 (1,119) 58.39 <.001 (1,119) 58.40 <.001 
Stress (W-S) (1,6432) 1499.25 <.001 (1,6434) 1497.18 <.001 (1,6445) 1517.39 <.001 
Group * cycle phase (3,839) 13.02 <.001 (3,839) 13.11 <.001 (3,839) 13.29 <.001 
Stress (W-S) * cycle phase (3,6370) 1.86 .134 (3,6380) 1.85 .135 -1) -1) -1) 
Stress (W-S) * group (1,6433) 1.56 .212 (1,6435) 1.59 .208 -1) -1) -1) 
Stress (W-S) * group * 
cycle phase 
(3,6371) 1.20 .308 -1) -1) -1)    
Outcome Rumination          
Fixed effects          
Intercept (1,152) 376.80 <.001 (1,152) 377.26 <.001 (1,152) 376.80 <.001 
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Group (1,118) 10.79 .001 (1,118) 10.82 .001 (1,118) 10.89 .001 
Cycle phase (3,825) 10.63 <.001 (3,824) 10.76 <.001 (3,824) 10.72 <.001 
Aggregated mean stress (1,118) 16.10 <.001 (1,118) 16.09 <.001 (1,118) 16.18 <.001 
Stress (W-S) (1,6543) 591.80 <.001 (1,6546) 588.87 <.001 (1,6546) 588.87 <.001 
Group * cycle phase (3,825) 13.06 <.001 (3,825) 13.16 <.001 (3,824) 13.10 <.001 
Stress (W-S) * cycle phase (3,6484) 1.48 .217 (3,6493) 1.35 .258 -1) -1) -1) 
Stress (W-S) * group (1,6544) 22.35 <.001 (1,6546) 22.52 <.001 (1,6547) 22.28 <.001 
Stress (W-S) * group * 
cycle phase 
(3,6485) 1.51 0.211 -1) -1) -1)    
Note. Aggregated mean: Aggregated mean at the person level. W-S: within-subject (person mean-centered). Models include random 
intercepts at level 2 and 3 as well as fixed effects for time, (time² if significant), and assessment day. 1) Non-significant interactions 
were excluded stepwise. 
 
Table S2. Fixed effects of group, cycle phase, and time on basal cortisol activity (CAR and DCS).  
  Model 1 Model 2 Model 3 
 df F p df F p df F p 
Outcome CAR          
Fixed effects           
Intercept (1,156) 3002.81 <.001 (1,155) 3013.69 <.001 (1,155) 3013.69 <.001 
Time (1,1418) 66.04 <.001 (1,1418) 66.04 <.001 (1,1511) 64.25 <.001 
Study 1: Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder (PMDD) 
58 
Time² (1,1435) 20.90 <.001 (1,1435) 20.90 <.001 (1,1547) 16.59 <.001 
Group (1,142) .10 .758 (1,141) .15 .697 (1,141) .15 .697 
Cycle phase (3,1468) 2.87 .035 (3,678) 2.49 .059 (3,678) 2.49 .059 
Group * cycle phase (3,1467) 1.44 .230 (3,678) .88 .451 -1) -1) -1) 
Cycle phase * time (3,1401) 1.44 .231 (3,1512) 2.81 .038 -1) -1) -1) 
Cycle phase * time² (3,1415) .93 .426 (3,1558) 2.48 .059 -1) -1) -1) 
Group * time (1,1391) .30 .587 (1,1418) .83 .361 (1,1511) 4.15 .042 
Group * time² (1,1403) .54 .463 (1,1434) 1.31 .253 (1,1547) 5.87 .016 
Group * cycle phase * time (3,1401) 1.15 .329 -1) -1) -1)    
Group * cycle phase * time² (3,1415) 1.03 .379 -1) -1) -1)    
Outcome DCS          
Fixed effects          
Intercept (1,930) 523.32 <.001 (1,31) 525.12 <.001 (1,31) 525.12 <.001 
Time (1,6241) 287.88 <.001 (1,6247) 289.01 <.001 (1,6253) 286.93 <.001 
Time² (1,6238) 22.47 <.001 (1,6244) 22.21 <.001 (1,6251) 22.74 <.001 
Group (1,158) .04 .850 (1,158) .04 .852 (1,158) .04 .838 
Cycle phase (3,5035) 4.00 .007 (3,5042) 3.99 .007 (3,791) 2.61 .051 
Group * cycle phase (3,5042) 1.79 .148 (3,788.48) .71 .549 -1) -1) -1) 
Cycle phase * time (3,6275) 1.89 .128 (3,6259) 1.88 .130 -1) -1) -1) 
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Cycle phase * time² (3,6285) 1.89 .129 (3,6282) 1.87 .132 -1) -1) -1) 
Group * time (1,6247) 5.99 .014 (1,6254) 5.94 .015 (1,6260) 5.72 .017 
Group * time² (1,6271) 8.07 .005 (1,6270) 7.79 .005 (1,6277) 7.53 .006 
Group * cycle phase * time (3,6253) 1.27 .283 -1) -1) -1)    
Group * cycle phase * time² (3,6276) .79 .499 -1) -1) -1)    
Note. The dependent variable cortisol was entered log-transformed. CAR: Cortisol awakening response. DCS: Diurnal cortisol slope. 
Models include random intercepts at level 2 and 3. Confounding variables were only retained in the models when significant (p < 0.05), 
which applies to workday (yes, no) for CAR and time of awakening for DCS. 1) Non-significant interactions were excluded stepwise. 
 
Table S3. Fixed effects of momentary NAhigh, NAlow, PAhigh, PAlow, rumination, cycle phase, and group on cortisol output. 
  Model 1 Model 2 Model 3 
Outcome cortisol df F p df F p df F p 
Fixed effects (predictor 
stress) 
         
Intercept (1,783) 333.62 <.001 (1,783) 333.28 <.001 (1,782) 335.99 <.001 
Group (1,116) .95 .332 (1,116) .94 .335 (1,116) .97 .326 
Cycle phase (3,758) 2.91 .034 (3,756) 2.97 .031 (3,758) 2.88 .035 
Aggregated mean stress  (1,116) 5.46 .021 (1,116) 5.47 .021 (1,116) 5.43 .022 
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Stress (W-S) (1,5505) .03 .874 (1,5505) .02 .895 (1,5527) .02 .879 
Group * cycle phase (3,756) .61 .610 (3,757) .59 .619 -1) -1) -1) 
Stress (W-S) * cycle phase  (3,5454) 1.17 .319 (3,5464) 1.10 .350 -1) -1) -1) 
Stress (W-S) * group (1,5500) .02 .878 (1,5500) .03 .853 -1) -1) -1) 
Stress (W-S) * group * 
cycle phase 
(3,5479) .35 .787 -1) -1) -1)    
Fixed effects (predictor 
NAhigh) 
         
Intercept (1,300) 204.42 <.001 (1,300) 203.67 <.001 (1,298) 204.61 <.001 
Group (1,117) .69 .409 (1,117) .63 .429 (1,116) .66 .419 
Cycle phase (3,783) 3.48 .016 (3,777) 3.69 .012 (3,768) 3.69 .012 
Aggregated mean NAhigh  (1,116) .39 .535 (1,116) .37 .544 (1,116) .37 .542 
NAhigh (W-S) (1,5373) 13.65 <.001 (1,5380) 13.45 <.001 (1,5236) 13.94 <.001 
Group * cycle phase (3,782) .59 .619 (3,774) .54 .653 -1) -1) -1) 
NAhigh (W-S)  * cycle phase  (3,5550) .38 .765 (3,5531) .18 .905 -
1) -1) -1) 
NAhigh (W-S) * group (1,6376) .04 .846 (1,5372) .07 .797 -
1) -1) -1) 
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NAhigh (W-S)  * group * 
cycle phase 
(3,5548) .82 .484 -1) -1) -1)    
Fixed effects (predictor 
NAlow) 
         
Intercept (1,286) 152.48 <.001 (1,286) 153.91 <.001 (1,284) 153.25 <.001 
Group (1,117) .03 .854 (1,117) .03 .856 (1,117) .03 .867 
Cycle phase (3,782) 3.21 .023 (3,777) 3.16 .024 (3,765) 3.19 .023 
Aggregated mean NAlow  (1,118) 4.07 .046 (1,118) 4.04 .047 (1,117) 4.01 .048 
NAlow (W-S) (1,6314) 2.87 .090 (1,5318) 2.85 .092 (1,6168) 2.35 .125 
Group * cycle phase (3,781) .63 .598 (3,774) .65 .587 -1) -1) -1) 
NAlow (W-S)  * cycle phase  (3,5523) .59 .625 (3,5500) .66 .575 -
1) -1) -1) 
NAlow (W-S) * group (1,5319) 1.18 .277 (1,5311) 1.23 .268 -
1) -1) -1) 
NAlow (W-S)  * group * 
cycle phase 
(3,5524) .13 .945 -1) -1) -1)    
Fixed effects (predictor 
PAhigh) 
         
Intercept (1,189) 109.93 <.001 (1,189) 110.01 <.001 (1,189) 109.69 <.001 
Group (1,117) .39 .536 (1,116) .38 .541 (1,116) .39 .534 
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Cycle phase (3,782) 3.27 .021 (3,777) 3.23 .022 (3,765) 3.36 .018 
Aggregated mean PAhigh (1,116) .02 .882 (1,116) .02 .822 (1,116) .03 .868 
PAhigh (W-S) (1,5303) 5.37 .021 (1,5305) 5.34 .021 (1,5201) 4.58 .032 
Group * cycle phase (3,781) .53 .665 (3,771) .54 .658 -1 -1) -1) 
PAhigh (W-S)  * cycle phase  (3,5523) .50 .683 (3,5507) .58 .631 -
1) -1) -1) 
PAhigh (W-S) * group (1,5311) 2.57 .108 (1,5310) 2.61 .106 -
1) -1) -1) 
PAhigh (W-S)  * group * 
cycle phase 
(3,5520) .16 .922 -1) -1) -1)    
Fixed effects (predictor 
PAlow) 
         
Intercept (1,178) 92.01 <.001 (1,178) 92.06 <.001 (1,181) 90.68 <.001 
Group (1,117) .58 .449 (1,117) .55 .461 (1,116) .63 .429 
Cycle phase (3,784) 3.17 .024 (3,778) 3.32 .019 (3,703) 3.28 .021 
Aggregated mean PAlow  (1,117) .34 .560 (1,117) .33 .565 (1,117) .32 .572 
PAlow (W-S) (1,5381) 12.22 <.001 (1,5384) 12.19 <.001 (1,4901) 9.26 .002 
Group * cycle phase  (3,784) .46 .708 (3,774) .45 .720 -1) -1) -1) 
PAlow (W-S)  * cycle phase  (3,5556) .41 .743 (3,5540) .33 .802 -
1) -1) -1) 
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PAlow (W-S) * group (1,5384) 3.00 .083 (1,5389) 3.03 .082 -
1) -1) -1) 
PAlow (W-S)  * group * 
cycle phase 
(3,5556) .42 .740 -1) -1) -1)    
Fixed effects (predictor 
rumination) 
         
Intercept (1,445) 276.55 <.001 (1,445) 276.61 <.001 (1,443) 278.90 <.001 
Group (1,116) .62 .434 (1,116) .62 .431 (1,116) .69 .409 
Cycle phase (3,770) 3.05 .029 (3,765) 2.99 .030 (3,765) 2.83 .038 
Aggregated mean 
rumination  
(1,118) .58 .449 (1,118) .60 .439 (1,117) .62 .435 
Rumination (W-S) (1,5530) 5.67 .017 (1,5533) 5.76 .016 (1,5513) 5.89 .015 
Group * cycle phase (3,769) .70 .555 (3,766) .67 .571 -1) -1) -1) 
Rumination (W-S)  * cycle 
phase  
(3,5586) 1.37 .250 (3,5590) 1.69 .167 -1) -1) -1) 
Rumination (W-S) * group (1,5531) 4.65 .031 (1,5531) 4.71 .030 (1,5517) 4.21 .040 
Rumination (W-S)  * group 
* cycle phase 
(3,5587) .46 .713 -1) -1) -1)    
Note. Aggregated mean: Aggregated mean at the person level. W-S: within-subject (person mean-centered). The dependent variable 
cortisol was entered log-transformed. Models include random intercepts at level 2 and 3 as well as fixed effects for time and time². 
Confounding variables were only retained in the models when significant (p < 0.05), which applies to time of awakening, physical 
activity and sleep duration. 1) Non-significant interactions were excluded stepwise.  
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3 STUDY 2: RECIPROCAL EFFECTS BETWEEN COGNITIVE AND 
AFFECTIVE STATES IN WOMEN WITH PREMENSTRUAL 
DYSPHORIC DISORDER: AN ECOLOGICAL MOMENTARY 
ASSESSMENT STUDY 
An adapted version of this chapter is under 2nd review as „Beddig, T., Reinhard, I., 
Ebner-Priemer, U., and Kuehner, C. Reciprocal effects between cognitive and 
affective processes in women with Premenstrual Dysphoric Disorder: An Ambulatory 
Assessment Study.“  
 
3.1 Abstract 
Premenstrual Dysphoric Disorder (PMDD) is characterized by cyclical mood changes 
resulting in clinically significant distress and functional impairment. Studies on 
momentary cognitive and affective states and their interplay during daily life over the 
menstrual cycle in affected women are still lacking. Using Ecological Momentary 
Assessment with electronic diaries, 61 women with current PMDD and 61 healthy 
control women reported their current mood, rumination, and self-acceptance eight 
times a day over two consecutive days per cycle phase (menstrual, follicular, 
ovulatory, and late luteal phase). Results revealed that women with PMDD showed 
significant increases in negative affect and rumination and decreases in positive 
affect and self-acceptance toward the end of the cycle. Lagged analyses 
demonstrated stronger within-person reciprocal effects of cognitions and mood in 
PMDD women compared to controls with the effect of rumination on subsequent 
negative affect being limited to the late luteal phase. Identified stronger prospective 
associations between cognitive processes and mood deteriorations in women with 
PMDD suggest that affected women are more sensitive to detrimental effects of 
either dimension. Hence, therapeutic strategies aiming at reducing ruminative 
thoughts and improving self-acceptance such as mindfulness-based interventions 
could be promising for reducing the burden of PMDD. 
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3.2 Introduction 
3.2.1 Background 
Premenstrual Dysphoric Disorder (PMDD) is the most severe form of premenstrual 
burden, causing clinically significant distress and marked impairment of psychosocial 
functioning (Lanza di Scalea & Pearlstein, 2019). Outlined as a new diagnostic 
category in DSM-5, PMDD is defined by the presence of at least five symptoms 
during the late luteal phase of the menstrual cycle including at least one out of four 
marked affective symptoms such as affective lability, irritability, depressed mood or 
anxiety (APA, 2013). A full diagnosis requires daily symptom ratings over two 
symptomatic cycles, although a provisional diagnosis of PMDD can be made without 
(APA, 2013). While the less severe premenstrual syndrome has a prevalence of 
about 13-20% in community samples depending on the underlying diagnostic criteria 
(Beddig & Kuehner, 2017; Wittchen et al., 2002), PMDD afflicts 3-8% of women in 
fertile ages (Dennerstein et al., 2012; Lanza di Scalea & Pearlstein, 2019). PMDD 
frequently takes a chronic course (Wittchen et al., 2002), and suicidality is increased 
(Owens & Eisenlohr-Moul, 2018; Pilver et al., 2013).  
In light of the high comorbidity and symptom overlap between PMDD with Major 
Depression and anxiety disorders shared vulnerability factors have been proposed. 
One such transdiagnostic factor might be rumination, defined as the tendency to 
passively and repetitively analyze one’s distress, problems, and concerns, without 
taking actions (Nolen-Hoeksema & Watkins, 2011). Previous research showed that 
rumination in response to negative mood is a stable risk factor for mental disorders, 
especially for depression  (e.g. Huffziger, Reinhard, & Kuehner, 2009; Lyubomirsky et 
al., 2015; Nolen-Hoeksema et al., 2008) but also for other common mental disorders 
(Nolen-Hoeksema & Watkins, 2011). Following the transdiagnostic perspective, 
maladaptive cognitive processes such as rumination could also play a role in the 
etiology and maintenance of PMDD. In women with PMDD, cognitive processes have 
been relatively understudied and if so have been dominated by investigations of 
respective traits or habitual coping styles. It is thought that those women suffering 
from premenstrual changes who have a ruminative response style may be more 
vulnerable to developing PMDD (cf. Craner et al., 2014; 2015) pointing toward a 
multifactorial model in which psychological factors interact with physiological cycle 
changes. In fact, former studies found that women with premenstrual disorders tend 
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to use less helpful coping strategies such as rumination (Craner et al., 2014), 
behavioral impulsivity (Petersen et al., 2016), non-acceptance of emotional 
responses (Reuveni et al., 2016), catastrophizing (Eggert et al., 2016) or harm-
avoidance (Hsu, Liu, & Hsiao, 2007; Miller et al., 2010). There is also some evidence 
that trait rumination is associated with steeper increases in premenstrual depressive 
symptoms (Dawson et al., 2018). Furthermore, trait rumination was found to mediate 
the relationship between anxiety sensitivity and premenstrual distress (Sigmon et al., 
2009). A study by Craner et al. (2015) examined momentary maladaptive 
psychological processes showing that in response to experimentally induced 
negative affect (NA) women with premenstrual disorders reacted with high levels of 
self-focused attention. Affected women also reported higher general use of 
ruminative coping and self-focused attention compared to controls. The authors 
propose that the tendency of affected women to use a passive, emotion-focused, 
ruminative coping style is likely to increase emotional symptoms. Correspondingly, in 
a recent randomized controlled trial the use of active coping strategies was 
associated with symptom relief in PMDD (Weise et al., 2019).  
In contrast to studies investigating trait aspects of rumination, research on moment-
to-moment relationships between state cognitions and distress during daily life in 
women with PMDD is lacking. To study such phenomena, an Ecological Momentary 
Assessment (EMA) study design is most appropriate. Here, multiple real-time 
assessments take place during daily life, and the resulting longitudinal data series 
allow the investigation of variability of momentary affect and cognitions and their 
temporal relationship within individuals (cf. Trull & Ebner-Priemer, 2013). In the 
context of PMDD research, EMA also enables to study variability of such phenomena 
across the menstrual cycle within persons and to compare women with and without 
PMDD with this regard. In contrast to PMDD research, there is growing EMA-
literature examining prospective effects of momentary cognitive processes on affect 
and vice versa in other populations. For example, momentary rumination predicted 
subsequent levels of NA in clinical (e.g. Kircanski et al., 2018; Ruscio et al., 2015) 
and in community samples (e.g. Moberly & Watkins, 2008). Naturally occurring NA 
was in turn found to be followed by increased levels of rumination, suggesting a 
reciprocal relation between these two constructs (Moberly & Watkins, 2008). 
Furthermore, effects of momentary cognitive processes on positive emotions have 
been documented in the context of mindfulness (Garland et al., 2015; Jimenez, Niles, 
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& Park, 2010; Timm et al., 2018; Welz, Reinhard, Alpers, & Kuehner, 2018). There is 
evidence that dispositional mindfulness is associated with higher levels of positive 
emotions and self-acceptance during daily life (Jimenez et al., 2010), and a recent 
study by Timm et al. (2018) demonstrated that mindfulness training led to improved 
positive affect (PA) and self-acceptance in remitted depressed patients, whereas NA 
and rumination decreased. Following these findings, rumination and NA as well as 
self-acceptance and PA appear to be tightly linked in daily life. While ruminative 
thinking and negative mood seem to be driven by a downward spiral especially in 
clinical samples (e.g. Kircanski et al., 2018; Nolen-Hoeksema et al., 2008), an 
upward spiral has been proposed for positive thinking and PA (Garland, et al. 2015). 
Given the strong affective component in PMDD, the possible role of cognitive 
processes in influencing affective processes is of particular interest. Since symptoms 
occur in a cyclical recurring pattern, it is likely that women with PMDD are especially 
vulnerable to dysfunctional cognitions during the late luteal phase of the menstrual 
cycle (cf. Read, Perz, & Ussher, 2014). Hence, similar to studies with other clinical 
samples (e.g. Kircanski et al., 2018), a downward spiral of increased rumination and 
decreased self-acceptance exerting mood worsening and vice versa might be 
effective in PMDD women particularly in the late luteal phase. Using EMA in PMDD 
research has been repeatedly called for (see Bosman et al., 2016; Owens & 
Eisenlohr-Moul, 2018), and we have implemented a first EMA study in this context 
(Beddig, Reinhard, & Kuehner, 2019). Here, we could already demonstrate that 
women with PMDD showed heightened subjective stress reactivity towards daily life 
stressors particularly during the late luteal phase and a blunted activity of the 
hypothalamic-pituitary-adrenal axis (HPAA) across the menstrual cycle. 
3.2.2 Study aims 
Aims of the present paper were as follows. We first sought to examine possible 
menstrual cycle-related variations in affective and cognitive states in the PMDD 
sample by Beddig, Reinhard, et al. (2019). It was expected that in PMDD women 
negative mood and rumination would be highest whereas positive mood and self-
acceptance would be lowest during the late luteal phase compared to other cycle 
phases, while no such cycle-related effects were expected for controls. The second 
aim was to investigate possible reciprocal time-lagged relationships between 
rumination and NA as well as between self-acceptance and PA by also checking for 
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possible cycle-dependent effects. Specifically, it was hypothesized that prospective 
effects of cognitive on affective states and vice versa would be stronger in PMDD 
women compared to controls, particularly in the late luteal phase. 
3.3 Method 
3.3.1 Participants 
Women were recruited via local family doctors and gynecologists, flyers, social 
networks, and the homepage of the Central Institute of Mental Health (CIMH, for 
detailed information see also Beddig, Reinhard et al., 2019). To take part in the 
study, women had to fulfill the following inclusion criteria: a) age between 20 and 42, 
b) consistent length of menstrual cycle between 22 and 34 days, c) fulfillment of 
diagnostic criteria of a PMDD diagnosis based on DSM-5 criteria (PMDD group) or 
exempt from any PMDD affective core symptoms (control group). Exclusion criteria 
were being pregnant or lactating during the last six months, a history of gynecological 
diseases, use of hormonal contraceptives and pharmaceutical medication, late 
evening or night shifts, body mass index < 18 or > 35, a lifetime history of psychotic 
or bipolar disorder, and current alcohol or substance abuse or dependence. Controls 
were matched regarding age and education. Initially 140 women were enrolled, of 
whom 18 (12.9%, nine per group) withdrew from the study during the EMA phase. 
Reasons for discontinuating included inconsistencies with menstrual cycle reports (n 
= 14), severe technical problems (n = 2), decision to start hormonal contraceptives (n 
= 1), and positive pregnancy test (n = 1). Hence, the final sample consisted of 61 
women diagnosed with PMDD and 61 controls. The study protocol was approved by 
the ethics committee of the Medical Faculty Mannheim, Heidelberg University. All 
participants gave written informed consent and were paid 100€ for completing the 
study. 
3.3.2 Ecological Momentary Assessment (EMA) procedure 
EMA was carried out using Motorola Moto G 2nd Generation smartphones with the 
software movisensXS, version 0.6.3658 (movisens GmbH, Karlsruhe, Germany). 
EMA took place during four cycle phases of a menstrual cycle with two consecutive 
EMA-days per cycle phase. Individual calendars were prepared for each woman 
based on the date of her last menstruation onset and the average length of her 
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menstruation and of her menstrual cycle. Assessments during the menstrual phase 
took place on the second and third day of menstruation (M = 2.95 days, SD = 2.21). 
The follicular phase was examined on the second and third day after the end of 
menstruation (M = 8.61 days, SD = 1.94). The ovulatory phase (M = 17.15 days, SD 
= 2.0) was determined by a chromatographic ovulation test (gabControl hlH 
Ovulationsteststreifen, gabmed, Cologne) indicating a rise in luteinizing hormone 
levels in urine. Participants were asked to start testing a few days before the 
predicted ovulation until the result was positive, and then to complete the diary on the 
next two days. If ovulation did not occur, participants were asked to repeat the test in 
the following menstrual cycle. Assessments of the late luteal phase took place on the 
fourth and third day before the next menstruation was expected (M = 26.38 days, SD 
= 3.02). Phases were validated according to the ovulation test and the exact time of 
the onset of the next menses. To avoid sequence effects, participants started EMA in 
different cycle phases.  
There were eight assessments per day, with the first assessment taking place at 9.00 
a.m. and the remaining seven assessments taking place between 10:00 a.m. and 
09:30 p.m. at random time points at averaged 103 min apart (SD = 25.0) with a 
minimum interval of 45 min. Each assessment was announced by an acoustic signal 
and took 3-4 min to complete. Participants had 5 min to respond, and assessments 
could be delayed by 15 min. If participants were unable to respond or rejected the 
alarm, the assessment was saved as missing. After having completed the EMA days 
participants returned the device and were compensated for their participation. 
3.3.3 Structured assessment of psychopathology 
The diagnosis of PMDD was verified using the Structured Interview for DSM-IV TR 
PMDD (SCID-PMDD; Accortt et al., 2011) during the diagnostic baseline session. 
The SCID-PMDD includes all symptom criteria together with the required impairment 
criterion and the exclusion criterion of a mere exacerbation of symptoms of another 
disorder. The interview format is modeled after SCID-I (see below) and has shown 
high interrater reliability (α = 0.96) (Accortt et al., 2011). For the PMDD group, the 
criteria for PMDD according to the SCID-PMDD had to be met with the diagnostic 
algorithm adapted for DSM-5. To avoid further participant burden, prospective daily 
ratings during at least two symptomatic cycles before study inclusion were not 
required. Control women had to be free of any PMDD affective core symptoms. 
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Premenstrual physical symptoms were not an exclusion criterion for controls, given 
the fact that the majority of naturally cycling women are experiencing physical 
symptoms of varying degree during the late luteal and menstrual phase (Tschudin, 
Bertea, & Zemp, 2010). 
Other mental health comorbidities and exclusion criteria were assessed with the 
SCID-I Interview (Wittchen et al., 1997), a psychometrically sound semi-structured 
interview for mental disorders. Furthermore, demographics were assessed during the 
baseline session together with the severity of depressive symptoms, measured with 
the 21-item Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996) and trait 
anxiety measured with the 20-item Spielberger Trait Anxiety Inventory (STAI-T; 
Spielberger, Gorsuch, & Lushene, 1970). Interviews were conducted by a trained 
research psychologist.   
3.3.4 Ecological Momentary Assessment (EMA) variables 
NA and PA. At each assessment, participants responded on a 7-point Likert scale to 
negative and positive mood adjectives. For NA, participants were asked to rate how 
upset, irritated, nervous, listless, down and bored they felt and for PA how cheerful, 
energetic, enthusiastic, satisfied, relaxed and calm they felt. These items were 
derived from the Positive and Negative Affect Schedule (PANAS; Watson et al., 
1988) and have been used in previous EMA-studies (Kuehner et al., 2017; Timm et 
al., 2018; Welz et al., 2018).  
Rumination. Rumination was assessed on a 7-point Likert scale with the item “At the 
moment I am stuck on negative thoughts and cannot disengage from them”, 
capturing the uncontrollability facet of rumination (cf. Kuehner et al., 2017; Raes, 
Hermans, Williams, Bijttebier, & Eelen, 2008; Timm et al., 2018).  
Self-acceptance. Self-acceptance was assessed with the item “At the moment I 
accept myself how I am” on a Likert scale 1-7 (cf. Timm et al., 2018).  
Daily stress events. To assess daily stress events subjects reported on a 7-point 
bipolar scale (−3 = very unpleasant, 0= neutral, and 3 = very pleasant) the most 
important event between the current and the previous beep (cf. Wichers et al., 2009). 
3.3.5 Data Analysis 
Statistical analyses were performed using multilevel models, taking into account that 
the present data were organized within nested levels. Analyses showed that for all 
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dependent variables the three-level model including the day-level had a better fit than 
the two-level model according to fit indices (AIC and BIC) (Hox et al., 2017). 
Therefore, for each outcome a multilevel model assuming three levels was applied 
with single assessments (level 1) nested within days (level 2), nested within persons 
(level 3). All models included random intercepts at level two and three, allowing 
individual baseline levels of the dependent variables to differ between persons and 
days. All statistical models included group status (PMDD/controls), cycle phase 
(menstrual, follicular, ovulatory, and late luteal) as a categorical variable, and the 
interaction group*menstrual cycle phase. Further we controlled for day (sampling 
days 1 to 8) to account for assessment reactivity and for time of the day to account 
for time-dependent variation within days in respective outcomes. For each outcome 
we checked whether time² was significant, and if so retained it in the models. The 
quadratic time effect was only significant for NA which was highest in the mid-
afternoon.  
To examine prospective effects of daily life variables, lagged values were constructed 
for all observations, except for those representing the first response of a day. In the 
respective models, all main effects as well as the 2- and 3-way interactions between 
predictors were included. The models tested the effect of the lagged predictor 
variable (e.g. rumination) at time t on the respective outcome variable (e.g. NA) at 
time t + 1, while controlling for the lagged outcome at time t to account for any 
carryover, and for the lagged predictor aggregated at the person level at time t to 
adjust for time invariant between-subject effects (B-S). To facilitate interpretation, 
predictor variables were person-mean centered prior to the analyses. This produced 
within-subject (W-S) predictors that vary within, but not between individuals. 
Importantly, these predictors, originally measured on a continuous scale, were 
entered as dichotomized variables via person mean split due to the application of 
complex multilevel models. Dichotomization resulted in binary variables. Here, the 
focus of analysis was to compare worse states than usual with usual or better states 
(e.g. NA (W-S) > 0 describes NA above the intraindividual average level compared to 
NA (W-S) ≤ 0, which describes NA equal or below average level). In doing so we 
were able to estimate and test conditional interactions (in case of significant 3-way 
interactions) and to evaluate simple effects (in case of significant 2-way interactions), 
which is essential especially if checking for cycle-dependent changes (i.e., 3-way 
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interactions group*cycle phase*predictor, in which interactions of each pair of 
variables are allowed to vary with the level of the third variable).  
As an example of such a multilevel model (here: lagged rumination predicting 
negative affect (NA)), the level 1 model can be described as: 
Y (negative affect) ijk = π0jk  +  π1jk(cp_nr) * cycle phase(cp_nr)ijk   +   π2jk * lagged 
negative effectijk +  π3jk * time of dayijk   +   π4jk * (time of day)
2
ijk   +   π5jk * lagged 
rumination (dich)ijk + π6jk(cp_nr) * cycle phase(cp_nr)ijk  X   lagged rumination (dich)ijk    
+  εijk .  
Here, Yijk represents the level of negative affect at time i at assessment day j for 
person k. The π coefficients represent the intercept and the fixed main and 
interaction effects at level 1, the εijk denote the residuals at level 1. The level 2 model 
can be described as: 
π0jk = β00k +  β01k * assessment dayjk  +  u0jk (and π1jk = β10k;  π2jk = β20k; π3jk = β30k; 
π2jk = β20k; …; π6jk = β60k) with the u0jk representing random intercepts for the 
assessment day j within person k. The level 3 model can be described as: 
β00k = γ000  +  γ001 * groupk  +  γ002 * lagged rumination (B-S)k  +   v00k ; 
β01k = γ010 ;  β10k = γ100  +  γ110  * groupk ;   β20k = γ200 ;  β30k = γ300 ;  β40k = γ400 ;   
β50k = γ500  +  γ510 * groupk ;    β60k = γ600  +  γ610 * groupk   .      
Here the v00k indicate the random intercept for person k. Note that we included three 
dummy variables for the categorical variable cycle phase, and the appendix “(cp_nr)” 
indicates a specific cycle phase.   
To control for possible confounding effects of depressive symptom severity, trait 
anxiety symptoms and daily stress events, analyses were repeated by controlling for 
these variables.  
Our hypotheses-driven main analyses investigating 3-way interactions (cycle 
phase*lagged predictor*group) were not Bonferroni-adjusted. In case of a 
nonsignificant effect with cycle phase, we looked at possible significant 2-way 
interactions (group*lagged predictor) in the model, the latter indicating phase-
independent group differences in the association between lagged predictor and 
outcome. Since these analyses were explanatory, respective significance levels were 
Bonferroni-corrected for multiple testing. Similarly, all post hoc tests were Bonferroni-
adjusted. All statistical analyses were performed using the statistical software IBM 
SPSS Version 23. The significance level was set at α = 0.05. 
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3.4 Results 
3.4.1 Compliance 
Statistical analyses were based on 122 participants (PMDD group: N = 61; control 
group: N = 61). Altogether, 6818 of 7808 possible assessments were recorded, which 
corresponds to an overall response rate across participants of 87.3%, reflecting a 
high level of compliance (cf. Courvoisier, Eid, & Lischetzke, 2012). 
 
Table 1 
Descriptions of Women with PMDD and Controls 
 PMDD (n = 61) 
% / M (SD) 
Controls (n = 
61) 
% / M (SD) 
Test statistic p 
Demographic Variables     
Age 29.4 (5.8) 29.5 (5.1) t=-0.03 .977 
Education (% with high 
school degree  
72.1% 75.4% Chi
2
=0.17 .681 
Work Situation (% in regular 
job or education) 
80.3% 90.2% Chi
2
=2.35 .126 
Marital Status (% married or 
living together) 
60.7% 59.0% Chi
2
=0.03 .853 
Children (%) 24.6% 26.2% Chi
2
=0.04 .835 
BMI 23.6 (4.1) 23.5(4.3) t=0.12 .903 
Clinical Variables     
Lifetime Diagnosis of 
Depression (SCID-I) 
54.1% 21.3% Chi
2
=13.96 <.001 
BDI-II
1 
score at baseline 10.9 (8.9) 4.8 (5.6) t=4.53 <.001 
STAI-T² score at baseline 45.6 (11.3) 37.2 (8.6) t=4.61 <.001 
EMA³ Variables     
Compliance Rate  86.6% 88.0% Chi
2
=33.62 .071 
Duration (in days) of 
Menstrual Cycle during 
EMA 
29.0 (3.1) 29.4 (3.7) t=-0.77 .444 
Duration (in days) of Period 
during EMA 
5.3 (1.1) 5.6 (1.7) t=-0.85 .399 
1BDI-II=Beck Depression Inventory-Revised.²STAI-T= Spielberger Trait Anxiety Inventory. 
³EMA=Ecological Momentary Assessment 
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3.4.2 Descriptives 
Descriptive information on demographic, clinical, and EMA variables are listed in 
Table 1. Groups did not significantly differ with respect to age, education, marital 
status, work situation, percentage with children, and mean duration of the menstrual 
cycle. In contrast, PMDD women displayed higher BDI-II mean scores, higher trait 
anxiety levels, and a larger percentage had a lifetime diagnosis of depression. 
3.4.3 Cycle dependent variation of affect and cognitions 
To investigate whether women with and without PMDD differed in cognitive and 
affective states over the menstrual cycle, four separate models were calculated. As 
shown in Table 2, the group*cycle phase interaction was significant in predicting NA 
(p < 0.001), PA (p < 0.001), rumination (p < 0.001), and self-acceptance (p < 0.001). 
Post hoc tests using Bonferroni correction revealed higher levels of NA and 
rumination as well as lower levels of PA during the late luteal phase in women with 
PMDD compared to all other cycle phases (p’s ≤0.01) and decreased levels of self-
acceptance compared to the follicular and ovulatory phase (pmenstrual = 0.164, pfollicular 
< 0.001, povulatory < 0.001). In contrast, no cycle phase effect on momentary states 
was observed in control women (all p’s > 0.55). For graphical demonstration, see 
Figure 1. 
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Table 2 
Fixed Effects of Menstrual Cycle Phase and Group on Negative Affect, Positive Affect, 
Rumination, and Self-Acceptance  
Outcome  Menstrual Cycle Phase Group * Cycle Phase  
 Group Menstrual  Follicular Ovulatory Late 
Luteal 
df  F p 
Negative 
Affect 
PMDD 
Controls 
2.8±1.2 
2.1±1.1 
2.4±1.1 
2.1±1.1 
2.6±1.1 
2.2±1.2 
3.2±1.2 
2.2±1.1 
(3,836) 20.07 <.001 
Positive 
Affect 
PMDD 
Controls 
3.8±1.3 
4.4±1.2 
4.2±1.2 
4.5±1.1 
4.2±1.2 
4.4±1.2 
3.5±1.1 
4.3±1.2 
(3,845) 15.87 <.001 
Rumina-
tion 
PMDD 
Controls 
2.5±1.5 
1.8±1.1 
2.1±1.4 
1.9±1.3 
2.2±1.5 
1.9±1.3 
2.8±1.7 
1.9±1.3 
(3,830) 15.80 <.001 
Self- 
Accep-
tance 
PMDD 
Controls 
4.7±1.6 
5.6±1.3 
5.2±1.5 
5.5±1.3 
5.1±1.4 
5.5±1.4 
4.5±1.5 
5.5±1.4 
(3,840) 18.92 <.001 
Note. Models included random intercepts at level 2 and 3 as well as fixed effects for time, 
time² (if significant), day, group, and cycle phase.  
 
 
Fig. 1. Estimated mean scores of daily life variables (NA: negative affect; PA: positive affect; 
RUM: rumination; SA: self-acceptance) over the menstrual cycle for women with PMDD and 
controls. Note. Error bars represent standard error of the mean. Models include random 
intercepts at level 2 and 3 as well as fixed effects for time, time² (if significant), assessment 
day, group, and cycle phase. 
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3.4.4 Time-lagged models of predictors and outcomes 
3.4.4.1 Time-lagged models of NA and rumination 
The analysis investigating lagged rumination predicting NA revealed significant time-
lagged associations varying across menstrual cycle phases and groups (group* cycle 
phase* rumination lag (F(3, 4935) = 2.87, p = 0.035, see Table 3). Post hoc tests 
using Bonferroni correction revealed that in PMDD women, momentary levels of 
rumination (at time t) above their individual average significantly predicted a 
premenstrual increase in NA at the subsequent time point (t+1) (p < 0.01), whereas 
for controls no menstrual cycle-related effect was observed (all p’s > 0.37) (see 
Figure 2 A).  
 
Fig. 2. Estimated mean values of the time-lagged outcomes negative affect (NA, with 
predictor rumination (RUM), Fig. 2 A) and RUM (with predictor NA, Fig. 2 B) as well as time-
lagged outcomes positive affect (PA, with predictor self-acceptance (SA), Fig. 2 C) and SA 
(with predictor PA, Fig. 2 D) for women with PMDD and controls. Note. Error bars represent 
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standard error of the mean. W-S: within-subject (person mean-centered). Models include 
time, time² (if significant), assessment day, group, cycle phase, lagged outcome and lagged 
predictor aggregated at the person level as covariates.  
 
The analysis investigating lagged NA predicting rumination revealed no significant 
three-way interaction group* cycle phase* NA lag (F(3, 5270) = .24, p = 0.868). 
However, we identified a significant group* NA lag effect (F(1, 5242) = 7.42, p = .018 
(Bonferroni-corrected), see Table 3). Figure 2 B indicates that in PMDD women 
momentary NA levels (at time t) above average resulted in a stronger increase in 
momentary rumination at the subsequent time point (t+1) compared to controls 
regardless of cycle phase. Post hoc tests revealed that for both groups the 
prospective effect of NA on rumination was significant (PMDD: p < 0.001, controls: p 
< 0.001). 
 
Table 3  
Time-lagged Models of Negative Affect and Rumination  
  3-way Interaction Model 
 df F p 
Outcome Negative 
Affect  t+1 
   
Fixed effects    
Intercept (1,160) 90.33 <.001 
Group (1,121) 13.75 <.001 
Cycle phase (3,585) 16.05 <.001 
Negative Affect  (W-S) (t) (1,4814) 355.84 <.001 
Rumination (B-S)  (1,119) 167.01 <.001 
Rumination (W-S) (t) (1,5257) .25 .618 
Group * Cycle phase (3,588) 16.86 <.001 
Rumination * Group  (1,5306) .11 .746 
Rumination *  
Cycle phase 
(3,4942) .55 .648 
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1before Bonferroni correction 
Note. W-S: within-subject (person mean-centered). B-S: between-subject. Models include 
random intercepts at level 2 and 3 as well as fixed effects for time, and assessment day. 
Time t+1 denotes the following prompt 
3.4.4.2 Time-lagged models of PA and self-acceptance 
The analysis investigating lagged self-acceptance predicting PA revealed no 
significant effect of group*cycle phase*self-acceptance lag  (F(3, 2779) = 0.49, p = 
0.689). We identified a significant interaction group*self-acceptance lag (F(1, 44400) 
= 7.86, p = 0. 015 (Bonferroni-corrected), see Table 4). Figure 2 C indicates that in 
PMDD women momentary levels of self-acceptance below average (at time t) 
resulted in a stronger decrease in PA at the subsequent time point (t+1) compared to 
controls regardless of cycle phase. Post hoc tests revealed that the prospective effect 
of self-acceptance on PA was only significant in women with PMDD (p < 0.001), not 
in controls (p = 0.936). 
Rumination *  
Group * Cycle phase 
(3,4935) 2.87 .035 
Outcome Rumination 
t+1 
   
Fixed effects    
Intercept (1,128) 3.81 .053 
Group (1,118) .24 .624 
Cycle phase (3,5215) 9.82 <.001 
Rumination (W-S) (t) (1,5207) 168.78 <.001 
Negative Affect (B-S) (1,117) 168.19 <.001 
Negative Affect (W-S) (t) (1,5244) 56.77 <.001 
Group * Cycle phase (3,5216) 12.68 <.001 
Negative Affect *  
Group  
(1,5242) 7.42 .0061 
Negative Affect * 
Cycle phase 
(3,5271) 1.43 .233 
Negative Affect *  
Group * Cycle phase 
(3,5270) .24 .868 
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While the analysis investigating lagged PA predicting self-acceptance revealed no 
significant three-way interaction group*cycle phase* PA lag  (F(3, 5212) = 0.90, p = 
0.438), the interaction group* PA lag demonstrated a significant effect on self-
acceptance (F(1, 5201) = 16.70, p < 0.001 (Bonferroni-corrected), see Table 4). 
Figure 2 D indicates that in PMDD women momentary levels of PA below average (at 
time t) resulted in a stronger decrease in self-acceptance to the subsequent time 
point (t+1) compared to controls regardless of cycle phase. Post hoc tests revealed 
that the prospective effect of PA on self-acceptance was only significant in women 
with PMDD (p < 0.001), not in controls (p = 0.147). 
 
Table 4  
Time-lagged Models of Positive Affect and Self-acceptance 
  3-way Interaction Model 
 df F p 
Outcome  
Positive Affect t+1 
   
Fixed effects    
Intercept (1,128) 124.89 <.001 
Group (1,120) 8.07 .005 
Cycle phase (3,486) 13.73 <.001 
Positive Affect (W-S) (t) (1,4758) 372.84 <.001 
Self-acceptance (B-S)  (1,120) 125.69 <.001 
Self-acceptance (W-S) (t) (1,4886) 5.80 .016 
Group * Cycle phase (3,487) 8.61 <.001 
Self-acceptance * Group  (1,4440) 7.86 .0051 
Self-acceptance *  Cycle 
phase 
(3,2797) 2.39 .067 
Self-acceptance * Group 
* Cycle phase 
(3,2779) .49 .689 
Outcome  
Self-acceptance  t+1 
   
Fixed effects    
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1 before Bonferroni correction 
Note. W-S: within-subject (person mean-centered). B-S: between-subject. Models include 
random intercepts at level 2 and 3 as well as fixed effects for time, and assessment day. 
Time t+1 denotes the following prompt.  
3.4.4.3 Confounder analysis 
Including the severity of depressive symptoms (BDI-II), anxiety symptoms (STAI-T) 
and daily stress events as covariates did not change any of the reported effects. 
Therefore, the present results were not affected by possible group differences in 
depressive and anxiety symptom severity and daily stress events. 
3.5 Discussion 
3.5.1 Summary of Results 
The purpose of the current EMA study was to explore menstrual cycle-related 
variations of affective and cognitive states during daily life and to examine time-
lagged associations between these states in women with PMDD and healthy 
controls. While affective symptoms of low mood, decreased interest, irritability, and 
anxiety occur as part of many mental disorders, the prominent feature that 
distinguishes PMDD from similar entities is its time course, with the late luteal phase 
confinement of symptoms (APA, 2013). In this regard, our EMA data - prospectively 
Intercept (1,120) .20 .656 
Group (1,119) .02 .894 
Cycle phase (3,5199) 7.23 <.001 
Self-acceptance (W-S) (t) (1,5197) 789.63 <.001 
Positive Affect (B-S) (1,119) 133.12 <.001 
Positive Affect (W-S)  (t) (1,5200) 31.79 <.001 
Group * Cycle phase (3,5199) 11.05 <.001 
Positive Affect * Group  (1,5201) 16.70 <.0011 
Positive Affect * Cycle 
phase 
(3,5212) 2.35 .071 
Positive Affect *  
Group * Cycle phase 
(3,5212) .90 .438 
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collected over the menstrual cycle and analyzed with multilevel models – show that 
women with PMDD exhibited the highest NA and the lowest PA in the late luteal 
phase, thereby clearly confirming a symptomatic state of mood deterioration during 
this phase in a naturalistic, real-time context in the present PMDD sample. Moreover, 
PMDD women also reported highest levels of rumination and lowest levels of self-
acceptance during the late luteal phase. In contrast, healthy women did not show any 
cycle-dependent variation of mood and cognitions.  
Lagged models revealed that especially in the late luteal phase PMDD women 
reacted to high levels of rumination with increased levels of NA. Therefore, intensive 
rumination seems to have a particular mood-impairing effect toward the end of the 
cycle in these women. Previous studies have indicated that habitual rumination is 
associated with experiencing premenstrual distress (Craner et al., 2014; Dawson et 
al., 2018). By focusing on momentary within-person associations this study adds 
significantly to existing research by showing that particularly in the late luteal phase 
intraindividual high levels of rumination predicted deterioration in NA in women with 
PMDD. Our results further indicate that in PMDD women increased NA levels 
predicted a stronger subsequent increase in rumination compared to controls 
regardless of cycle phase. This adds to previous research examining habitual coping 
styles in the context of premenstrual disorders (e.g. Craner et al., 2014, 2015; 
Petersen et al., 2016; Reuveni et al., 2016). By focusing on state cognitions the 
present study shows that women with PMDD tend to ruminate in response to 
negative affective states more strongly than nonaffected women across the 
menstrual cycle, thereby pointing toward a trait-like characteristic of ruminative 
responses to negative affect in PMDD.  
Taking both lagged paths together our findings suggest a reciprocal relationship 
between rumination and NA especially in the late luteal phase. Following the 
transdiagnostic perspective of rumination as a dysfunctional key mechanism in 
mental disorders (e.g. Lyubomirsky et al., 2015; Nolen-Hoeksema et al., 2008, Nolen-
Hoeksema & Watkins, 2011) our findings align with this concept by demonstrating a 
characteristic cycle-dependency in the context of PMDD.  
Moreover, momentary levels of low self-acceptance resulted in a stronger decrease 
in PA and vice versa in PMDD women compared to controls. These observations 
further indicate a stronger sensitivity of affected women for the effects of negative or 
lack of positive self-referential thoughts. Again, we did not identify cycle-dependency 
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for these associations, thereby pointing toward a more general underlying 
vulnerability of negative self-referential thoughts that could make women also more 
likely to developing PMDD. Importantly, controlling for daily stress events, depressive 
symptom severity as well as for trait anxiety levels did not affect the study results. 
Therefore, although comorbidity with lifetime depression was high, our study 
suggests that PMDD characteristics uniquely contributed to the present findings. 
In conclusion, our study  points to the relevance of assessing affective and cognitive 
processes by EMA in real world settings to be able to demonstrate heightened 
vulnerability in women with PMDD towards worsening of their mood and towards 
increased negative and decreased positive self-referential thinking during the late 
luteal phase of their menstrual cycle. Furthermore, EMA enabled us to identify phase-
specific and phase-unspecific reciprocal associations between dysfunctional 
momentary affective and cognitive states in respective within-person associations in 
these women. In general, our findings also strengthen previous research highlighting 
the role of psychological factors in premenstrual disorders (e.g. Craner, et al., 2016; 
Kleinstauber et al., 2016; Reuveni et al., 2016; Weise et al., 2019). 
3.5.2 Future perspectives and clinical implications 
This is likely the first EMA study assessing menstrual cycle-related variations of 
cognitive and affective daily life processes and their interplay in women with PMDD. 
In this context, EMA can clearly improve PMDD research due to higher ecological 
validity of assessed phenomena compared to retrospectively assessed clinical 
symptoms. EMA also typically covers more basic affective and cognitive features and 
may therefore provide greater sensitivity for connecting psychological with biological 
processes (cf. Conner & Barrett, 2012; Huffziger et al., 2013). Furthermore, EMA 
appears to be optimally suited to capture between- as well as within-person variability 
in momentary states and their interplay across the menstrual cycle, which is 
particularly important for studying premenstrual disorders (cf. Bosman et al., 2016; 
Owens & Eisenlohr-Moul, 2018).  
Study findings might be relevant for therapeutic perspectives in PMDD. Results 
revealed that women with PMDD seem to be more prone of using rumination as a 
trait-like emotion regulation strategy to deal with negative affect states across cycle 
phases, whereas high intraindividual rumination levels seem to trigger affect 
deterioration particularly in the late luteal phase. Hence, rumination, identified as 
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transdiagnostic risk factor for a series of mental disorders (cf. Nolen-Hoeksema & 
Watkins, 2011)  may also be a potential therapeutic target for reducing the burden of 
PMDD. In this context mindfulness based interventions appear to be promising (cf. 
Petersen et al., 2016). For example a non-clinical study by Lustyk et al. (2011) found 
that high dispositional mindfulness was linked to less premenstrual symptoms, and 
studies with other clinical samples (e.g. Garland et al., 2015; Timm et al., 2018) 
showed that mindfulness training reduced negative and enhanced positive daily life 
cognitions such as momentary rumination and self-acceptance, and improved affect. 
However, methodological sound randomized controlled trials examining mindful 
interventions in women with PMDD are still lacking, which might be an important 
purpose for future research. In parallel, a first randomized controlled trial examining 
internet-based cognitive-behavioral therapy for PMDD by Weise et al. (2019) 
demonstrated that active coping when dealing with premenstrual symptoms predicted 
better treatment outcome, thereby underlining the importance to address coping 
styles. Clearly, further research is warranted to assess which interventions are 
effective in women with PMDD. Moreover, longitudinal research would aid in 
identifying predictive effects of momentary cognitive and affective processes and 
their interplay for the clinical course of PMDD, which could, in turn, provide targeting 
aims for therapy. 
3.5.3 Strengths and limitations 
Strengths of the current study include the investigation of a relatively large PMDD 
sample together with a control sample strictly matched regarding age and education 
level, the intensive longitudinal EMA-design covering all four cycle phases, the 
validation of the ovulation phase by a chromatographic ovulation test and the focus 
on temporal within-person processes to understand the momentary relationships 
between cognitive and affective states.  
The study also has some limitations. First, given the exclusion of antidepressant and 
hormonal treatments, which are currently the most frequent treatments for PMDD 
(Epperson et al., 2012; Marjoribanks et al., 2013) the results might not be 
representative of all women with PMDD. Second, even though overall compliance 
was high and comparable between groups, nine women per group (12.9%) dropped 
out due to different reasons. This could have led to a sample of more highly 
motivated women. Third, we did not apply the criterion of confirmation of daily 
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symptom ratings during two consecutive symptomatic cycles prior to study inclusion. 
The reason for this was to reduce participant burden in this type of intensive repeated 
random measurement design. Thus, the diagnosis of PMDD must be considered 
provisional. However, prevalence rates of moderate to severe premenstrual 
symptoms derived from retrospective epidemiological studies have been found to be 
consistent with those using prospective ratings (Cunningham et al., 2009). Fourth, 
model complexity of multilevel models resulted in dichotomizing the main time-lagged 
variables of interest, which may have led to reduced explanatory variance. Fifth, to 
further increase the accuracy of conclusions, it would be beneficial to apply the EMA 
protocol over two or more consecutive menstrual cycles, which was not possible in 
the present study due to limited resources and may also provoke participant burden.  
Sixth, the EMA items were administered in a fixed order, thus a potential inflation of 
their associations cannot be excluded. Seventh, our study design does not allow to 
determine causal pathways between PMDD and daily life experiences. So it is 
unclear whether strong time-lagged associations between cognitive and affective 
daily life variables represent a vulnerability factor for developing PMDD or are rather 
the consequence of the disorder. Here, clearly more longitudinal research is 
warranted. A further  limitation refers to the assessment of only two days per cycle 
phase. Although a regular cycle was a premise to take part in the study, we 
sometimes might have missed days with the highest impairment. Finally, we did not 
assess the content of ruminative thoughts. Ruminating about symptoms might be 
especially crucial for affect deteriorations in women with PMDD (cf. Craner et al., 
2014). Further research might address these aspects as well. 
3.5.4 Conclusions 
This EMA-study examined cycle-related variations of momentary cognitive and 
affective characteristics and their time-lagged associations in women with PMDD. 
Findings suggest stronger associations between cognitive (rumination and self-
acceptance) and mood variables (NA and PA) in affected women compared to 
controls. These findings highlight the role of cognitive processes in everyday settings 
and may have important implications for interventions aimed at preventing and 
treating PMDD. 
Study 3: Ambulatory Assessment characteristics predict the clinical course of premenstrual dysphoric 
disorder 
85 
4 STUDY 3: AMBULATORY ASSESSMENT CHARACTERISTICS 
PREDICT THE CLINICAL COURSE OF PREMENSTRUAL 
DYSPHORIC DISORDER  
An adapted version of this chapter has been published as „Beddig, T. & Kuehner, C. 
(2020). Ambulatory Assessment Characteristics predict the Clinical Course of 
Premenstrual Dysphoric Disorder. Psychotherapy and Psychosomatics, 1-2. DOI: 
10.1159/000505999 [Epub ahead of print].” 
4.1 Manuscript 
Premenstrual dysphoric disorder (PMDD, DSM-5) is characterized by severe key 
mood symptoms (mood lability, irritability, depression, anxiety) accompanied by 
cognitive and/or physical symptoms starting during the week before menses (late 
luteal phase) and becoming minimal or absent within the first week after menses 
onset. Symptoms must be severe enough to cause significant suffering or 
psychosocial impairment. The symptom pattern must have been present during a 
majority of cycles within the past year and may not merely represent a premenstrual 
exacerbation of another mental disorder. Research has provided satisfactory 
empirical evidence for the diagnosis which finally led to its inclusion in DSM-5 and 
ICD-11(Reed et al., 2019).  
PMDD affects 2-8% of women of fertile age (Kuehner, 2017). Lifetime comorbidity 
with depressive and anxiety disorders is high, and an overlap with reproductive 
subtypes of depression is common (Kuehner, 2017). Potential etiological factors 
include central nervous system sensitivity to reproductive hormones, genetic factors, 
and psychosocial factors such as stress (Hantsoo & Epperson, 2015). PMDD 
frequently develops a chronic course: in a community sample of affected women the 
syndrome was stable across 48 months with <10% complete remissions (Wittchen et 
al., 2002). Furthermore, suicide risk was elevated even after controlling for 
psychiatric comorbidity. Therefore, it appears of primary importance to identify risk 
factors contributing to the clinical course of PMDD.  
There is still a striking lack of course-related PMDD research in general, and most 
studies do not distinguish between PMDD and the less severe premenstrual 
syndrome (PMS), which does not require key mood symptoms for diagnosis. 
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Furthermore, the possible course-related significance of momentary affect, 
cognitions, and physiological stress responses during daily life in women with PMDD 
has so far been totally neglected. To study such phenomena, electronic Ambulatory 
Assessment (AA) is most appropriate. Here, multiple real-time assessments take 
place during daily life, and the resulting longitudinal data series allow the 
investigation of momentary processes and their temporal relationship within 
individuals (Myin-Germeys et al., 2018). In PMDD, AA also enables to study 
variability of such phenomena across the menstrual cycle (Owens & Eisenlohr-Moul, 
2018). We recently conducted a first AA-study where we showed that PMDD women 
compared to healthy control women demonstrated heightened subjective stress 
reactivity towards daily life stressors and a blunted activity of the hypothalamic-
pituitary-adrenal (HPA) axis across the cycle (Beddig, Reinhard, et al., 2019), thereby 
paralleling patterns of other stress-related disorders.  
Aim of the present paper was to examine whether AA-characteristics measured at 
baseline in the Beddig, Reinhard, et al. (2019) study would predict the clinical PMDD 
symptom course during a four-month interval, over and above relevant demographic 
and clinical predictors. Specifically, we aimed to test the degree to which a) levels of 
negative affect, positive affect, rumination and cortisol, and b) subjective and 
psychoendocrinological stress reactivity during daily life might improve the prediction 
of future PMDD symptomatology. 
Non-medicated women with current PMDD at baseline (n=61, cf. Beddig, Reinhard, 
et al. (2019)) reported negative affect, positive affect, rumination, and daily events via 
electronic diaries at semi-random time points eight times a day over two consecutive 
days per cycle phase (menstrual, follicular, ovulatory, and late luteal; ovulation was 
validated by an ovulation test). Twenty minutes after each assessment they collected 
saliva cortisol samples. PMDD symptomatology was measured at baseline and four 
months after AA using a structured clinical interview, the SCID-PMDD (Accortt et al., 
2011). The SCID-PMDD includes all PMDD-DSM criteria, is modeled after the SCID-I 
and has shown good psychometric properties (Accortt et al. 2011). One woman 
dropped out at follow-up, resulting in a sample of n=60 women.  
Predictor analysis followed a two-step procedure. In a first step, random effects 
parameters (i.e., intercepts and slopes of stress appraisal) of negative affect, positive 
affect, rumination, and cortisol across the menstrual cycle were estimated with 
Restricted Maximum Likelihood using the PROC MIXED procedure of SAS. Here, 
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person-specific intercepts reflect individual differences in the mean levels of 
momentary cognitive, affective and endocrinological states and slope values reflect 
individual differences in stress appraisal effects on these states. In a second step, 
regression analyses were carried out in SPSS. Standardized SCID-PMDD symptom 
scores at follow-up served as outcome while controlling for age, baseline SCID-
PMDD and depressive (BDI-II) symptom scores, and use of psychotropic medication 
at follow-up. In the following, the standardized random effects of AA-predictors were 
added a) in separate regression analyses to the control variables to analyze the 
incremental value of each predictor separately, and b) in a stepwise multiple 
regression analysis where AA-predictors were entered stepwise. All models were 
compared to the control model in terms of proportion of explained variance (see 
online supplement for methodological details of the study).  
Compliance with AA was high (86.5% completed prompts; sample description see 
online Table S1). Multilevel analyses showed significant variation of mood and 
rumination across the cycle with worse outcomes during the late luteal compared to 
all other cycle phases (see online supplement). Separate regression analyses 
showed that high negative affect (beta=0.330, p=.005), rumination (beta=0.265, 
p=.033), ruminative stress reactivity (beta=0.240, p=.039) and low positive affect 
(beta=0.298, p=.015) significantly predicted higher levels of PMDD-symptom scores 
at follow-up, and low cortisol levels showed a trend (beta=0.197, p=.098). These 
individual AA-derived predictors explained between 3.5% and 9.6% incremental 
outcome variance (see online Table S2). In the multiple regression model, high 
negative affect (beta=0.370, p=.001) and low cortisol levels (beta=0.254, p =.023) 
remained as significant independent AA-predictors. This model explained 15.4% 
incremental outcome variance compared to the control model (p=.002; see online 
Table S3).  
Summarized, our study revealed that levels of momentary negative and positive 
affect, rumination, cortisol, and ruminative stress-reactivity improved the prediction of 
the clinical course of PMDD over and above well-known clinical risk factors such as 
symptom severity at baseline. While individual AA-predictors were partially 
overlapped (probably mainly due to their common overlap with negative affect), high 
negative affect and low cortisol output independently predicted a worse clinical 
course of PMDD. The identified substantial added value of individual AA-predictors 
points to the importance to consider such daily life variables more systematically in 
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future longitudinal PMDD research. In a next step, it could be tested whether 
addressing such AA characteristics as direct targets in therapy will improve 
psychological and/or pharmacological interventions for PMDD. Particularly 
rumination, a transdiagnostic factor in psychopathology, may constitute a promising 
therapy target, e.g., in the context of mindfulness-based interventions, which have 
already proven effective in reducing daily life rumination in patients with recurrent 
depression (Timm et al., 2018). Respective research could also investigate whether 
changes in momentary mood, rumination, subjective stress reactivity and/or HPA axis 
activation during daily life will mediate intervention effects on clinical symptomatology 
in PMDD. Strengths and limitations of the study are discussed in the online 
supplement. 
 
4.2 Online supplement material 
4.2.1 Supplementary Materials and Methods 
4.2.1.1 Participants 
Women with Premenstrual Dysphoric Disorder (PMDD) were recruited using different 
sources (e.g., newspapers, gynecologists practices, homepage of the Central 
Institute of Mental Health (CIMH). They underwent a clinical baseline interview to 
assess study in- and exclusion criteria and baseline sociodemographic and clinical 
variables. Inclusion criteria were fulfilling the DSM-5 criteria for PMDD A to E using 
the Structured Interview for DSM-IV TR Defined PMDD (SCID-PMDD, Accortt et al., 
2011) with the diagnostic algorithm adapted for DSM-5. To avoid further participant 
burden, criterion F (prospective daily ratings during at least two symptomatic cycles 
before study inclusion) was not required. Exclusion criteria included age < 20 and > 
42, a reported cycle length of < 22 or  > 34 days, a reported variation of cycle length 
of more than five days, use of hormonal contraceptives, psychotropic medication or 
other medication affecting the HPAA during the last three months, heavy exercise (≥1 
h per day), late evening or night shifts, body mass index <18 or >35, birth of a child or 
lactation/breastfeeding during the last 6 months, history of gynecological diseases, 
bipolar or psychotic disorders, and substance dependence, or current substance 
abuse. 
In total, n=61 women with PMDD completed the baseline interview including the 
Ambulatory Assessment (AA). One woman dropped out during the four-month 
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interval between baseline assessment and follow-up, resulting in a sample of n=60 
PMDD women for the present paper. 
4.2.1.2 Study Procedure 
Data were collected from 3/2016 to 12/2018. During the baseline session at the 
CIMH the Structured Clinical Interview for DSM-IV TR PMDD (SCID-PMDD, Accortt 
et al., 2011) was administered to assess inclusion and exclusion criteria for PMDD. 
The SCID-PMDD is a structured clinical interview modeled after SCID-I that includes 
all symptom criteria relevant for DSM-5 together with the required impairment and 
exclusion criterions. The interview has shown high interrater reliability (kappa=0.96, 
Accortt et al., 2011). Interviews were performed by a trained research psychologist. 
For each woman individual calendars were prepared based on the date of her last 
menstruation onset and the average length of her menstruation and of her menstrual 
cycle. The menstrual cycle was divided into the menstrual, follicular, ovulatory, and 
late luteal phase (see Wolfram et al., 2012). Assessments during the menstrual 
phase took place on the second and third day of menstruation, and the follicular 
phase was examined on the second and third day after the end of menstruation. The 
ovulatory phase was determined by a chromatographic ovulation test (gabControl hlH 
Ovulationsteststreifen, gabmed, Cologne). Participants started testing a few days 
before the predicted ovulation and continued daily testing until the ovulation test was 
positive. The AA for the ovulatory phase was then performed on the two days 
following ovulation. Assessments of the luteal phase took place on the fourth and 
third day before the next menstruation was expected. The calendar specified the 
exact days on which the respective AA was to be carried out and when to begin with 
the ovulation test. Participants were asked to repeat assessments during the next 
cycle if the assessment days were not accurate (e.g., if the actual menses onset was 
several days earlier or later than expected). To prevent sequential effects, women 
started the AA in different phases of their menstrual cycle. Four months after 
completion of the AA procedure, participants underwent a clinical follow-up interview 
at the CIMH where the SCID-PMDD was reassessed. The study protocol was 
approved by the ethics committee of the Medical Faculty Mannheim, Heidelberg 
University. All participants gave written informed consent. 
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4.2.1.3 Measures 
Interview and questionnaire scores 
For the present analysis, the sum score of PMDD symptoms assessed with the 
SCID-PMDD (see above) was used as a predictor variable at baseline and as the 
dependent variable at follow-up. Furthermore, depressive symptoms were measured 
at baseline and at follow-up with the 21-item Beck Depression Inventory (BDI-II, 
German version (Hautzinger et al., 2006)). 
Ambulatory Assessment (AA) 
The AA took place following the diagnostic baseline interview. It was carried out 
using Motorola Moto G 2nd Generation smartphones with the software My 
Experience movisensXS, Version 0.6.3658 (movisens GmbH, Karlsruhe, Germany). 
There were eight subjective assessments per day, with the first at 9 am and the last 
at 9:30 pm. Inter-assessment intervals were semi-randomized and varied between 45 
and 120 min. Each assessment was announced by a beep and took 3-4 min to 
complete. Participants had 5 min to respond, and assessments could be delayed by 
15 min. If participants were unable to respond or rejected the alarm, the assessment 
was saved as missing. At each assessment participants rated momentary mood and 
rumination on 7-point likert scales (1=not at all, 7=very much).  
Momentary negative and positive affect were assessed with six items each which 
were balanced with respect to arousal (negative affect: upset, irritated, nervous, 
listless, down, bored; positive affect: cheerful, energetic, enthusiastic, satisfied, 
relaxed, calm). Outcomes for negative and positive affect were calculated by 
averaging the respective item scores. Rumination was assessed with the item “at the 
moment I am stuck on negative thoughts and cannot disengage from them”, thereby 
capturing the uncontrollability facet of rumination. In accordance with other AA 
studies on daily life stress (e.g. van Stouwe et al., 2019; Wichers et al. 2010), stress 
appraisal of recent daily life events was measured as the degree of unpleasantness 
of the most important event subjects encountered since the last beep (ranging from -
3=very pleasant to +3=very unpleasant). 
Twenty minutes after the subjective ratings, participants collected saliva cortisol 
samples with standard salivettes (Sarstedt, Germany). Participants were instructed to 
refrain from strenuous exercise during the AA day and not to eat, drink other than 
water, smoke, physically exercise or brush their teeth 20 min before completing 
saliva sampling (further details see (Beddig, Reinhard, et al., 2019)). Three further 
samples were collected after awakening (without subjective ratings) to determine the 
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cortisol awakening response (Beddig, Reinhard et al., 2019). These samples were 
excluded from the present analyses. Saliva cortisol concentrations were measured 
using commercially available chemiluminescence-immunoassay with high sensitivity 
(IBL International, Hamburg, Germany). The intra- and interassay coefficients for 
cortisol were <8%. 
4.2.1.4 Data analytic strategy 
Data were analyzed using SAS and IBM SPSS version 23. Stress appraisal was 
transformed by centering around the person mean, thereby varying within but not 
between individuals (Curran & Bauer, 2011). With this approach, interindividual 
differences in mean stress appraisal do not affect the parameter estimates but are 
controlled (see Nezlek, 2014, p. 365), and the predictor indicates higher/lower stress 
appraisal than usual. Cortisol data were log-transformed to adjust for skewness. Log 
cortisol data were examined for outliers, and outliers more than three standard 
deviations from the group mean were winsorized to 3 standard deviations (cf. 
Schlotz, 2019; Stalder et al., 2016).  
Predictor analysis followed a two-step procedure. In a first step, random effects 
parameters (i.e., intercepts, slopes of stress appraisal) for four AA variables (negative 
affect (average of six items), positive affect (average of six items), rumination, and 
salivary cortisol secretion) over the total menstrual cycle  for each woman were 
estimated with Restricted Maximum Likelihood using the PROC MIXED procedure of 
SAS with time, time-squared (if significant), sampling day and stress appraisal as 
fixed effects. Hence, the estimated person specific intercept values reflect 
interindividual differences in the average level of momentary negative affect, positive 
affect, rumination and cortisol secretion over the menstrual cycle, while the estimated 
slope values reflect interindividual differences in the effect of stress appraisal levels 
on these state variables over the menstrual cycle.  
All random effects for AA variables were then standardized and these standardized 
parameters were entered as predictors of the intensity of PMDD symptomatology at 
follow-up. For this purpose, regression analyses were carried out in SPSS in a 
second step. The standardized SCID-PMDD symptom score at follow up served as 
the outcome variable while controlling for baseline SCID-PMDD symptom scores and 
baseline BDI-II scores (raw means and standard deviations of these variables see 
Table S1). In addition, we included further possible confounding variables: age, 
psychotropic medication intake at follow-up (selective serotonin reuptake inhibitors: n 
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= 2, tricyclic antidepressants: n = 1, methylphenidate: n=1), oral contraceptive use (n 
= 4), and time lag in days between the last day of AA and follow up (Mean = 134, SD 
= 20, Min = 104, Max = 206). If any of these variables were significant or showed a 
trend (p ≤ .10), they were retained in the regression models. This was true for age 
and psychotropic medication intake, indicating lower PMDD symptom scores in 
younger women and in those taking respective medication at follow-up.  
Thus, all following regression models were corrected for age, baseline PMDD 
symptoms, baseline depressive symptoms and psychotropic medication intake, which 
were entered as standardized covariates in a single step. This model including only 
baseline predictors without any AA variables served as the control model. 
Finally, the standardized random effects for all AA variables were used as predictors 
1) in separate regression analyses to analyze the incremental effect of each predictor 
compared with the control model in terms of proportion of explained variance 
separately, and 2) in a stepwise multiple regression analysis to identify significant 
independent predictors of follow-up PMDD symptomatology compared with the 
control model. 
4.2.2 Supplementary results 
4.2.2.1 Sample characteristics 
Compliance with AA was high (3381 of 3904 = 86.6% completed prompts). 
Sociodemographic and clinical characteristics of the sample (n=60) together with 
mean levels of the AA variables are presented in Table S1. 
4.2.2.2 Variation of mood, rumination, and cortisol over the menstrual cycle    
Multilevel analyses with cycle phase, time, time² (if significant) and day as fixed 
effects showed significant effects of cycle phase on mood, rumination and cortisol in 
the PMDD sample. The cycle phase effect was significant in predicting NA (F (3,412) 
= 34.0, p<.001), PA (F (3,418) = 30.2, p<.001), rumination (F (3,413) =19.7, p≤.005) 
and cortisol (F (3,395) = 2.6, p=.05). Post hoc tests using Bonferroni correction 
revealed higher negative affect and rumination as well as lower positive affect during 
the luteal phase compared to all other cycle phases (ps ≤ .005) but no differences in 
cortisol levels between the late luteal and other cycle phases (p ≥ .082). 
4.2.2.3 Predictors of PMDD symptomatology at follow-up 
Online Table 2 shows the results of separate regression models of random effect 
parameters of individual AA variables as predictors of PMDD symptoms at follow up. 
Table S3 shows the results of the stepwise multiple regression model of random 
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effect parameters of negative affect and cortisol as the remaining independent 
predictors of PMDD symptoms at follow up after stepwise regression. Further 
explanations see main text. 
4.2.3 Supplementary section: Strengths and limitations of the study 
Strengths of the present study include the investigation of a relatively large sample 
size of women with PMDD, the validation of ovulatory cycles through an ovulation 
test, and the combination of data assessed on the micro (AA) and macro (clinical 
symptom) level within the framework of a longitudinal study. Here, we could show 
that AA-variables at baseline yielded unique predictive information and did not merely 
reflect clinical symptoms but additionally contributed to these known risk factors in 
affecting the clinical course of PMDD. AA of daily life experiences have also been 
proposed to provide greater sensitivity for connecting psychological with biological 
processes than retrospectively assessed symptoms and traits (cf. Conner & Barrett, 
2012), which we could previously show in a study with depressed patients (Huffziger 
et al. 2013). The AA approach may similarly help to advance knowledge regarding 
psychological and biological mechanisms and their interplay involved in PMDD 
(Owens & Eisenlohr-Moul, 2018). Finally, AA may constitute a fruitful tool for 
identifying possible transdiagnostic risk factors at the micro-level of experience which 
can eventually be addressed by transdiagnostic therapy approaches.   
A limitation of the study is the provisional diagnosis of PMDD, since we did not 
request prospective daily ratings of PMDD symptoms over at least two symptomatic 
cycles prior to study entry to prevent participant burden. Therefore, the PMDD 
diagnosis has to be regarded as provisional. However, this approach is in line with a 
majority of studies using retrospective reports to assess PMDD, and prevalence rates 
of moderate to severe premenstrual symptoms derived from retrospective 
epidemiological studies have been found to be consistent with those using 
prospective ratings (cf. Cunningham et al., 2009). The use of a single item to assess 
uncontrollable rumination, although it has already shown good sensitivity as well as 
construct and predictive validity in previous studies (Kuehner et al., 2017; Lydon-
Staley et al., 2019; Timm et al., 2018), may be regarded as a potential further 
limitation of the study. 
 
  
Study 3: Ambulatory Assessment characteristics predict the clinical course of premenstrual dysphoric 
disorder 
94 
Table S1. Sample characteristics of women with PMDD (n=60) 
Variables  
 
% / M (SD) 
Demographic variables   
Age  29.4 (5.8) 
Education level (% with high school 
degree)  
 73.3% 
Marital status (% married or living with 
partner) 
 60.0% 
Children (%)  23.3% 
Clinical variables   
SCID-PMDD
1
 symptom score at baseline   7.7 (1.6)  
SCID-PMDD
1
 symptom score at follow-up  6.8 (2.2) 
BDI-II
2 
score at baseline  11.0 (9.0)  
BDI-II
2
 score at follow-up  11.5 (8.9) 
Psychotropic treatment at baseline³  0% 
Psychotropic treatment at follow-up   6.7% 
Ambulatory Assessment variables  
(baseline) 
  
Compliance Rate  86.5% 
Negative affect
4
    2.8 (0.5) 
Positive affect
4 
  4.2 (0.6) 
Rumination
4 
  2.4 (0.7) 
Stress appraisal
4
  -0.7 (0.5) 
Cortisol levels (nmol/l)
4
  11.0 (4.9) 
1SCID-PMDD = Structured Interview for DSM-IV TR Defined 
Premenstrual Dysphoric Disorder. 2BDI-II = Beck Depression Inventory-
Revised. 3Psychotropic treatment at baseline was an exclusion criterion. 
4For illustrative purposes, AA-variables are presented as aggregated 
variables at the person level. 
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Table S2. Results of simple regression models of random effect parameters of AA 
variables as predictors of PMDD symptoms at follow up 
Predictors1 df Fincrease Beta SE p Explained 
variance 
Random Intercepts (AA
2
)        
Negative Affect (1,53) 8.489 0.330 0.113 0.005 9.6% 
Positive Affect (1,53) 6.376 -0.298 0.118 0.015 7.5% 
Rumination (1,53) 4.783 0.265 0.121 0.033 5.8% 
Cortisol (1,53) 2.846 -0.197 0.117 0.098 3.5% 
Random Slopes for 
stress reactivity (AA
2
)  
      
Stress on Negative 
Affect 
(1,53) 0.861 0.114 0.123 0.358 1.1% 
Stress on Positive 
Affect 
(1,53) 1.100 -0.129 0.123 0.299 1.4% 
Stress on Rumination (1,53) 4.458 0.240 0.114 0.039 5.4% 
Stress on Cortisol (1,53) 0.293 0.064 0.119 0.590 0.4% 
1All models include baseline PMDD symptom scores (Structured Interview for DSM-IV TR 
Defined Premenstrual Dysphoric Disorder, SCID-PMDD), baseline depressive symptom 
scores (Beck Depression Inventory II, BDI-II), age, and psychotropic medication intake 
(0=no, 1=yes) at follow up. 2AA = Ambulatory Assessment. 
 
 
Table S3. Results of the stepwise multiple regression model of random effect 
parameters of AA variables as predictors of PMDD symptoms at follow up 
Predictors1 Beta SE p df Fincrease p Explained 
variance 
Random Intercepts 
(AA
2
)  
   (2,52) 7.36 0.002 15.4% 
Negative Affect 0.370 0.110 0.001     
Cortisol -0.254 0.108 0.023     
1Model includes baseline PMDD symptom scores (Structured Interview for DSM-IV TR 
Defined Premenstrual Dysphoric Disorder, SCID-PMDD), baseline depressive symptom 
scores (Beck Depression Inventory II, BDI-II), age, and psychotropic medication intake 
(0=no, 1=yes) at follow up. 2AA = Ambulatory Assessment. 
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5 GENERAL DISCUSSION 
5.1 Summary of the present findings 
Important results of Study 1 
Objective of Study 1 was to investigate whether women diagnosed with PMDD and 
asymptomatic controls differed with regard to within-person influences of daily life 
stress on mood, cognitions and cortisol activity and with regard to their basal cortisol 
activity over the menstrual cycle. Findings revealed that PMDD women in contrast to 
controls demonstrated a premenstrual increase in stress appraisal and high arousal 
negative affect in response to daily life stressors. Affected women also showed 
heightened levels of rumination towards daily stressors irrespective of menstrual 
cycle phase. Furthermore, PMDD was associated with blunted basal cortisol 
secretion across the menstrual cycle: the CAR peak was delayed and the diurnal 
cortisol slope was flattened in comparison to controls. In both groups within-person 
increases in high arousal negative affect and decreases in positive affect predicted 
higher subsequent cortisol levels, whereas there was no evidence for cortisol 
changes after experiencing within-person increases in stress appraisal in any group. 
Another key finding of the study was that the link between rumination and cortisol 
appeared to be decoupled in women with PMDD: a distinct cortisol response to 
rumination was only identified in healthy women, which was irrespective of cycle 
phase. Together, these results point towards heightened subjective stress appraisal 
and subjective stress reactivity during the late luteal phase and blunted basal HPAA 
dysfunction in women with PMDD compared to healthy control women. 
 
Important results of Study 2 
Study 2 examined menstrual cycle-related variations in emotional and cognitive 
states and their time-lagged associations in PMDD women and controls. Findings 
showed that women with PMDD reported highest levels of negative affect and 
rumination and lowest levels of positive affect and self-acceptance in the late luteal 
phase, thereby lending empirical support to the cyclic pattern of symptoms. In 
addition, lagged models revealed that intraindividually increased rumination and 
decreased self-acceptance predicted subsequent mood worsening more strongly in 
the PMDD group, with the effect of rumination being limited to the late luteal phase. 
General discussion 
97 
Findings point toward a contribution of momentary cognitions to premenstrual mood 
worsening in PMDD women. In turn, decreased positive affect and increased 
negative affect were more strongly associated with subsequent deterioration in 
rumination and self-acceptance in affected women. These results suggest that PMDD 
women are more sensitive than healthy women to detrimental effects of both 
dysfunctional thinking and low mood.    
 
Important results of Study 3 
Study 3 investigated the role of AA-characteristics for the prediction of the clinical 
course of PMDD. Findings revealed that a number of daily life characteristics were 
linked to a more severe clinical PMDD psychopathology four months later. 
Specifically, high levels of negative affect, rumination, and ruminative stress-reactivity 
as well as low levels of positive affect and cortisol secretion explained incremental 
proportions of variance after controlling for relevant conventional demographic and 
clinical course-related factors. Mean negative affect and low cortisol output 
independently predicted a worse clinical course of PMDD explaining more than 15% 
incremental variance of interviewer-rated PMDD symptoms at follow-up. Importantly, 
these findings were not attributable to levels of depressive and anxiety symptoms at 
baseline. 
5.2 Interpretation of study results in light of previous studies and future directions    
As a whole, this thesis adds to the PMDD-literature by performing an electronic AA 
with smartphones as a method for a repeated collection of a woman’s momentary 
psychological and physiological states across the menstrual cycle, which has been 
repeatedly called for in the respective up-to-date literature on PMDD (e.g. Bosman et 
al., 2016; Craner et al., 2014; Owens & Eisenlohr-Moul, 2018). Knowledge of 
possible disease-related mechanisms in daily life, as identified in the present study, 
may be beneficial for future research and treatment.  
 
Study 1 
In Study 1 we identified significant stress-related psychological and endocrinological 
within-person variability in women with PMDD during daily life. While sensitivity to 
daily life stressors has been identified as an important psychological mechanism for 
many psychiatric disorders (Myin-Germeys et al., 2018), little is known about stress-
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related characteristics in PMDD such as momentary stress appraisal, and subjective 
as well as endocrinologic stress-responsitivity. 
In line with evidence from previous crosssectional studies showing that PMDD is 
linked to higher stress appraisal toward the end of the cycle (for reviews see 
Epperson et al., 2012; Owens & Eisenlohr-Moul, 2018; Beddig & Kuehner, 2017), our 
findings revealed that women with PMDD appraised daily life stressors as more 
aversive in the late luteal phase compared to the follicular phase, pointing toward a 
relationship between perception of daily life stressors and menstrual cycle phase in 
PMDD women.  
Subjective reactivity to daily life stressors is usually expressed through momentary 
affect and cognitions. While previous studies with other clinical populations mostly 
focused on negative affect in response to a stressor (e.g. van der Stouwe et al., 
2019; Wichers et al., 2009), our study differentiated between specific mood facets 
(e.g., negative affect high versus low in arousal), thereby highlighting the importance 
of arousal in the context of PMDD. In particular, we observed premenstrual within-
person elevations in high arousal negative affect states (i.e. being upset, nervous or 
irritated) in response to increased momentary stress-levels in affected women. These 
findings are consistent with previous epidemiological research emphasizing the role 
of premenstrual irritability and anger as the most frequent and impairing symptoms in 
the context of PMDD (e.g. Epperson et al., 2012; Hantsoo & Epperson, 2015; 
Hartlage et al., 2012; Owens & Eisenlohr-Moul, 2018). The preponderance of high 
arousal negative affect and mood lability over depressed mood has led to a change 
in the respective listing of symptoms from DSM-IV to DSM-5 (Hantsoo & Epperson, 
2015). In this context, it has been discussed whether the location of the PMDD 
diagnosis in the chapter on depressive disorders in DSM-5 is appropriate, 
considering that women with PMDD experience very diverse symptoms and respond 
to high stress situations particular with high intensity negative affect. Hence, it has 
been suggested that PMDD should not be classified as a variant of depression 
(Landen & Eriksson, 2003). A different point of view is taken by Payne et al. (2009) 
and Kuehner (2017). They propose the presence of a female-specific reproductive 
phenotype of depression given that PMDD links to postpartum and perimenopausal 
depression due to shared clinical characteristics, significant lifetime comorbidity and 
susceptibility to normal hormone fluctuations. Here, further AA-studies may aim at 
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identifying possible common or different daily life phenotypes underlying PMDD and 
Major Depression. 
Notably, we identified an enhanced within-subject effect of stress on rumination in 
PMDD women irrespective of cycle phase. The only study to date investigating 
cognitive stress responses in women with premenstrual disorders found evidence for 
increased levels of self-focused attention to an elicited stressor (Craner et al., 2015). 
Given these findings, affected women seem to respond to more stressful situations 
with heightened dysfunctional attentional and cognitive features (ruminative thinking, 
self-focused attention). The lacking cycle effect of rumination in the present study 
suggests that this reflects a trait-like characteristic. 
Some authors propose that the altered perception of stressful events may be linked 
to an altered biological stress reaction (e.g. Girdler et al., 2007; Kleinstauber et al., 
2016), and a few previous studies have found differences in basal cortisol activity 
(Hoyer et al., 2013; Odber et al., 1998) and in endocrinologic stress reactivity (Huang 
et al., 2015; Klatzkin et al., 2014; Roca et al., 2003) between women with 
premenstrual disorders and asymptomatic controls. However, results have been 
inconclusive by now (cf. Kiesner & Granger, 2016). With regard to endocrinologic 
stress reactivity, the current results provide no evidence for altered cortisol reactivity 
to daily stressors in women with PMDD. Explanations for the null finding might be 
attributable to several factors: First, given the naturalistic everyday life context, 
stressors were minor daily life events and thus may have had less impact on the 
HPAA compared to induced strong single-event stressors in standardized laboratory 
research paradigms. Second, as our stress data refer to self-reports in a time-
sampling protocol, a potential recall bias cannot be excluded. Third, some research 
suggests that cortisol responses are particularly increased following interpersonal 
stressors (Gilbert et al., 2017; Lustyk, Olson, Gerrish, Holder, & Widman, 2010). 
However, due to a lack of power, we did not differentiate between specific event 
types (e.g. social interaction, work stressors). Therefore, future PMDD research with 
larger samples might consider a possibly heterogeneous activation of the HPAA in 
response to different stressor types. 
Apart from responses to daily life stress events, our results indicate a different 
relationship between rumination and HPAA activity in women with and without 
PMDD. While cortisol levels in response to rumination rose in asymptomatic controls, 
reports of increased rumination in PMDD women did not significantly affect their 
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cortisol levels, suggesting a decoupling of cognitive and neuroendocrinological 
processes. This may reflect a general impaired ability to adapt cortisol levels 
depending on situational demands and might therefore point to an important 
pathophysiological marker of PMDD. Similar findings of reduced stress-cortisol 
coupling in daily life have been reported from other clinical populations. For instance, 
Peeters, Nicholson, and Berkhof (2003) showed that in acutely depressed patients, 
cortisol levels did not significantly increase following everyday negative events as 
seen in controls. Therefore, adaptive cortisol responses might represent a protective 
factor to buffer negative mood (Heim et al., 2000; Het et al., 2012; Schlotz, 2008).  
With regard to basal cortisol, the present data suggest that PMDD is linked to blunted 
basal cortisol activity throughout the menstrual cycle. Blunted HPAA activity has also 
been identified in other stress-related conditions such as posttraumatic stress 
disorder, chronic fatigue syndrome or atypical depression (Adam et al., 2017; Heim et 
al., 2000; Tak et al., 2011), and in individuals with genetic or cognitive vulnerability to 
depression (Kuehner et al., 2007; 2011). In this context, it has also been proposed 
that women with PMS, in contrast to women with PMDD, show adaptive cortisol 
activation (Hoyer et al., 2013), which should be however addressed in more detail in 
future research. Furthermore, we observed that alterations in cortisol activity were not 
confined to the luteal phase, suggesting that they represent a more stable or traitlike 
feature. Finally, it remains to be investigated whether basal cortisol characteristics 
contribute to or are merely a consequence of PMDD. Accordingly, more research is 
needed in order to assess the exact mechanisms behind the identified blunted basal 
cortisol activity in PMDD.  
Taking together, this study expanded previous work on PMDD by assessing stress-
related psychological and neuroendocrinological characteristics across the menstrual 
cycle with electronic AA, by distinguishing arousal facets of affect as well as basal 
and stress-related components of cortisol activity, and by examining within-person 
associations between stress and respective factors.  
 
Study 2 
Study 2 investigated menstrual cycle-related variations in emotional and cognitive 
states and their possible reciprocal effects in PMDD women compared to controls. 
Results suggest that women with PMDD are more sensitive to detrimental effects of 
dysfunctional cognitive states on subsequent mood and vice versa.    
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Affective symptoms of low mood, decreased interest, irritability, and anxiety occur as 
part of many mood and anxiety disorders, including PMDD. The feature that most 
highly distinguishes PMDD from similar entities is its time course with the luteal 
phase confinement of symptoms (APA, 2013). Not surprisingly, results of the study 
confirm characteristics of PMDD as delineated in DSM-5, including menstrual cycle 
related variations in affective and cognitive states in women with PMDD but not in 
asymptomatic controls, such as state reports of substantial mood worsening and 
increase in dysfunctional thinking in the late luteal phase.  
Furthermore, the findings of our study suggest that cognitions and affect may 
mutually reinforce each other during everyday life in PMDD women, and may thereby 
contribute to a vicious circle. Notably, this was true even when adjusting for 
depressive symptoms, trait anxiety levels and daily life stressors, suggesting that the 
identified sensitization is not a direct or indirect effect of comorbid depressive or 
anxiety symptoms or heightened stress experience. Therefore, our study contributes 
to the existing literature in two important ways. First, while previous studies 
investigated trait aspects of rumination with various self-report measures (cf. Craner 
et al., 2014, 2015; Dawson et al., 2018), our AA study focused on moment-to-
moment within-person relationships between affective and cognitive states across 
different menstrual cycle phases. Second, in line with the transdiagnostic perspective 
of rumination as a dysfunctional key mechanism in mental disorders (e.g. 
Lyubomirsky et al., 2015; Nolen-Hoeksema et al., 2008; Nolen-Hoeksama & Watkins, 
2011), we identified a characteristic rumination-related cycle dependency in the 
PMDD sample. Therefore, while reciprocal effects between affective and cognitive 
states have already been identified for patients with Major Depression using daily life 
studies (e. g. Kircanski et al., 2018; Ruscio et al., 2015), our study showed a specific 
mutually reinforcing relationship between rumination and negative affect which was 
particularly pronounced during the late luteal phase in women with PMDD.   
In general, our findings provide empirical support that affected women are more 
sensitive to detrimental effects of dysfunctional thinking and mood deterioration in a 
kind of vicious circle, particularly toward the end of the menstrual cycle. Findings also 
support previous findings by highlighting the contribution of psychological factors for 
premenstrual disorders (e.g. Craner et al., 2016; Kleinstauber et al., 2016; Reuveni et 
al., 2016; Weise et al., 2019). Future research could examine whether interventions 
addressing dysfunctional cognitive states such as momentary rumination are able to 
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interrupt the identified cycle-dependent vicious circle between cognitions and mood 
worsening in PMDD. 
 
Study 3 
AA is seen as a promising approach to examine mental states at the micro-level of 
experience during daily life that can be connected to macro-levels of mental health 
(Myin-Germeys et al., 2018; Wichers, 2014). A respective recent review by Brietzke 
et al. (2019) provides encouraging results thereby emphasizing the potential of AA-
phenotypes for clinically relevant outcomes such as symptom course, relapses and 
recurrences, and functional impairment. In contrast, to date there is a complete gap 
in research examining the predictive value of possible AA-derived experience 
sampling phenotypes for the clinical course of PMDD. Given that PMDD shows a 
high risk for chronification (Wittchen et al., 2002) and increased suicidality (Pilver et 
al., 2013), it is of primary importance to identify possible course-related risk factors. 
The results of Study 3 suggests that cognitive, affective and cortisol-related daily life 
states and processes may represent important AA-phenotypes that are prospectively 
linked to the clinical course of symptoms in PMDD, even after controlling for relevant 
demographic and clinical predictors. Here, AA characteristics at baseline provided 
unique predictive information and yielded substantial incremental explained variance 
of PMDD symptomatology at the four-months follow-up. The present results also 
point to AA as a fruitful tool for identifying transdiagnostic risk factors such as 
negative affect and rumination. In this context, it has also been proposed that AA of 
daily life experiences may provide greater sensitivity for connecting psychological 
with biological processes than retrospectively assessed symptoms and traits (cf. 
Conner & Barrett, 2012), which are therefore particularly suitable for being studied 
across domains and units of analysis within the Research Domain Criteria (RDoC) 
framework (Insel et al., 2014) and may also be addressed through transdiagnostic 
intervention approaches. Future research in this area should also take a look at 
longer follow-up intervals. In doing so, it would be interesting to see whether the 
present findings represent reliable phenotypes with prognostic value for the longer-
term course of PMDD. In a next step, it could be investigated whether explicitly 
targeting these AA-characteristics in psychological or pharmacological therapy will 
improve treatment and outcome for PMDD.  
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5.3 Strengths and Limitations 
5.3.1 Strengths 
The current study has several strengths to mention. First, it was based on a relatively 
large and carefully selected sample of women with PMDD. The final criteria for study 
inclusion were assessed by a trained research psychologist using structured clinical 
interviews, namely the SCID-PMDD (Accortt et al., 2011) for PMDD criteria (DSM-5) 
and the SCID-I (Wittchen et al., 1997) for comorbid mental disorders.  We applied 
strict exclusion criteria (for a detailed overview see Beddig, Reinhard et al., 2019); for 
instance, women were excluded if they took hormonal contraceptives, 
antidepressants, or other medication affecting the HPAA. Moreover, in previous 
studies women with PMDD and PMS were often pooled together. However, it is of 
particular importance to distinguish PMDD from milder forms of premenstrual 
disorders when investigating potential disease mechanisms (cf. Hoyer et al., 2013; 
Odber et al., 1998). In order to address this issue, only women were included who 
fulfilled DSM-5 core and accompanying criteria for PMDD. In addition, the control 
sample was narrowly matched with regard to age and education level. A further 
advantage of the study design was the gathering of all four cycle phases (menstrual, 
follicular, ovulatory, and late luteal). The ovulatory phase of the cycle was determined 
by a chromatographic ovulation test indicating a rise in luteinizing hormone levels in 
urine. If ovulation did not occur, subjects had to repeat the missing phases (ovulatory 
and late luteal phase) in the following cycle. Thus, in contrast to previous studies 
which frequently made use of self-report data to determine different menstrual cycle 
phases, we included an objective measure of ovulation and ensured that only 
ovulatory cycles were assessed. Besides, possible sequence effects were avoided by 
having participants start AA in different phases of their menstrual cycle.  
Furthermore, the innovative assessment approach using electronic diaries with semi-
randomly high-frequency sampling enabled to collect prospective data in the 
participants’ natural environment with high accuracy as well as high generalizability 
and external validity (cf. Schlotz, 2019; Trull & Ebner-Priemer, 2013). As in all 
naturalistic studies, missing data were inevitable. However, we reached high 
compliance rates for our daily life subjective variables and cortisol samples 
(Courvoisier et al., 2012), which represents a further strength of this study.  
Regarding item selection, we made use of affective items allowing to differentiate 
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valence (positive versus negative) and degree of arousal (high versus low), which 
has been called for recently in the relevant up-to-date literature on PMDD (Bosman et 
al., 2016).  
In the statistical analyses, three-level multilevel models were performed (level 1 = 
single assessments, level 2 = days, level 3 = individuals) with random intercepts for 
individuals and days. This approach allows the consideration of the hierarchical data 
structure and includes an improved handling of missing data (cf. Hox, 2010). 
Bonferroni correction was used for multiple comparisons. As we could rely on 
intensive longitudinal data, our analyses are based on higher statistical power 
compared to traditional group comparisons (cf. Hox, 2010). 
A key methodological advantage of the realized electronic AA approach with 
multilevel analysis was the ability to focus on within-person processes. The multiple 
measurement occasions allowed the investigation of intraindividual changes by 
allowing each woman to serve as her own control. By using person‐mean centering, 
the influence of between‐person effects was controlled for in respective analyses.  
While previous studies have shown an increased subjective sensitivity to stress in 
women with PMDD (cf. Owens & Eisenlohr-Moul, 2018), there is minimal work tying 
this to physiological measures of stress responses such as cortisol. By contrast, our 
cortisol assessment included the repeated measurement of standard cortisol 
parameters (CAR, daily slope) and the linking of cortisol outcomes to subjective daily 
life experiences, thereby enhancing reliability and generalizability. Further 
advantages in this context include: 1) We log-transformed raw cortisol data to 
account for skewed distribution and windsorized outliers more than three standard 
deviations from the group mean. 2) For every cortisol pattern we tested a linear and a 
quadratic model. 3) Our CAR included three time-points. Even though in most studies 
only two time points were included, at least three assessments (on awakening, 30 
min and 45 min) are highly recommended for research in adult populations (Stalder 
et al., 2016). 4) Our daily slope included nine cortisol samples, thereby clearly 
exceeding the recommended minimum of three samples for estimating diurnal slopes 
(Adam et al., 2017; Hoyt, Ehrlich, Cham, & Adam, 2016). 5) By realizing a time-lag of 
20 min between subjective assessments and cortisol samples, we took into account 
the delayed cortisol rise in response to subjective experiences (Schlotz, 2019) and 
were able to control for a number of possible confounding variables (e.g. eating, 
drinking, physical exercise). 6) Data from noncompliant participants with saliva 
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samples of more than 10 min after the prompts were excluded. 7) Salivary measure 
ratings were time-verified by the demand to note a random three-digit number on the 
salivettes.  
Finally, in recent years experts became increasingly aware of the potential of AA to 
predict psychiatric symptoms and clinical outcomes in mental disorders (Barnett et 
al., 2018; Brietzke et al., 2019; van Os et al., 2017; Wenzel, Kubiak, & Ebner-
Priemer, 2016). In Study 3, we used this approach to investigate for the first time the 
role of micro-level psychological and physiological processes at baseline for the 
prediction of the clinical course of symptomatology in our PMDD sample.  
Taken together, with the application of electronic AA, the coverage of four menstrual 
cycle phases, the focus on within-person-effects and the investigation of the 
predictive value of AA-derived experience sampling phenotypes, we believe that the 
study was characterized by an innovative approach and by methodological strengths 
offering novel opportunities to explore PMDD. 
5.3.2 Limitations 
Apart from the strengths of the study, a number of limitations have to be considered, 
which will be discussed in the following. A first limitation relates to the diagnostic 
procedure for determining the PMDD diagnosis. The study inclusion criteria were 
based on the Structured Clinical Interview for PMDD (SCID-PMDD, Accortt et al., 
2011) following the requirements of DSM-5 (APA, 2013) that symptom criteria of 
PMDD should be fulfilled in more than half of the cycles during the last 12 months.  
Therefore, although the PMDD diagnosis was made by clearly defined, replicable 
DSM-5 criteria, it was nevertheless based on the retrospective recall of premenstrual 
symptoms within the last year. A prospectively-confirmed diagnosis with daily 
charting of symptoms for two symptomatic cycles, as defined by DSM-5 (APA, 2013), 
was not required before study inclusion to avoid participants burden as the study 
already demanded the participating women to intensively track one menstrual cycle 
with multiple AA-measurements. Consequently, the diagnosis of PMDD should be 
considered ‘provisional’ and some women might have experienced a cycle with lower 
symptom load, during the covered AA period. However, this fact may partly reflect a 
general problem concerning the lack of precision and consistency in how PMDD is 
defined in DSM-5, particularly that symptoms must be present in the majority of 
cycles (i.e. implicating that there might also be nonsymptomatic cycles in PMDD) and 
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that symptom criteria should be confirmed by prospective ratings during two 
symptomatic cycles (i.e. again implicating that there might also be nonsymptomatic 
cycles, which would not exclude a PMDD diagnosis) (APA, 2013). In clinical practice, 
symptom diaries are not commonly used; instead, a diagnosis is predominantly 
based on retrospective reports (Craner et al., 2014). Importantly, however, studies 
showed that prevalence rates of moderate to severe premenstrual symptoms derived 
from retrospective epidemiological studies are consistent with those using 
prospective ratings (Cunningham et al., 2009). Another possible limitation concerns 
the representativity of our sample. Participants were not necessarily treatment-
seeking, and their symptom levels may have been less severe and impairing 
compared to women presenting for treatment of PMDD in medical settings. 
Additionally, participants were recruited from different sources (i. e. newspapers, 
local family doctors and gynaecologists practices, homepage of the CIMH, social 
networks), which may represent a further limitation. Moreover, we explicitly excluded 
participants with ongoing hormonal or antidepressant treatment, since these 
medications could blur normal fluctuating cortisol activity. However, given that 
antidepressant and hormonal treatments are currently the most frequent treatments 
for PMDD (Epperson et al., 2012; Marjoribanks et al., 2013), the results of our study 
might not be representative for all women with PMDD. Furthermore, we only 
examined participants between 20 and 42 years of age as a regular menstrual cycle 
was obligatory for this study. Thus, the results cannot necessarily be generalized to 
younger or older women. Besides, even though our sample was heterogeneous with 
regard to age, education, job and family situation, women with higher education 
levels were somewhat overrepresented. Regarding potential demand characteristics, 
women with diagnosed PMDD presumably were aware that affect and stress are 
expected to vary across the menstrual cycle. Therefore, their subjective responses 
might have been biased in some way. Nonetheless, results regarding the cycle-
specific heightened subjective stress reactivity and the tendency to react with 
rumination in face of stressful events were unlikely to be biased, decreasing the 
likelihood that demand characteristics were an important factor.  
With regard to the AA procedure, several limitations need to be considered. First, 
limited resources and the time-consuming procedure with multiple measurements per 
day did not allow for the daily assessment over the whole menstrual cycle. Instead, to 
reduce participants’ burden while undergoing daily routines, we used shorter 
General discussion 
107 
timeframes of two days duration to characterize different phases of the cycle, which 
may have resulted in a lack of power. Furthermore, due to the small number of days 
per cycle phase we might have missed the days with the highest impairment. 
Second, we did not measure sex hormone levels, which would have further increased 
confidence in an accurate assessment of menstrual cycle phases given that each 
menstrual cycle phase features specific fluctuations of estrogen and progesterone. 
Instead, we determined the luteal phase based on participants’ reports of their first 
day of their last menses and the typical duration of the cycle length. Hence, even 
though a regular cycle was a premise to take part in the study and the ovulation 
phase was confirmed by a chromatographic ovulation test, future research might 
benefit from an extension of the AA over the whole menstrual cycle and from 
measurements of hormonal parameters to verify correct phasing. Third, to further 
increase the accuracy of conclusions the AA could be performed over two or more 
consecutive menstrual cycles in future studies (cf. Kiesner, 2011; although this would 
have to be balanced out against even greater burden for participants). Fourth, the 
assessment of daily stressful events was still retrospective as it asked for the most 
important event since the last assessment. On the other hand, a higher sampling 
frequency might have deluted the effects of stressful events by including more events 
of relatively minor importance. Fifth, we did not assess additional specific features of 
stress responses (i.e. recovery and pile-up) which may be of interest to broaden the 
examination of stress-related features in future research (cf. Smyth et al., 2018). 
Sixth, constructs of rumination and self-acceptance were assessed using single 
items. While previous studies have demonstrated high sensitivity as well as construct 
and predictive validity of these measures (e.g., Kuehner et al., 2017; Lydon-Staley et 
al., 2019; Timm et al., 2018), they do not allow for robust psychometric testing. 
Finally, the focus of the present AA-study was on affective, cognitive or 
endocrinological factors in everyday life. Respectively, our design did not account for 
specific premenstrual symptoms involved in PMDD including physical (e.g., 
cramping, swelling, bloating) and vegetative (e.g., changes in sleep or food cravings) 
symptoms. Therefore, future studies could include additional items to assess specific 
facets of premenstrual symptoms. This procedure would also allow to investigate how 
premenstrual symptoms directly influence the assessed subjective and 
endocrinologic daily life experiences. 
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5.4 Conclusions and implications for further research and the treatment of PMDD    
The present thesis provides several methodological and clinical implications for the 
assessment and treatment of PMDD. Our study showed that AA is well-suited to 
assess daily life mood and cognitions in PMDD women across the menstrual cycle. 
Given the widespread availability of smartphones and tablets, electronic AA 
applications are increasingly considered a useful tool for diagnostic issues and 
treatment in clinical practice (cf. Barnett et al., 2018; Brietzke et al., 2019; van Os et 
al., 2017). AA also offers the possibility to capture the variability of affect in more 
detail (cf. Brietzke et al., 2019), which is of particular importance given that mood 
swings represent one of the cardinal symptoms of PMDD. Instead of the required 
daily symptom ratings in routine monitoring, which are typically assessed with single-
point assessments via paper-pencil at the end of the day and thus prone to recall 
bias, the implementation of electronic AA with multiple repeated real-time sampling 
might help to more accurately identify affected women. Furthermore, the within-
person approach provided by AA may allow for rapid personalized feedback of 
current symptomatology and impairment, and the temporal relationship between 
various symptoms, e.g. between rumination and mood deterioration. Such individual 
profiles might serve as an important tool to improve professional PMDD treatment 
and clearly deserve more attention in future research. If proven effective, the 
implementation of electronic AA symptom tracking in the treatment of women with 
PMDD would be desirable in the long term.  
Another important avenue of future research are studies addressing and increasing 
the understanding of possible different subtypes of PMDD (cf. Pearlstein, 2010; 
Yonkers & Simoni, 2018). Recent studies revealed heterogeneity within the diagnosis 
of PMDD with respect to symptom patterns and timing of symptom onset (Eisenlohr-
Moul et al., 2019; Schmalenberger et al., 2017; Yonkers & Simoni, 2018). On top of 
that, women with PMDD are known to suffer from high rates of comorbid disorders 
(e.g., Cohen et al., 2002; Landen & Eriksson, 2003; Pilver et al., 2011), probably 
further increasing diagnostic heterogeneity. It is conceivable that different PMDD 
subtypes are associated with partly distinct underlying disease mechanisms and may 
also differ with regard to their responsivity to treatments (cf. O’Brien et al., 2011). 
Therefore, knowledge of diversified subtypes of PMDD might influence treatment 
recommendations. In this context, AA might be particularly suitable for helping to 
identify and to examine respective subtypes over the course of the menstrual cycle. 
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An additional area in need of improvement is the establishment of clear guidelines for 
psychotherapy. Up to now, the German National Disease Management Guideline for 
unipolar depression does not provide evidence-based treatment recommendation for 
PMDD due to a lack of well-designed RCT studies (DGPPN et al., 2017). The present 
thesis provides important starting points for the development of intervention studies 
by highlighting the role of cognitions as a driver for mood deteriorations and for long-
term severity of symptomatology in PMDD. Specifically, we could show that PMDD 
women seem to be more prone to using rumination as a trait-like emotion regulation 
strategy in response to stressful situations (Study 1) and towards negative affect 
states (Study 2) irrespective of menstrual cycle phase. Beyond that, high 
intraindividual rumination levels seem to trigger affect deterioration particularly in the 
late luteal phase, suggesting a vicious circle between rumination and affect (Study 2). 
Finally, both average levels of momentary rumination as well as stress-reactive 
rumination during everyday life contribute to a more severe clinical course (Study 3). 
In this context, future research might benefit from investigating the impact of specific 
contents of ruminative thoughts. Our study revealed that rumination had particular 
detrimental effects on mood in the late luteal phase (Study 2). Together with the 
results by Craner et al. (2014) showing that ruminating about premenstrual symptoms 
might be particularly toxic, it can be suspected that PMDD women primarily ruminate 
about their premenstrual complaints. However, this should be examined in deeper 
detail in future research.  
Our findings further suggest that it appears worthwhile to specifically target 
dysfunctional cognitive processes in women with PMDD and to investigate which 
interventions aimed at reducing ruminative thoughts and at preventing a vicious circle 
between dysfunctional thinking and mood worsening might reduce burden. In this 
regard, particularly mindfulness-based interventions have been suggested that have 
proven effective to modulate affect, stress, arousal, and emotion regulation in 
patients with various disorders (e.g. Bluth et al., 2015; Eggert et al., 2016; Petersen 
et al., 2016). Furthermore, a recent study by our group has shown that a 
mindfulness-based training reduced momentary rumination and improved momentary 
mood during daily life in patients with recurrent depression (Timm et al., 2018). Two 
studies have already demonstrated that such interventions may help women suffering 
from premenstrual disorders (Bluth et al., 2015; Panahi & Faramarzi, 2016). 
However, well-controlled mindfulness-based intervention studies for women with 
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PMDD are still lacking, highlighting the need for further clinical trials. Until then, 
treatment implications should be drawn with caution. 
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6 SUMMARY 
Premenstrual Dysphoric Disorder (PMDD), outlined as a new diagnostic category in 
DSM-5, is characterized by key affective and accompanying psychological and 
physical symptoms during the premenstrual (late luteal) phase of the menstrual cycle, 
resulting in clinically significant distress and functional impairment. Despite its high 
prevalence (3%-8% in women of fertile age) and risk of chronic developments, 
psychological and biological mechanisms underlying PMDD are so far not well 
understood. Among other factors, a dysregulation of the stress axis is being 
discussed.   
The present thesis integrates three substudies from a project using Ambulatory 
Assessment (AA) with electronic diaries (smartphones) to compare the course of 
mood, cognitions, and cortisol release in the daily life of women diagnosed with 
PMDD and healthy control women over the course of the menstrual cycle. AA took 
place at semi-random time points eight times a day during two consecutive days per 
cycle phase (menstrual, follicular, ovulatory, and late luteal). In particular, the thesis 
focused on identifying possible cycle-related within-person changes in affective, 
cognitive, and endocrinological states and their interrelations as captured in real time 
and real life. A clinical follow-up was conducted four months after baseline.    
Study 1 examined the stress-related facets of mood, cognition and cortisol together 
with basal cortisol activity over the menstrual cycle in women suffering from PMDD 
and asymptomatic controls. Findings revealed that affected women showed 
increased subjective stress appraisal and enhanced high arousal negative affect 
towards daily life stressors particularly in the late luteal phase of the menstrual cycle. 
Furthermore, PMDD was associated with blunted basal activity of the hypothalamic-
pituitary adrenal axis (delayed cortisol awakening response peak, flatter daily cortisol 
slope) and reduced cortisol reactivity toward periods of enhanced rumination 
irrespective of menstrual cycle phase. This study revealed substantial cycle-related 
intraindividual variability in stress appraisal and psychological responses to stress 
together with blunted basal cortisol activity in PMDD, with the latter similarly observed 
in other stress-related disorders. 
Study 2 focused on menstrual cycle-related variations in momentary cognitive and 
affective daily life states as well as on their time-lagged reciprocal effects in women 
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with PMDD and controls. PMDD women, in contrast to controls, showed higher levels 
of momentary negative affect and rumination, and lower levels of positive affect and 
self-acceptance toward the end of the menstrual cycle. Lagged analyses showed 
stronger reciprocal within-person effects of cognitions and mood in PMDD women, 
whereby the effect of rumination on subsequent negative affect was limited to the late 
luteal phase. Stronger prospective associations of daily life cognitions and affective 
states in PMDD suggests that affected women seem to be more sensitive to 
detrimental effects of either dimension in a kind of vicious cycle. The study 
emphasizes the role of cognitions in the context of PMDD suggesting that ruminative 
thinking might be an important therapeutic target. 
Study 3 investigated whether AA-characteristics of momentary mood, cognitions, and 
cortisol, measured across the menstrual cycle at baseline, would predict the four-
month clinical symptom course in women with PMDD. Levels of momentary negative 
and positive affect, rumination, cortisol, and ruminative stress-reactivity improved the 
prediction of clinical PMDD symptomatology at follow-up after controlling for relevant 
demographic and clinical risk factors. High negative affect and low cortisol output 
independently predicted higher PMDD symptom scores and explained more than 
15% incremental outcome variance. The identified substantial added value of 
individual AA-predictors points to the importance to consider such AA-derived 
phenotypes more systematically in future longitudinal PMDD research.  
In conclusion, with the application of electronic AA the three studies add to existing 
knowledge on cycle-related variations in daily life affect, cognitions, and stress 
hormone release, and their temporal within-person associations in women with 
PMDD. Moreover, the combination of AA data at the micro-level of daily life 
experiences with longitudinal data at the macro-level of clinical symptomatology 
confirmed predictive validity of AA-derived phenotypes for the clinical course of 
PMDD. Findings may provide a starting point for future intervention research to 
provide respective evidence-based therapeutic strategies for affected women.  
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